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Abstract 
Atherosclerosis is the leading cause of cardiovascular disease related deaths world-wide. Accumulation 
of lipoprotein-derived cholesterol in the arterial wall leads to both initiation and progression of the 
disease. To reach the arterial wall, pro-atherogenic low-density lipoprotein (LDL) and anti-atherogenic 
high-density lipoprotein (HDL) are known to pass through the intact endothelial cell monolayer. It has 
been previously shown that endothelial cells transcytose HDL involving ATP binding cassette 
transporter G1 (ABCG1), scavenger receptor BI (SR-BI), endothelial lipase (EL) as well as ectopic β-
ATPase. The transport of LDL through the endothelial cells was evidenced to be mediated by SR-BI 
and activin like kinase 1 (ALK1). Although a few protein interactors for the lipoprotein endothelial 
uptake were identified, the role of signaling kinases in regulating the lipoprotein uptake has not been 
well understood. This thesis focused on identifying the molecular interactors involved in regulating the 
HDL and LDL uptake and transport through the endothelial cells.  
In the present thesis based on a hypothesis or candidate driven approach, the role of sphingosine-1-
phosphate and its cognate receptors known to regulate the endothelial barrier function have been 
investigated with respect to their effect on the transendothelial transport of HDL and LDL. We used 
pharmacological inhibitors and agonists against S1P1 and S1P3, which are the two S1P receptors mainly 
expressed in the human aortic endothelial cells (HAECs). The treatment of the endothelial cells with 
either S1P1 or S1P3 agonist increased the cellular binding, uptake and transport of HDL by up-
regulating the translocation of SR-BI from cytosol to the plasma membrane. In contrast, the treatment 
of cells with either S1P1 or S1P3 agonist decreased the LDL transport through HAECs. However, 
treatment with either S1P1 or S1P3 inhibitor increased the transport of LDL across the HAECs involving 
different mechanisms. Inhibition of S1P1 increased the transport of LDL through fluid-phase whereas 
the S1P3 increased the LDL transport through an unknown candidate. Therefore, through this study we 
identified that S1P1 and S1P3 regulate the transport of HDL and LDL through HAECs in an antagonistic 
manner. 
Next, using a hypothesis-free approach we focused on investigating the role of signaling kinases in 
regulating the uptake of HDL and LDL by HAECs. We performed a microscopy based high-content 
screening in HAECs with 141 kinase inhibitor small compound drugs. The screen identified the limiting 
role of vascular endothelial growth factor (VEGFR) in regulating the uptake of HDL but not LDL 
through HAECs. Interestingly, the biochemical validation studies have not only confirmed the 
involvement of VEGFR2 in the transport of HDL but also identified that vascular endothelial growth 
factor (VEGF) is required for the localization of SR-BI to the plasma membrane. The presence of VEGF 
was also found to affect the cellular binding, uptake and transport of HDL through downstream signaling 
kinases PI3K/Akt and p38 MAPK.  
Lastly, we validated the role of VEGF on the uptake of lipoproteins through clear-cell renal cell 
carcinoma (ccRCC), which is a major form of renal cancer driven by increased VEGF activity. To 
understand the pathogenetic basis of cholesterol accumulation and hence the histological appearance of 
ccRCC, we investigated the expression of (apo)lipoproteins and receptors in tumors as well as the uptake 
of HDL and LDL by cultivated RCC cells. Interestingly, the ccRCC cell line showed enhanced uptake 
of both HDL and LDL via SR-BI into a non-degrading compartment in response to the increased VEGF 
activity.  
Currently, lipid-lowering strategies are implemented widely for the prevention and treatment of 
atherosclerotic vascular diseases. The data of our work point to the regulation of lipoprotein uptake and 
transport through endothelial and tumor cells as additional potential targets for treatment or prevention 
of atherosclerosis and cancer, respectively. 
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Zusammenfassung 
Atherosklerose, die häufigste Todesursache weltweit, ist eine chronische, entzündliche Gefässkrankheit. 
Charakteristisch für diese Erkrankung ist die Einlagerung von Cholesterin aus Lipoproteinen in die 
Arterienwand. Sowohl die pro-atherogenen Low Density Lipoproteine (LDL) als auch die anti-
atherogenen High Density Lipoproteine (HDL) passieren die intakte innerste Schicht der Blutgefässe, 
das Endothelial. Am Transport von HDL durch das Endothel sind mehrere Proteine beteiligt: der ATP 
binding cassette transporter G1 (ABCG1), der Scavenger Rezeptor BI (SR-BI), die Endotheliale Lipase 
(EL) sowie die ektopisch exprimierte β-ATPase. Am Transport von LDL ist neben SR-BI auch Activin 
Like Kinase 1 (ALK1) beteiligt. In dieser Arbeit wurde untersucht wie Aufnahme und Transport von 
HDL und LDL durch reguliert wird.  
In einem ersten Teil wurde die Rolle von Sphingosine-1-Phosphate (S1P) im transendothelialen 
Transport von HDL und LDL analysiert. S1P ist ein wichtiger Modulator der Barrierenfunktion des 
Endothels. Die aus menschlicher Aorta isolierten Endothelzellen (HAEC) exprimieren zwei der fünf 
bekannten S1P Rezeptoren, S1P1 und S1P3. Mit Hilfe von spezifischen pharmakologischen Inhibitoren 
und Agonisten wurde deren Beitrag zur Regulation von Aufnahme und Transport von HDL und LDL 
durch Endothelzellen analysiert. Die Zugabe von spezifische Agonisten für S1P1 und S1P3 verstärkte 
die Bindung, Internalisierung sowie den Transport von HDL. Weitere Untersuchungen zeigten, dass die  
S1P Agonisten die Expression von SR-BI in der Zellmembran verstärkt und dadurch die Bindung und 
Aufnahme von HDL verstärkt. Bindung, Aufnahme und Transport von LDL wurde durch die Zugabe 
von spezifischen S1P1 oder S1P3 Agonisten verringert und durch Inhibitoren von S1P1 oder S1P3 
verstärkt. Durch die Blockierung von S1P1 erfolgte die LDL-Aufnahme via fluid-phase Endozytose.  
Die Blockierung von S1P3 resultierte in einem erhöhten LDL Transport, jedoch unabhängig von fluid-
phase Endozytose oder SR-BI. Insgesamt zeigten die Untersuchungen, dass S1P1 und S1P3 den 
transendothelialen Transport von HDL und LDL antagonistisch regulieren. 
Im einem zweiten Teil wurde untersucht, welche Kinase-Signalwege an der Aufnahme von HDL und 
LDL in HAEC beteiligt sind.  In einem Hochdurchsatz-Screen mit vollautomatischen Mikroskopen 
wurde die Aufnahme von Fluoreszenz markierten HDL und LDL in Gegenwart von Kinase Inhibitoren 
in primären HAEC untersucht. Die Wirkung von 141 klein-molekularen Kinase Inhibitoren wurde bei 
7 verschiedenen Konzentrationen analysiert. Diese Untersuchungen identifizierten den Vascular 
Endothelial Growth Factor Receptor (VEGFR) als wichtigen Regulator für die Aufnahme von HDL aber 
nicht LDL in HAEC.  In den biochemischen Validierungsexperimenten wurde gezeigt, dass von den 
drei VEGF-Rezeptoren (nur VEGFR2 für die Regulation der HDL Aufnahme wichtig ist. Durch 
Aktiiverung von VEGFR2 stimuliert VEGF die Translokalisation von SR-BI aus dem Zytosol in die 
Plasmamembran. Weiter wurde gezeigt, dass VEGF via die Signalkinasen PI3K/Akt und p38 MAPK, 
HDL Bindung, Internalisation sowie Transport reguliert.  
Im letzten Teil wurde die Rolle von VEGF in der Lipoprotein Aufnahme im klarzelligen 
Nierenkarzinom (clear-cell renal cell carcinoma (ccRCC)) untersucht.  Diese häufigste Form des 
Nierenkrebs ist sehr häufig durch somatische Mutationen im Von-Hippel-Lindau-Gen verursacht, 
welche zu einer unkontrollierten Produktion von VEGF führen. Das namengebende Charakteristikum 
des ccRCC ist die Akkumulation von Cholesterin ist dieser Zellen, deren Ursprung aber nicht bekannt 
ist.  Unsere Untersuchungen zeigten eine Akkumulation von ApoA-I und ApoB sowie eine starke 
Expression von SR-BI in ccRCC. In Zellkultur, internalisieren ccRCC Zellen HDL und LDL via SR-
BI. Auch in diesen Zellen stimuliert VEGF die Translokalisation von SR-BI vom Zytoplasma an die 
Zelloberfläche und so die Aufnahme von Lipoproteinen. Weitere Analysen zeigten, dass die 
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Tumorzellen die aufgenommenen Lipoproteine weder abbauen noch ausscheiden können.  In 
Kombination erklären diese Befunde die Lipidakkumulation im ccRCC. 
Lipidsenkende Strategien werden bereits im grossen Umfang für die Prävention und Behandlung von 
atherosklerotischen Gefässkrankheiten eingesetzt. Die Ergebnisse dieser Arbeit weisen darauf hin, dass 
auch die Aufnahme und der Transport von Lipoproteinen durch das Endothel und Karzinomzellen 
interessante therapeutische Ziele sind. 
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Abbreviations 
ABC transporter: ATP binding cassette transporter 
AJ: Adherens junction 
Akt: Protein Kinase B 
ALK1:  Activin like kinase 1 
apoA-I: Apolipoprotein A-I 
apoB: Apolipoprotein B 
ccRCC: Clear-cell renal cell carcinoma 
CE: Cholesterol ester 
CETP: Cholesteryl ester transfer protein 
CVD: Cardiovascular disease 
EC: Endothelial cells 
EL: Endothelial lipase 
eNOS: Endothelial nitric oxide synthase 
ERK: Extracellular signal-related kinases 
FITC: Fluorescein isothiocyanate 
GLUT: Glucose transporter 
GPCR: G protein-coupled receptor 
HAEC: Human aortic endothelial cells 
HDL: High-density lipoprotein 
HL: Hepatic lipase 
HIF-α: Hypoxia-inducible factor 
IDL: Intermediate-density lipoprotein 
IDOL: Inducible degrader of the LDL receptor 
kDa: Kilo daltons 
LCAT: Lecithin-cholesterol acyl transferase 
LDL: Low-density lipoprotein 
LDLR: Low-density lipoprotein receptor 
LRP: LDL receptor related protein 
MAPK: Mitogen-activated protein kinase 
MEK: Mitogen-activated protein kinase kinase 
NO: Nitric oxide 
NPCL1: Niemann-Pick C1-like 1 
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NRP1: Neuropilin 1 
NS control: Non-silencing control 
PCSK9: Proprotein convertase subtilisin/kexin type 9 
PDZK1: PDZ domain containing 1 
PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PLTP: Phospholipid transfer protein 
p38 MAPK: p38 mitogen-activated protein kinase 
S1P: Sphingosine-1-phosphate 
S1PR: Sphingosine-1-phosphate receptor 
SREBP: Sterol regulatory element binding protein 
SR-BI: Scavenger receptor class B type 1 
VEGF: Vascular endothelial growth factor 
VEGFR: Vascular endothelial growth factor receptor 
VHL: von-Hippel Lindau 
VLDL: Very low-density lipoprotein 
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1.  Introduction 
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1.1 Cholesterol Metabolism 
Biological significance of cholesterol 
The name cholesterol originates from Greek words chole (bile) and stereos (solid) and the suffix –ol for 
alcohol (Figure 1). Cholesterol was discovered by François Poulletier de la Salle in bile and gallstones 
in the year 1769 1. Since then, it has been connected to numerous human diseases such as atherosclerosis, 
Alzheimer's disease and diverse malformative syndromes. At a cellular level, cholesterol is found in 
membranes, where it increases both bilayer stiffness and impermeability for water and ions. 
Furthermore, cholesterol is integrated into specialized lipid-protein membrane microdomains with 
critical topographical and signaling functions. At an organismal level, cholesterol is the precursor for all 
steroid hormones, including gluco- and mineralo-corticoids, sex hormones and vitamin D, all of which 
regulate carbohydrate, sodium, reproductive and bone homeostasis, respectively. This sterol is also the 
precursor for bile acids, which are important for intestinal absorption of dietary lipids as well as energy 
and glucose metabolic regulation 2. The undisputed biomedical importance of cholesterol continuous to 
fuel the molecular and cell biological research into this molecule. 
                                      
Figure 1: Two-dimensional chemical structure of cholesterol. (Source: PubChem) 
Sources of cellular cholesterol 
In humans, the body cholesterol is derived from two sources – diet and de novo synthesis. The 
contribution of de novo cholesterol synthesis versus dietary intake for total body cholesterol has been 
estimated as a ratio of 70:30. In principle, this probably varies considerably between individuals, 
depending both on the genetic constitution (effectiveness of cholesterol production versus absorption) 
and dietary cholesterol supply 3. 
De novo synthesis of cholesterol  
The elucidation of cholesterol's structure and synthesis was determined through the works of Nobel 
laureates H.O Wieland (1927), L. Ruzicka (1939), R. Robinson (1947), K. Bloch and F. Lynen (1964) 
and J. W. Cornforth (1975) 4, 5. 
Cholesterol is synthesized in the endoplasmic reticulum (ER) by the action of more than 30 enzymes. 
The first part of this pathway involves four fundamental steps (Figure 2): 1) condensation of three acetyl-
CoA units to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA); 2) HMG-CoA reduction mediated 
by NADPH to generate mevalonate (a 30-carbon linear molecule); 3) conversion of mevalonate into 
activated isoprenoids 3-isopentenyl pyrophosphate and dimethylallyl pyrophosphate; and 4) 
polymerization of six isoprenoids units into squalene. Next, linear squalene undergoes series of 
oxygenation and cyclization steps to form lanosterol, and finally, lanosterol is converted to cholesterol 
by sequential oxidative demethylations and double bond isomerizations and reductions. The rate-
limiting reaction in cholesterol biosynthesis is the conversion of HMG-CoA into mevalonate catalyzed 
by HMG-CoA reductase (HMG-CoA-R). This enzyme is tightly regulated at both transcriptional and 
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post-translational levels and is the pharmacological target of statins, currently, the most widely used 
cholesterol lowering agents5.  
                            
Figure 2: Overview of the metabolic and transport pathways that control cholesterol levels in mammalian 
cells. Cholesterol is synthesized from acetyl-CoA and four key enzymes that regulate cholesterol synthesis are 
indicated. Cells also obtain cholesterol by uptake and hydrolysis of LDL (low-density lipoprotein) cholesteryl 
esters (CE). End products derived from cholesterol or intermediates in this pathway include bile acids, oxysterols, 
cholesteryl esters and non-steroidal isoprenoids. ACAT: acyl-CoA:cholesterol acyltransferase. 
Regulation of cholesterol homeostasis 
Cholesterol may be deleterious or even lethal for cells and many protective mechanisms have evolved 
to prevent this cellular toxicity. The underlying causes of cholesterol's cytotoxicity are not completely 
clear, but may include: 1) abnormalities in the conformational plasticity of membrane proteins, 2) 
increased production of oxysterols by oxidative stress, 3) intracellular cholesterol crystallization leading 
to mechanical membrane disruption, and 4) increased apoptosis 6. Cellular cholesterol is kept within 
homeostatic levels by the concerted action of both transcriptional and post-transcriptional mechanisms. 
At the transcriptional level (Figure 3), sterol regulatory element binding protein (SREBP), a membrane 
bound member of the basic helix-loop-helix family of transcription factors, controls the gene expression 
of  multiple genes of the mevalonate pathway 7. SREBP-cleavage activating protein (SCAP), a multi-
spanning ER membrane protein, directly binds cholesterol and interacts with SREBP and other ER 
proteins to regulate SREBP activation. Specifically, when ER cholesterol levels are high, SCAP 
physically interacts with insulin-induced genes 1 and 2 (INSIG1 and INSIG2) and the SCAP/SREBP 
complex is retained in the ER preventing its translocation towards the golgi 8, 9. In contrast, when 
cholesterol levels are low, the SCAP-INSIGs interaction is abolished, and the SCAP/SREBP complex 
is transported into the golgi, where SREBP is released from the membrane by the sequential action of 
site-1 and site-2 proteases (S1P and S2P, respectively). This mature membrane-free SREBP is 
translocated into the nucleus where it binds to sterol responsive element (SRE) sequences of target 
genes, activating their transcription 10.  
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Figure 3: The SREBP pathway. When mammalian cells are deprived of cholesterol, SCAP escorts SREBPs from 
ER to Golgi. Two Golgi proteases (S1P and S2P) then sequentially cleave SREBP, releasing the active NH2-
terminal transcription factor domain, which travels to the nucleus and activates genes involved in the cholesterol 
synthesis and uptake. High sterol levels trigger the binding of SCAP to an ER retention protein, INSIG. Transport 
of SREBP to Golgi and subsequent transcriptional activation is then blocked 11. 
Further, the acetylation (increased by p300 12, and reduced by sirtuin 1 (SIRT1)) prevents the rapid 
degradation of SREBPs13.Deacetylation of SREBPs facilitates the action of ubiquitin ligases, thus 
resulting in proteosomal degradation 14, 15. Small ubiquitin-like modifier 1 (SUMO-1) mediates 
degradation of SREBPs independently of the 26S proteasome 16. The transcription of SREBPs also 
stimulates the expression of intronic micro-RNAs -33a and -33b, which lie within the genomic sequence 
of Srebf-2 and Srebf-1. Array of the targets of miRNA 33a suppresses the translation of ATP binding 
cassette transporter A1 (ABCA1) and thereby limiting the efflux of cholesterol from the cell. This 
response ensures that newly synthesized cholesterol remains within the cell, rather than effluxed to 
extracellular acceptors. Indeed, a number of microRNA sequences are involved in the regulation of 
cholesterol homoeostasis, either directly, by repressing the expression of genes and proteins involved in 
cholesterol synthesis and transport, or indirectly, by modulating the lipid metabolism and energy status 
of the cell 17. 
HMG-CoA reductase is additionally regulated at the post-translational level. When cholesterol 
concentration in the endoplasmic reticulum is high, HMG-CoA reductase directly binds to cholesterol 
and to a membrane ubiquitin ligase, gp78. This interaction results in HMG-CoA reductase 
polyubiquitination and subsequent 26S proteasome-mediated degradation. Conversely, when the 
cholesterol levels are low in the ER, turnover of HMG-CoA reductase protein is reduced because of 
decreased polyubiquitination and proteosomal degradation 9, 18. The activity of HMG-CoA reductase is 
also controlled by 5΄-AMP-activated protein kinase (AMPK), that senses the energy status of the cell, 
and suppresses sterol synthesis following increases in the AMP/ATP ratio 19.  
Cholesterol transfer between tissues 
Like other lipids, cholesterol is hydrophobic and mostly insoluble in blood. Therefore, it requires 
transport within lipoproteins, which possess amphipathic surface proteins (apolipoproteins) that together 
with phosphatidyl cholines mediate the solubilization of lipids in the aqueous phase and are cofactors 
and ligands for lipid-processing enzymes. Lipoproteins are classified (Table I) by size and density. The 
differences in their densities arise from two circumstances 20.  
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1. Lipids are lighter than protein. Within the particles, proteins are found only at the surface, whereas 
the interior contains only lipids; therefore, the fractional content of protein is lower with larger 
particles than with smaller ones. Chylomicrons are the largest and least dense lipoprotein species. 
2. Triacylglycerol is lighter, but cholesterol is heavier than water. Accordingly, a high content of 
cholesterol in the lipid fraction will also increase the overall density. 
Lipoprotein Density (kg/L) Diameter 
(nm) 
% proteins Predominant apolipoproteins 
Chylomicron < 0.95 100-1000 < 2 A-I & II, B48, C-I, II, III, E, H 
VLDL 0.95-1-006 30-80 10 B100, C-I, C-II, C-III, E 
IDL 1.006-1.019 25-50 18 B100, C-II, C-III, E 
LDL 1.019-1.063 18-28 25 B100 
HDL > 1.063 5-15 33 
A-I, A-II, A-IV, C-I, C-II, C-III, 
C-IV, D, E, F, H, J, L-I, M 
 
Table I: Classification of lipoproteins based on their density, diameter, protein percentage and apolipoprotein 
composition. 
1.2 Lipoprotein metabolism 
Lipoprotein metabolism is differentiated into the exogenous or endogenous pathways, depending 
whether the particles transport lipids of dietary or hepatic origin.  
Exogenous (dietary) lipid metabolism 
Triglycerides are the major lipids found in the human diet, contributing to 90-95% of energy provided 
by dietary fat, and the remaining are phospholipids, free fatty acids, cholesterol and fat-soluble vitamins 
21. Triglycerides from the diet are digested in the gastrointestinal tract to form monoglycerides and free 
fatty acids through various processes, including bile emulsification, gastric lipase, and pancreatic lipase 
22. Similarly, cholesterol esters from the diet undergo a process of de-esterification to form cholesterol 
and free fatty acids. Monoglycerides, free fatty acids and cholesterol are soluble in the bile acid micelles 
and can be absorbed from the chymus into the enterocytes by specific transporters (NPCL1, CD36, 
FABP). Inside the enterocytes, lipids are re-esterified into triglycerides, cholesterol esters and 
phospholipids. The microsome triglyceride transfer protein helps to assemble the lipids with 
Apolipoprotein B-48 to form chylomicrons. Chylomicrons are associated with other apolipoproteins 
ApoA-II and Apo-C’s and then secreted into the lymph of the thoracic duct. Thereby they reach the vena 
cava superior and hence the blood circulation 23. 
In the capillaries of adipose and muscle tissue, apolipoprotein C-II (apo C-II) on the chylomicron 
activates lipoprotein lipase (LPL) to convert 90% of chylomicron triglycerides to fatty acids and 
glycerol, which are taken up by adipocytes and muscle cells for energy storage 24. 
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) is an 
endothelial cell protein that is needed for basolateral to apical transport of LPL25. Depleted of 
triglycerides and enriched in cholesterol, chylomicron remnants are transported to the liver to be cleared 
from the body. Apolipoprotein E (apo E) serves as a ligand of multiple receptors LDLR 26, VLDLR 27, 
syndecan-1 (HSPG) 28 , LRP1, LRP5 29 and SR-BI 30.  
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Figure 4: Schematic representation of exogenous and endogenous lipoprotein metabolism pathways. 
Cholesterol in the circulation will originate either from the exogenous or endogenous pathway. Dietary cholesterol 
and fat are transported in the exogenous pathway. All cholesterol will be packaged into lipoprotein particles as 
part of their metabolism pathway and covered with a specific complement of apolipoproteins. As part of the 
endogenous pathway, the liver is responsible for the packaging of VLDL particles which are hydrolyzed by IDL, 
returned to the liver so that they may be repackaged as LDL then taken from the circulation by peripheral tissues. 
(Soure: Walker.R and Williams H, Dyslipidaemia, Chapter 24, Clinical gate) 
Endogenous lipid metabolism 
Lipoproteins synthesized by the liver transport endogenously synthesized triglycerides and cholesterol. 
VLDL circulate through the blood continuously until the triglycerides are cleared by peripheral tissues 
or the lipoproteins themselves are cleared by the liver. Factors that stimulate hepatic lipoprotein 
synthesis generally lead to elevated plasma cholesterol and triglycerides levels. 
Very-low-density lipoproteins (VLDL) contain apoprotein B-100 (apo B), are synthesized in the liver, 
and transport triglycerides to peripheral tissues. Microsomal triglyceride transfer protein (MTP) is an 
intracellular lipid-transfer protein found in the endoplasmic reticulum. It is essential for the transfer of 
the lipid molecules (principally triglycerides) onto apolipoprotein (apo) B 100 31. VLDL is the way the 
liver exports excess triglycerides that are endogenously synthesized or taken up from plasma as albumin 
bound free fatty acids or chylomicron remnants; VLDL synthesis increases with increase in intrahepatic 
free fatty acids, for example due to high-fat diets or  excess adipose tissue release of free fatty acids 
directly into the circulation (eg, in obesity, uncontrolled diabetes mellitus). Apo C-II on the VLDL 
surface activates LPL in the capillaries of adipose tissue or muscle tissue to break down triglycerides 
into free fatty acids and glycerol, which are taken up by cells 32. 
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Intermediate-density lipoproteins (IDL) are the product of LPL-mediated processing of VLDL. IDL 
are rich in cholesterol and either cleared by the liver or metabolized by hepatic lipase into LDL. 
Low-density lipoproteins (LDL), are the final products of VLDL and IDL metabolism and the most 
cholesterol-rich of all lipoproteins. LDL particles contain a core of cholesterol esters, lesser amounts of 
triglyceride, and  apolipoprotein B-100, which is the ligand for binding to the LDL receptor 33. About 
90% of all LDL are cleared by the liver in a process mediated by apo B and hepatic LDL receptors. The 
rest are taken up by either hepatic LDL or nonhepatic non-LDL (scavenger) receptors. After binding to 
the LDL receptor on the surface of the hepatocyte, LDL particles are internalized through clathrin-coated 
pits, in a process dependent on the presence of an NPXY sequence in the cytoplasmic tail of LDLR 34. 
Upon fusion of these vesicles with early endosomes, the decrease in pH induces the dissociation of LDL 
from their receptor 35, 36. LDLR is either recycled back to the cell surface. However, when proprotein 
convertase subtilisin/kexin type 9 (PCSK9) binds to the LDLR, PCSK9 prevents the conformational 
change of the receptor-ligand complex. This inhibition redirects the LDLR to the lysosome instead of 
recyling 37. The LDL particle then is targeted to lysosomes where cholesterol is made available again by 
hydrolysis of the cholesteryl esters. LDLR expression is transcriptionally regulated in response to 
intracellular cholesterol concentrations. When cholesterol levels are low, membrane-bound precursors 
of sterol regulatory element-binding proteins (SREBPs) are transported from the ER to the Golgi 38, 39. 
Following a two-step proteolytic cleavage event, SREBPs are released from the Golgi membrane and 
translocated to the nucleus where they activate the transcription of genes, including the LDLR and 
HMG-CoA reductase, the ratelimiting enzyme in cholesterol biosynthesis. When cholesterol levels are 
elevated, ER-to-Golgi transport of SREBP is prevented. The cholesterol-sensing chaperone SCAP (for 
SREBP cleavage-activating protein) that escorts SREBPs towards the Golgi plays a key role in this 
regulation mechanism 40. Additionally, elevated levels of cellular cholesterol activates the sterol-sensing 
nuclear, liver X receptors, and transcriptional induction of one of their target gene, inducible degrader 
of the LDL receptor (IDOL) 41, 42. IDOL is an E3-ubiquitin ligase that binds to the LDLR, promotes its 
poly-K63-linked ubiquitylation, and ultimately leads to lysosomal degradation of the receptor 43, 44. 
Thus, the LXR-IDOL-LDLR axis offers cells an efficient mechanism, which circumvents the SREBP 
transcriptional pathway and the long half-life of the LDLR, to limit cholesterol uptake 45.  
The size of LDL particles varies from large and buoyant to small and dense. Small, dense LDL is 
especially rich in cholesterol esters, is associated with metabolic disturbances such as 
hypertriglyceridemia and insulin resistance, and is especially atherogenic. The increased atherogenicity 
of small, dense LDL derives from less efficient hepatic LDL receptor binding, leading to prolonged 
circulation and exposure to endothelium and increased oxidation 46.Nonhepatic scavenger receptors, 
most notably on macrophages, take up excess modified LDL not processed by hepatic receptors. 
Macrophages then take up modified LDL and form foam cells within atherosclerotic plaques 47.  
Lipoprotein (a) [Lp(a)]  Lp(a) is a specialized form of LDL that is assembled extracellularly from 
apolipoprotein (a) and LDL 48. Apo(a) links to apolipoprotein B-100 on the surface of LDL by disulfide 
bridges. The formation of apo(a):apo B complexes requires an LDL particle of a certain morphology 
and composition. The apo(a) chain contains domains known as kringles IV and V that are homologous 
with the fibrin-binding domains of plasminogen. Through this structural similarity to plasminogen, 
Lp(a) interferes with fibrinolysis by competing with plasminogen binding to plasminogen receptors, 
fibrinogen, and fibrin. The net effect is impaired plasminogen activation and plasmin generation at the 
thrombus surface, leading to decreased thrombolysis. Lp(a) can also bind to macrophages via a high-
affinity receptor, possibly promoting foam cell formation and localization of Lp(a) at atherosclerotic 
plaques 49, 50. Studies have shown that scavenger receptor BI binds and promotes cellular uptake of 
Lp(a), in particular selective lipid uptake of cholesteryl esters from Lp(a) 51. 
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High-density lipoproteins (HDL) are initially cholesterol-free lipoproteins that are synthesized by both 
enterocytes and hepatocytes. The role of HDL is to obtain cholesterol from peripheral tissues and other 
lipoproteins and transport it to where it is needed most—other cells, other lipoproteins (using cholesteryl 
ester transfer protein [CETP]), and the liver (for clearance) in a process called reverse cholesterol 
transport (Figure 5). Efflux of free cholesterol from cells is mediated by ATP-binding cassette 
transporter A1 (ABCA1) and converts lipid-free apoprotein A-I (apo A-I) into nascent discoidal HDL 
52. Nascent HDL acquires additional cholesterol and phospholipids via ABCA1 and ABCG1 mediated 
efflux 53. Free cholesterol in nascent HDL is then esterified by the enzyme lecithin-cholesterol acyl 
transferase (LCAT), producing mature HDL54. The phospholipid transfer protein (PLTP) mediates the 
phospholipid transfer from triglyceride-rich lipoproteins (chylomicrons and VLDL) to HDL 55.  Hepatic 
lipase (HL) and endothelial lipase (EL) remodel HDL by hydrolysing triglycerides and phospholipids 
56. HDL cholesterol is delivered back to the liver via interaction with scavenger receptor BI (SR-BI) 
which results in selective uptake of lipids 57 or via the CETP which mediates the exchange of cholesteryl 
esters from the core of HDL against triglycerides from apoB-containing lipoproteins (LDL, IDL, VLDL, 
and chylomicrons) 54. Cholesteryl esters from LDL are delivered to the liver via the LDL receptor. The 
cholesteryl esters are hydrolyzed in the hepatocytes to cholesterol, which are either recycled back 
entering the ABCA1 pathway, secreted in the bile as bile acids, or reassembled into lipoproteins that are 
secreted into the circulation 58.  
 
Figure 5: Schematic overview of HDL metabolism. Small discoidal high-density lipoprotein (HDL) particles 
are generated by the liver and intestine. Free cholesterol (FC) from macrophage foam cells is effluxed to these 
particles by ATP-binding cassette transporter A1 (ABCA1). Through the action of lecithin:cholesterol 
acyltransferase (LCAT), these particles mature and become spherical; ABCG1 and scavenger receptor class B 
type I (SR-BI) add more cholesterol onto these larger HDL. EL and HL hydrolyze HDL phospholipids and 
phospholipids/triglycerides (TG), respectively, thereby destabilizing the particle, resulting in shedding of poorly 
lipidated apolipoprotein (apo) A-I that is subject to clearance by the kidneys. Cholesteryl ester from these HDL 
particles becomes more susceptible towards SR-BI—mediated selective uptake. In turn, selective uptake is also 
required for HDL remodeling by these lipases to continue. Via SR-BI, HDL cholesterol enters the hepatic 
cholesterol pool and can either be directly secreted as free cholesterol into bile and feces or after metabolic 
conversion into bile acids. Cholesteryl ester transfer protein (CETP), mediates the hetero-exchange of 
cholesteryl ester (CE) originating from HDL with triglycerides originating from apoB-containing lipoproteins. 
On the other hand, cholesterol transferred to apoB-containing lipoproteins can be taken up into the liver via 
low-density lipoprotein receptors (LDLR) and then enters the hepatic cholesterol pool  59.  
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1.3 Arterial wall and atherogenesis 
The normal artery contains three layers (Figure 6) namely, intima, media and outer adventitia. The inner 
layer closest to the arterial lumen, the tunica intima, is lined by a monolayer of endothelial cells that is 
in contact with blood and overlies a basement membrane. The endothelium functions as an active 
metabolic barrier between blood and the arterial wall. In contrast to many animal species used for 
atherosclerosis experiments, the human intima contains resident smooth muscle cells (SMCs). The 
intima also consists of connective tissue which is composed of a matrix of collagen, proteoglycans and 
elastin. The middle layer, or tunica media, contains SMCs embedded in a complex extracellular matrix 
with contractile and synthetic function. As for the contractile function, SMCs enable vasoconstriction 
and vasodilatation. The arteries often studied in experimental atherosclerosis are elastic arteries, which 
have clearly demarcated laminae in the tunica media, where layers of elastin lie between strata of SMCs. 
The adventitia, the outer layer of arteries, contains fibroblasts, mast cells, nerve endings and vasa 
vasorum60. There is a constant dynamic interchange between the arterial wall and its cellular components 
and the surrounding extracellular matrix. By understanding the physiology of this dynamic interchange 
and the function of each cellular component, the dysfunction of these cellular components leading to 
atherogenesis can be better understood.  
 
Figure 6: Schematic representation of distinct layers of arterial wall. Left image depicts the top-view of layers 
of the artery and the right image depicts the cross-sectional view of layers in artery 61. 
Lipoproteins and atherosclerosis 
Atherosclerotic disease is the major cause of cardiovascular death worldwide, and although it is a 
complex process in which various environmental and genetic factors are involved, the deposition of 
lipoprotein-derived cholesterol in the arterial wall is the priming condition necessary for more advanced 
lesions 62. Atherogenesis can be divided into five key steps (Figure 7), which are 1) endothelial 
dysfunction, 2) formation of lipid layer or fatty streak within the intima, 3) migration of leukocytes and 
smooth muscle cells into the vessel wall, 4) foam cell formation and 5) degradation of extracellular 
matrix.   
The earliest readily visible atherosclerotic lesion is the fatty streak that forms within the subendothelial 
space 63.Arterial endothelial cells, which normally resist to the attachment of the circulating blood cells, 
express adhesion molecules that capture leukocytes on their surfaces when subjected to irritative stimuli 
such as dyslipidaemia, hypertension or pro-inflammatory mediators 64, 65. Parallel changes in endothelial 
permeability and the composition of the extracellular matrix beneath the endothelium promote the entry 
and retention of cholesterol-containing LDL particles in the artery wall 66. This critical initiating event 
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sparks an inflammatory response leading to monocyte recruitment into the intima, where they 
differentiate into macrophages and internalize native and modified lipoproteins, resulting in foam cell 
formation 67, 68.  
Figure 7: Stages in the development of atherosclerotic lesions. The normal muscular artery and the cell changes 
that occur during disease progression to thrombosis are shown. a, The normal artery contains three layers. The 
inner layer, the tunica intima, is lined by a monolayer of endothelial cells that is in contact with blood overlying a 
basement membrane. In contrast to many animal species used for atherosclerosis experiments, the human intima 
contains resident smooth muscle cells (SMCs). The middle layer, or tunica media, contains SMCs embedded in a 
complex extracellular matrix. Arteries affected by obstructive atherosclerosis generally have the structure of 
muscular arteries. The arteries often studied in experimental atherosclerosis are elastic arteries, which have clearly 
demarcated laminae in the tunica media, where layers of elastin lie between strata of SMCs. The adventitia, the 
outer layer of arteries, contains mast cells, nerve endings and microvessels. b, The initial steps of atherosclerosis 
include adhesion of blood leukocytes to the activated endothelial monolayer, directed migration of the bound 
leukocytes into the intima, maturation of monocytes (the most numerous of the leukocytes recruited) into 
macrophages, and their uptake of lipid, yielding foam cells. c, Lesion progression involves the migration of SMCs 
from the media to the intima, the proliferation of resident intimal SMCs and media-derived SMCs, and the 
heightened synthesis of extracellular matrix macromolecules such as collagen, elastin and proteoglycans. Plaque 
macrophages and SMCs can die in advancing lesions, some by apoptosis. Extracellular lipid derived from dead 
and dying cells can accumulate in the central region of a plaque, often denoted the lipid or necrotic core. Advancing 
plaques also contain cholesterol crystals and microvessels. d, Thrombosis, the ultimate complication of 
atherosclerosis, often complicates a physical disruption of the atherosclerotic plaque. Shown is a fracture of the 
plaque's fibrous cap, which has enabled blood coagulation components to come into contact with tissue factors in 
the plaque's interior, triggering the thrombus that extends into the vessel lumen, where it can impede blood flow 
69. 
Internalization of the apoB containing lipoproteins by macrophages promotes foam cell formation, 
which is the hallmark of the fatty streak phase of atherosclerosis 70, 71. Macrophage inflammation results 
in enhanced oxidative stress and chemokine secretion, causing more LDL oxidation, endothelial cell 
activation, monocyte recruitment, and foam cell formation 68, 72. More recently, uptake of cholesterol 
crystals has been linked to inflammation via the activation of the NLRP3 inflammasome, which might 
favour the amplification of a local and systemic immune-inflammatory response73 characterized by the 
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production of several proinflammatory cytokines; among them, Interleukin-6 (IL-6) and interleukin-1 
(IL-1) are well-established markers of inflammation and their possible causal role in atherosclerosis has 
been widely investigated 74, 75. Macrophage inflammatory chemoattractants stimulate proliferation and 
migration of smooth muscle cells infiltration into intima. Smooth muscle cells produce the extracellular 
matrix providing a stable fibrous barrier between plaque and the endothelium 76, 77. Eventually the 
apoptosis and defective efferocytosis of apoptotic cells results in the formation of necrotic core and 
increased smooth cell death, decreased extracellular matrix production, and collagen degradation by 
macrophage proteases. Rupture of the thinning fibrous cap promotes thrombus formation resulting in 
myocardial infarction, sudden cardiac death and stroke 78.  
Lipid-lowering strategy as a treatment for atherosclerosis 
The determination of the LDL pathway and the subsequent development of drug inhibitors of HMG-
CoA reductase, collectively known as statins, are conspicuous victories of cardiovascular science and 
medicine 79. But even in patients treated with statins, a considerable residual burden of cardiovascular 
risk remains 80. More than 20% of patients will have a recurrent event within 30 months of an acute 
coronary syndrome, despite receiving high-dose statin treatment 81. These findings indicate that 
treatments to decrease LDL-cholesterol levels even further, beyond the targets currently mandated by 
various national guidelines, could provide further clinical benefit. Unfortunately, at least one-quarter of 
high-risk patients who receive intensive statin therapy have LDL-cholesterol levels above current 
guideline-mandated goals82. New biological targets have emerged that may yield incremental lowering 
of LDL levels to a greater degree than that achieved by high-dose statin therapy. 
Ezetimibe, by inhibiting Niemann-Pick C1-Like 1 (NPC1L1), reduces the intestinal absorption of 
cholesterol and is utilized in clinical practice as monotherapy or when added to statins (Sudhop et al., 
2009), and has been extensively studied for the ability not only to decrease plasma LDL-C levels but 
also to improve the overall cardiovascular outcome. Two pooled analyses of randomized clinical trials, 
showed significant decrease in the LDL-C levels upon treatment with ezetimibe 83, 84.  
Genetic studies have shown that loss-of-function mutations in the gene that encodes the enzyme 
proprotein convertase subtilisin/kexin type 9 (PCSK9) augment LDL receptor levels on cell surfaces, 
boosting LDL clearance and yielding lower LDL concentrations in the blood 85. PCSK9 has emerged as 
an attractive target for lowering LDL-C levels to reduce the risk of coronary heart disease. Two anti-
PCSK9 monoclonal antibodies (alirocumab, evolocumab) subcutaneously administered either biweekly 
or monthly are currently being studied in phase III trials with large patient populations. By sequestering 
PCSK9, PCSK9 inhibitors block the binding of PCSK9 protein to LDLRs, preventing LDLR catabolism. 
In turn, this preserves LDLR recycling and increases receptor density on the hepatocyte surface 86. Both 
evolocumab and alirocumab lowered the LDL-cholesterol levels by 60% 87-90. Further Cardiovascular 
Outcome Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) clinical trial 
program showed that inhibition of PCSK9 with evolocumab on a background of statin therapy, lowered 
LDL cholesterol levels to a median of 30 mg per deciliter and reduced the risk of cardiovascular events 
91. Furthermore, the phase I trial of Inclisiran (Alnylam Pharmaceuticals, Inc, Cambridge, MA), a long-
acting RNA interference (RNAi) agent targeting the synthesis of PCSK9, showed no major adverse 
events as well as reductions of 75% and 51% in PCSK9 and LDL-C concentrations, respectively 92, 93. 
Thus, PCSK9 inhibitors are a promising therapeutic strategy to address additional reductions in LDL-C 
concentrations to reduce CVD in high-risk populations 94, 95. 
Plasma levels of Lp(a) are primarily genetically determined by variations in the LPA gene coding for 
Apo(a) 96. Because of the expanding evidence that high levels of Lp(a) are associated with the 
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cardiovascular disease risk, antisense oligonucleotide drugs targeting Apo(a) have emerged as a 
promising approach to reduce Lp(a) levels by 80% in the clinical setting 97.  ApoB is the backbone of 
all lipoproteins of the VLDL pathway. Interference with the transcription of the APOB gene was 
considered an attractive approach to decrease VLDL production and reduce the number of pro-
atherogenic LDL particles 98. These agents were identified to be very effective, but unfortunately were 
also associated with side effects and increased risk of liver steatosis in a significant proportion of treated 
patients 99. PCSK9 as well as CETP inhibitors lower Lp(a) levels by 30% through an unknown 
mechanism 100, 101. 
Consistent evidence has shown that HDL-C concentration is an independent inverse predictor of the risk 
for developing a cardiovascular event 102. Numerous approaches to increase HDL exist or are in 
development. Apolipoprotein A-I (Apo-AI), the major protein component of HDL, has received much 
attention as a possible therapeutic target for atherosclerosis 103-105. Several emerging therapeutic agents 
are also being designed to target HDL particles, not solely to increase HDL-C levels. These include 
intravenous infusions of HDL peptide mimetics. Three fully human HDL mimetic compounds are 
currently being evaluated in proof-of-concept clinical studies. Upon infusion, these drugs are expected 
to increase cholesterol efflux capacity106. Because of the heterogeneity in HDL particles, the complicated 
pathways of cholesterol flux mediated by HDL and the association of HDL with many proteins that may 
modify atherosclerosis, the steady-state levels of HDL cholesterol in blood reflect HDL function poorly 
107. In addition to mediating reverse cholesterol transport, HDL can exert anti-inflammatory properties 
both in vitro and in vivo 107. HDL particles carry dozens of proteins and hundreds of lipid species, many 
with biological activities that have relevance to atherogenesis 108. The lipid content of HDL particles can 
be remodeled for example by the plasma protein cholesteryl ester transfer protein (CETP) facilitates the 
exchange of cholesteryl esters in HDL for triglycerides from apolipoprotein-B-containing 
lipoproteins109, 110. The protein content of HDL particles can also be remodeled for example, when 
plasma levels of the acute-phase reactant serum amyloid A increase during inflammatory states 111. 
Typical clinical assays for HDL do not reflect this high degree of heterogeneity of the particles that 
influence plaque biology 112.Thus, the mere increase in HDL levels in response to some interventions 
may not necessarily confer clinical benefit, owing to qualitative changes in the particles.  
Of the approaches to increase HDL under study, the potential of CETP inhibition could be a novel 
therapeutic option for CVD. The CETP inhibitor torcetrapib failed in the clinic, probably owing to off-
target effects 113-115 and other CETP inhibitors, dalcetrapib, evacetrapib and anacetrapib, have entered 
clinical evaluation. In phase 2 studies, dalcetrapib increased HDL-C levels without any effects on LDL-
C levels 116. However, clinical evaluation of dalcetrapib was halted because of the compromised efficacy 
of the drug treatment. Similarly, evacetrapib was discontinued due to lack of efficacy even though the 
drug treatment increased HDL-C levels and decreased LDL-C levels 117. The safety of anacetrapib was 
recently affirmed by a phase III clinical trial, which provided evidence for reduced clinical events 118, 
119. Finally, TA-8995 (Amgen Inc, Thousand Oaks, CA) is a new promising CETP inhibitor. In the phase 
II trial in patients with mild dyslipidaemia (TULIP), treatment with TA-8995 showed significant 
reduction in the LDL-C and ApoB levels, whereas HDL-C and ApoA-I levels were significantly 
increased. Moreover, TA-8995 was well tolerated without any safety concerns or apparent adverse 
effects on the liver and muscle. In summary, CETP inhibitors exert beneficial effects on lipid parameters 
in patients with dyslipidemia 101. However, the potential of CETP inhibition to improve overall 
cardiovascular outcome appears to be moderate only.  
1.4 Endothelium and lipoproteins 
The vascular endothelium lines the inner surface of blood vessels and serves as the first interface for 
circulating blood components to interact with cells of the vascular wall and surrounding extravascular 
tissues. In addition to regulating blood delivery and perfusion, a major function of the vascular 
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endothelium is to provide a semipermeable barrier that controls blood–tissue exchange of fluids, 
nutrients, and metabolic wastes while preventing pathogens or harmful materials in the circulation from 
entering into tissues. Thereby, the endothelium has multiple roles including regulation of nitric oxide 
synthesis, monocyte diapedesis, lipid metabolism, and vessel growth and remodeling, thrombogenesis, 
platelet activation and inflammation 120-122. Endothelial cells are involved in all stages of the atherogenic 
process and their dysfunction is a key early event in the atherosclerotic plaque formation 123. 
Therefore, maintenance of endothelial layer is crucial as dysfunction of the endothelium leads to severe 
pathological conditions. 
      
Figure 8: Functions of healthy endothelium. The healthy endothelium mediates endothelium-dependent 
vasodilation, actively suppresses thrombosis, vascular inflammation, and hypertrophy. Adapted from 124 
Both lipoproteins and endothelium play critical roles in the initiation and progression of atherosclerosis. 
The endothelial transport and accumulation of pro-atherogenic LDL into the subendothelial space is 
followed by their modification, which leads to the activation of endothelial cells, upregulation of 
endothelial adhesion molecules, increase of oxygen radicals, effects on cell viability and apoptosis and 
to a cascade of events associated with the accumulation of cholesterol in the intima and progression of 
atherosclerosis 125. Therefore, removal of cholesterol from the subendothelial space by cholesterol efflux 
and subsequent reverse cholesterol transport confers protection against atherosclerosis 126.  Recently, 
much emphasis has been placed on oxidised-LDL (ox-LDL) as a major toxic lipoprotein which is 
recognised by LOX-1 expressed on endothelial cells and facilitates the internalization and transcytosis 
through the endothelium 127. Activation of LOX-1 by oxLDL induces endothelial dysfunction and 
apoptosis 128 and deletion of LOX-1was found to improve endothelial function leading to reduction in 
atherogenesis by decreasing proinflammatory and prooxidant signals 129. Furthermore, LOX-1 was 
shown to be expressed in atherosclerotic lesions, including endothelial cells 130.  
It has been documented that HDLs and their major protein constituent, apolipoprotein (ApoA-I), cross 
endothelial cells to reach subendothelial space to accept cholesterol from lipid-laden macrophages and 
re-enter the bloodstream to deliver cholesterol to the liver. The endothelial barrier is thus crossed twice 
in this process, making the endothelium a key player in the RCT process 131, 132. While mediating the 
transendothelial transport of ApoA-I and HDL particles, endothelial cells also efficiently efflux 
cholesterol to these acceptors 133, 134. There are four distinct cholesterol efflux pathways which have been 
described by which HDL and their apolipoproteins remove cholesterol from the cells, i.e., cholesterol 
transport mediated by ATP-binding cassette transporter A1 (ABCA1), ABCG1 and scavenger receptor 
class B type I (SR-B1) 135, and by passive cholesterol diffusion following a cholesterol concentration 
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gradient between the plasma membrane and HDL 136. The fact that all these receptors also mediate 
transcytosis indicated that the two processes happen together in the endothelial cells. 
Lipoprotein transport through endothelium 
Plasma lipoproteins pass the endothelial barrier several times during their metabolic turnover, from the 
site of their synthesis to the blood, further to the extravascular tissues, and then back into circulation 
(through vasa vasorum or lymphatic vessels) and finally to the catabolizing organs (liver). The 
lipoprotein transport through the endothelium was shown to play a major role in the pathogenesis of 
atherosclerosis. Imbalance between influx and efflux of pro-atherogenic and anti-atherogenic 
lipoproteins through the arterial wall seems as an important factor for the disease susceptibility 66, 137. 
The endothelium is highly permeable to water and small molecules, which are with a diameter below 
6nm and nearly impermeable to larger molecules. This relative impermeability of endothelium to 
macromolecules is a prerequisite for the maintenance of a fluid equilibrium between plasma and 
interstitium according to the classical Starling principle 138. However, the macromolecules are known to 
pass the endothelial barrier in a regulated manner and two major pathways have been identified in the 
endothelial cells (Figure 9): the paracellular pathway regulates transport through interendothelial 
junctions whereas the transcellular pathway regulates transport through the cell139.  
                          
Figure 9: Possible pathways for lipoprotein transport through endothelium. The paracellular transport is 
performed by opening interendothelial junctions (IEJ). The transcellular pathway is either through receptor-
dependent vesicular transport or through fluid-phase uptake in the endothelium. 
The paracellular permeability of the endothelial barrier is maintained by the interendothelial junctions, 
the structures that connect adjacent endothelial cells into a monolayer and restrict the movement of 
plasma macromolecules from the luminal side to the basolateral side of the vessel 140. Two types of 
interendothelial junctions are present in the endothelium, tight junctions (TJ) and adherens junctions 
(AJ), both contributing to the maintenance of the endothelial barrier. Therefore, paracellular transport 
requires opening and closing of these junctions, which is a tightly regulated process. Mediators that 
induce endothelial barrier enhancement and attenuate the response to permeability-increasing mediators 
are also required for regulation of endothelial permeability. They are present in blood plasma or enriched 
in the interstitium and provide continuous support for vascular integrity. Suppression of their signaling 
leads to severe impairment of the endothelial barrier and loss of vessel integrity 141, 142. Interestingly, 
sphingosine-1-phosphate (S1P) mediates endothelial barrier enhancement through activation of the 
Gi protein–coupled S1P1 receptor and protects the lung microvasculature from inflammation-induced 
injury 143. Genetic disruption of S1P1 resulted in embryonic lethality due to defects in the development 
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of the vascular system 144. Paracrine S1P signaling was also shown to induce AJ assembly 145. Since, 
HDL is known to carry more than 50% of plasma S1P and S1P is a regulator of endothelial barrier 
integrity146, 147; it is probable that HDL is transported through transcellular rather than paracellular 
pathway. 
Electron microscopy studies of rat aortas perfused with LDL showed its internalization into cellular 
vesicles and delivery either to the lysosomes or the basolateral membrane of the cell 148. The size of 
LDL precludes paracellular passage without the opening of inter-endothelial junctions, yet an intact 
endothelium is observed overlying early atherosclerotic lesions 149-151. Thus, a number of studies have 
suggested that LDL crosses the endothelium by transcytosis 152-155. Others have instead suggested that 
LDL exits the vasculature at areas of damaged or dividing endothelium, implicating the paracellular 
route. However, the rate of endothelial mitosis is extremely low (<0.05%), and there is scant to no in 
vivo evidence of endothelial apoptosis in human atherosclerosis 151, 156-158.  
               
Figure 10: Transendothelial transport of HDL and LDL. In the endothelial cells, LDL undergoes 
internalization dependent on LDLR, which leads to the degradation of LDL. But the transendothelial transport is 
modulated by SR-BI and ALK1. On reaching the intima, LDL undergoes modification and is taken up by 
macrophages through scavenger receptor A (SR-A) to form foam cells. The transport of mature HDL is mediated 
by SR-BI, ABCG1 and endothelial lipase (EL) to reach the intima and scavenge excess cholesterol from the foam 
cells. Adapted from 155, 159-163  
The transcellular pathway is the dominant pathway of transporting macromolecules in endothelial cells 
139 which can be receptor-independent through fluid-phase uptake or receptor-dependent involving 
clathrin-coated pits or caveolae 164. The classical LDL internalization through LDL-receptor was shown 
to be dependent on clathrin-coated pits. However, the LDL uptake was reduced by endothelial cells from 
the caveolin-1 knockout mice, which suggests that transendothelial transport of LDL involves caveolae 
rather than clathrin-coated pits 152. Immunohistochemical studies showed colocalization of fluorescent 
and gold-labeled HDL with caveolin-1 in  bovine aortic endothelial cells 165. Recent studies have shown 
that LDL transport through the endothelial cells to be modulated by SR-BI and activin-like kinase 
1(ALK1)159 155. Previous in vitro data from our group showed that aortic endothelial cells are able to 
specifically bind, internalize and transport HDL in a saturable and temperature-dependent manner. We 
also demonstrated that transendothelial transport of mature HDL to be modulated by ABCG1, SR-BI, 
and endothelial lipase (Figure 10) 160, 161. Recently our lab showed also that HDL was not colocalized 
with clathrin or caveolin-1, and blocking of Na+/H+-channels essential for any fluid phase transport by 
Amiloride and/or EIPA even at high concentrations did not change HDL uptake. Neither any co-
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localization of fl-HDL with fluorescently labelled 40 kDa Dextran was found, which is taken up by cells 
through fluid phase endocytosis. Thus, this study demonstrated a possibility of non-classical endocytic 
route involving dynamin and cytosketal networks for HDL transport through endothelial cells where 
HDL were found in atypical large vesicles 166. 
1.5 Endothelial regulators of HDL transport 
Endothelial cells express several genes involved in the reverse cholesterol transport, such as ABCA1, 
ABCG1, ectopic β-ATPase, SR-BI and endothelial lipase, which were previously shown to promote 
HDL uptake into the endothelial cells.  
ATP-binding cassette transporters 
The ATP-binding cassette (ABC) transporters are ubiquitous membrane proteins that couple the 
hydrolysis of ATP to the transport of diverse substrates across cellular membranes. ABCs are grouped 
into seven subclasses labeled from ABCA to ABCG 167. The basic domain organization of ABC 
transporters consists of two transmembrane domains (TMDs) that provide the passage for the cargo and 
two cytoplasmic nucleotide-binding domains (NBDs) that bind and hydrolyze ATP. Structurally, ABCs 
fall into two groups: 1) Full transporters having two similar structural units encoded as a single gene 
product and 2) half-transporters of single structural units that form active heterodimers or homodimers. 
ABCA1 and ABCA7 are full transporters, whereas ABCG1 and ABCG4 are homodimeric half 
transporters 167.  
ATP-binding cassette A1 
ABCA1 is a member of the ABCA subfamily that plays a central role in HDL metabolism and lipid 
clearance from cells. ABCA1 mediates the transport of cholesterol, phospholipids and other lipophilic 
molecules across cellular membranes to lipid-poor HDL apolipoproteins. ABCA1 is broadly expressed 
with high levels in macrophages, liver cells, intestinal cells, adrenal gland, endothelial cells and placental 
trophoblast cells168 169.  
                                           
Figure 11: Topological model of ABCA1. The model is based on domain studies of ABCA1. Y indicates 
approximate glycosylation sites and S-S indicates one predicted disulfide bond. NBD-1 and NBD-2 are the 
nucleotide binding domains that contain the highly conserves Walker A and Walker B domains and the Walker C 
signature motif 58. 
ABCA1 is a 2,261-amino-acid integral membrane protein that comprises two halves of similar structure 
(Figure 11). Each half has a transmembrane domain containing six helices and a nucleotide binding 
domain (NBD) containing two conserved peptide motifs known as Walker A and Walker B, which are 
present in many proteins that utilize ATP, and a Walker C signature unique to ABC transporters. ABCA1 
is predicted to have an NH2 terminus oriented into the cytosol and two large extracellular loops that are 
highly glycosylated and linked by one or more cysteine bonds 167, 170. Binding and hydrolysis of ATP by 
the two cytoplasmic, nucleotide-binding domains control the conformation of the transmembrane 
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domains so that the extrusion pocket is available to translocate substrate from the cytoplasmic leaflet to 
the exofacial leaflet of the bilayer membrane. ABCA1 actively transports phosphatidylcholine, 
phosphatidylserine, and sphingomyelin with a preference for phosphatidylcholine 171 and this 
phospholipid translocase activity of ABCA1 leads to the simultaneous efflux of phospholipid and free-
cholesterol to lipid-free apoA-I. This protein therefore represents the first and rate-controlling step in 
the reverse cholesterol transport pathway 172. The cellular free-cholesterol released to apoA-I originates 
from both the plasma membrane and the endosomal compartments. This phenomenon occurs because 
plasma membrane constituents are internalized and recycled via endocytic compartments to the cell 
surface on a timescale of minutes 173, 174. Its homology with other better-characterized ABC transporters 
suggests that ABCA1 forms a channel in the membrane that promotes flipping of lipids from the inner 
to outer membrane leaflet by an ATPase-dependent process 175.  
Mutations in ABCA1 cause a severe HDL deficiency syndrome called Tangier disease (TD) 176. Lipid-
free apoA-I is unable to remove cholesterol and phospholipids from fibroblasts isolated from TD 
patients, consistent with a defective ABCA1 177. Patients with TD experience large yellow-orange 
tonsils, peripheral neuropathy, splenomegaly, hepatomegaly, ocular abnormalities, 
hypocholesterolemia, and accelerated atherosclerosis 178. The ability of HDL to preserve endothelial 
function is thought to contribute to its overall anti-atherogenic role. In humans, HDL-C levels correlate 
with endothelium-dependent vasodilation in atherosclerotic coronary arteries and infusion of 
cholesterol-poor reconstituted HDL improves forearm blood flow in subjects with heterozygous ABCA1 
deficiency and reduced HDL levels 179. Similarly, adenoviral overexpression of ABCA1 in the wild-type 
mice liver showed increased plasma HDL levels, whereas liver-specific ABCA1 ablation showed 90% 
decrease in HDL as well as apoA-I levels in the plasma 180. Studies with transgenic mice expressing 
human ABCA1 showed increase in HDL-C levels and eNOS mRNA levels in the aorta. The transgenic 
mice fed on high fat, high cholesterol diet showed 40% increase in plasma HDL and 40% decrease in 
the aortic lesions compared to the control mice. The hABCA1 transgenic mice also showed decreased 
expression of genes involved in the endothelial inflammation and apoptosis. Recent studies showed that 
deficiency of ABCA1 in endothelial cells was associated with decreased eNOS activity, enhanced 
endothelial cell inflammation, monocyte adhesion and monocyte infiltration into the atherosclerotic 
plaques 181. Thus, endothelial expression of ABCA1 plays an important role in the complex 
interrelationship between endothelial dysfunction, low HDL-C and atherosclerosis 182.  
ATP-binding cassette G1 
The ATP-binding cassette sub-family G member 1 (ABCG1) is a transmembrane half transporter that 
exports cellular lipids to extracellular acceptors 183, 184.  The primary function of ABCG1 is to efflux 
cholesterol to HDL particles 185, 186. ABCG1 also effluxes cholesterol to LDL, liposomes and 
cyclodextrin and exports sphingomyelin, phosphatidylcholine and oxysterols to HDL 187, 188. ABCG1 is 
ubiquitously expressed, with relatively high expression in the spleen, lung, brain and kidneys and is also 
highly expressed in the macrophages where it can be upregulated by liver X receptor (LXR) agonists 
189.   
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Figure 12: Structure of ABCG1. ABCG1 is a half-transporter with six-transmembrane domains and a single 
large intracellular region containing one ABC domain. The functional transporter represented in gray, might 
dimerize with related half-transporters to function 190. 
ABCG1 consists of six transmembrane alpha helices and one nucleotide binding domain at the N-
terminus (Figure 12). ABCG1 undergoes dimerization to function 191. Recent studies have shown that 
ABCG1 forms heterodimers with ABCG4, however, ABCG1 was not found to limit cholesterol efflux 
192. There has been significant debate about the cellular localization and function of ABCG1. A 
number of studies have reported that ABCG1 is localized and functions in lipid rafts in the plasma 
membrane and in endosomes that recycle to the cell surface where they efflux cholesterol  186, 193, 194. 
However, other reports have suggested that ABCG1 is restricted to the endosomes and functions 
intracellularly 195. Recent studies using TIRF microscopy identified ABCG1 in two distinct cellular 
pools that are located in the endoplasmic reticulum and plasma membrane. Treatment of cells with 
cholesterol was shown to increase plasma membrane associated ABCG1 levels indicating that 
ABCG1 cycles between the intracellular and plasma membrane pools based on cellular cholesterol 
levels. In addition to regulating ABCG1 localization, cholesterol was also seen to regulate ABCG1 
levels via inhibition of ubiquitination and subsequent degradation. Further systematic experiments 
with the cell membrane sheet preparation showed that cell-surface ABCG1 was associated with actin 
cytoskeleton and loading of cells with cholesterol significantly increased the organization of ABCG1 
in the cell membrane into filamentous structures196.  
Mice lacking ABCG1 accumulate lipids in macrophages and hepatocytes, and show significant 
reduction of plasma HDL-C levels after fed with the high cholesterol diet 197 189. Transgenic mice 
over-expressing human ABCG1 gene are protected against dietary fat-induced lipid accumulation in 
the liver and lungs 189. Moreover, over-expression of ABCG1 in macrophages significantly increases 
macrophage RCT in vivo, whereas knockdown or knockout of ABCG1 expression markedly decreases 
macrophage RCT in vivo 198. The ability of ABCG1 to preserve endothelial function was shown by its 
role in promoting efflux of oxysterol 7-ketocholesterol (7-KC) to HDL, whose delayed clearance is 
associated with decreased eNOS activity and increased coronary heart disease risk 199.  Atheroprotective 
effects of vascular ABCG1 were suggested by transplantation of ABCG1+/+ bone marrow into mice with 
whole body Abcg1 deficiency on the Ldlr-/- background 200. Aortic endothelial cells from the ABCG1 
knock-out mice have shown increased production of chemokines, increased surface expression of the 
adhesion molecules ICAM-1 and E-selectin that promote monocyte adhesion, leading to pro-
inflammatory endothelial phenotype 201. Along with ABCA1, recent studies also showed that cholesterol 
efflux pathway mediated by ABCG1 in endothelial cells is anti-atherogenic through increasing eNOS 
activity and decreasing endothelial inflammation. In endothelial cells, not only combined Abca1/g1 
deficiency showed accelerated atherosclerosis, but also single Abca1 and Abcg1 deficiency promoted 
atherosclerosis. These studies add to the understanding of the atheroprotective effects of ABCA1 and 
ABCG1 in the endothelium and provide a link between endothelial cell cholesterol accumulation, 
inflammation and atherosclerosis 181. 
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Endothelial lipase 
Endothelial lipase (EL) is a member of the triglyceride lipase family, which includes lipoprotein lipase 
and hepatic lipase. In principle, EL is a phospholipase, with insignificant triglyceride hydrolase activity 
202, 203. EL is synthesized by endothelial cells and hydrolyses phospholipids in HDL much more 
efficiently than in other lipoproteins 204, 205. EL contains 482 amino acids with a considerable molecular 
homology with lipoprotein lipase (LPL) and hepatic lipase (HL). Although alignment of EL with the 
human LPL and HL amino acid sequences revealed conservation of the catalytic triads, EL has a minimal 
homology in the lid domain which is known to be critical in determining substrate specificity 202.   
After secretion, EL binds to cell surface proteoglycans where it exerts its action. EL acts as bridge 
between circulating HDL and endothelial cells thus promoting lipoprotein incorporation 206. EL-
mediated hydrolysis of HDL particles determines the plasma levels of HDL-cholesterol, which was 
established in animal experiments using both overexpression as well as loss-of-function models. 
Transgenic expression of human EL in mice resulted in a reduction in plasma HDL-cholesterol levels 
compared with wild-type control animals 207. Consistent with this finding, adenovirus-mediated over-
expression of human EL in LDL receptor-deficient mice lead to significantly decreased plasma 
concentrations of HDL-cholesterol 203. Also, inhibition of EL using a polyclonal antimurine antibody in 
mice resulted in a  significant increase in HDL-C and phospholipid levels as well as an increased HDL 
particle size 208. HDL-induced angiogenesis in aortic rings from EL-deficient mice was markedly 
decreased compared with wild-type controls. In cell culture, small interfering RNA–mediated 
knockdown of EL also reduced HDL-promoted endothelial cell migration, tube formation and 
phosphorylation of eNOS and Akt, indicating that EL modulates HDL-dependent signaling responses 
209.  
Atherosclerosis is an inflammatory process and cytokines are thought to have an important role in 
initiating the expression of a variety of genes that promote cell adhesion and other processes that are 
required for disease progression 210. Two cytokines that have received the most attention in this regard 
are TNF-α and IL-1β. Thus, the expression of EL by these cytokines in endothelial cells was determined 
by Quertermous and colleagues 211. When cultured human endothelial cells were treated with IL-1β or 
TNFα, there was a significant increase in EL mRNA levels. Our group has shown that treatment of cells 
with IL-6 increased transcytosis of HDL through the endothelial cells via increase in the EL expression, 
marking the importance of endothelial lipase in the first step of RCT 160. Many studies have been 
performed to understand the role of EL in RCT and identified that EL works both as a promoting and 
inhibiting agent 212 213, 214.  
In a cohort of healthy subjects with a family history of premature coronary heart disease, increased 
human plasma EL concentrations were shown to be significantly associated with the metabolic 
syndrome and subclinical coronary heart disease event 215. Given the strong association between plasma 
HDL-cholesterol levels and cardiovascular disease risk in humans, many studies expected that alteration 
in plasma HDL levels by EL in experimental animals might affect the progression of atherosclerosis. 
Studies dedicated to this hypothesis have suggested 2 different opinions, where Ishida et al reported that 
the inactivation of EL was associated with an approximately 70% decrease in atherosclerotic disease 
area in apoE knockout mice compared with controls despite the presence of a proatherogenic lipid 
profile 216. Conversely, Ko et al found that although EL modulated the lipoprotein profile in mice, there 
was no effect of EL inactivation on atherosclerosis development in hyperlipidemic atherosclerosis- 
prone mice models 217. The single-nucleotide polymorphism of LIPG Asn396Ser increased plasma 
HDL-C levels, but did not reduce the risk of myocardial infarction 218. This discrepancy supports the 
concept that changes in HDL-cholesterol levels are not a surrogate for atheroprotection. 
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Scavenger receptor class B type I (SR-BI) 
SR-BI mainly functions as a receptor for HDL was first isolated and identified by Calvo et.al 219. The 
sequence of SR-BI is closely related to CD36 and LIMPII analogous-1 and the gene, now 
called SCARB1, was initially named CLA-1. SR-BI is primarily expressed in the liver and nonplacental 
steroidogenic tissues, but is also expressed in macrophages and endothelial cells, where it functions to 
reduce atherosclerosis220. Acton and colleagues demonstrated that SR-BI binds HDL with high affinity 
and mediates the selective uptake of HDL cholesteryl ester into the liver. SR-BI also mediates the 
bidirectional flux of free cholesterol between cells and HDL 221-223. SR-BI mediated influx of HDL 
cholesteryl esters and free cholesterol are trafficked to bile and is a major route of delivery of peripheral 
cholesterol to the liver for excretion in both mice and humans 224-227.  
                                                        
Figure 13: Structure of SR-BI: SR-BI has a single, large and highly glycosylated extracellular loop that is 
anchored by two transmembrane domains with short cytoplasmic extensions 190. 
SR-BI is a hairpin-looped structure with two short transmembrane domains, two cytoplasmic tails and 
a large extracellular loop (Figure 13). Studies using SR-BI/CD36 chimeric receptors demonstrated that 
the extracellular domain binds to multiple ligands and is critical for both selective cholesteryl esters 
uptake and bi-directional flux of free cholesterol 228. Binding of HDL to the extracellular loop is not 
necessary for cholesterol efflux, however, subdomains of the N-terminal half of the extracellular domain 
are required for cholesterol efflux and organization of the plasma membrane cholesterol domains. 
Binding of HDL to the subdomains of C-terminal half of the extracellular domain are important for the 
selective cholesteryl ester uptake 229. Lysosomal integral membrane protein type-2 is a CD36 family 
member, which shares structural protein homology with SR-BI and was crystallized for high-resolution 
analysis. According to this model, a large cavity traverses the entire length of the SR-BI molecules and 
mutagenesis of SR-BI showed that the cavity is a lipophilic tunnel through which cholesteryl esters are 
delivered from the bound lipoprotein to the outer leaflet of the plasma membrane 230. Using fluorescence 
resonance energy transfer, it has been shown that SR-BI forms oligomers at the C-terminal region of the 
extracellular domain 231. In addition, a glycine dimerization motif in the N-terminal transmembrane 
domain is critical to SR-BI oligomerization and cholesteryl ester transport, which is proportional to the 
degree of oligomerization 232. The C-terminal cytoplasmic and transmembrane domains are critical to 
SR-BI signaling. The C-terminal cytoplasmic domain contains a PDZ-binding domain that interacts with 
the adaptor protein PDZK1. In endothelial cells, activation of eNOS involves interaction of SR-BI with 
Src and then activation of Src further leads to the activation of phosphoinositide 3-kinase (PI3K), Akt 
and eNOS. However, PDZK1 interaction with SR-BI is not required for Src interaction with SR-BI 233. 
In macrophages, PDZK1 is also required for the HDL and SR-BI induced activation of Akt signaling 
234. In hepatocytes, PDZK1 interaction maintains steady-state levels of SR-BI by preventing its 
degradation 235. SR-BI acts as a membrane cholesterol sensor and the C-terminal transmembrane domain 
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binds to the cholesterol. Using a SR-BI C-terminal transmembrane point mutation Q445A, which 
showed reduced interaction with cholesterol, it has been demonstrated that SR-BI interaction with 
membrane cholesterol is not critical for interaction with Src or PDZK1 but is required for activation of 
the Src signaling pathway 236, 237.  
Inflammatory events are critical to the progression of fatty streaks to advanced atherosclerotic lesions 
and studies suggest that SR-BI protects against atherosclerosis by regulating the inflammatory response. 
Compared with LDLR−/− mice, SR-BI/LDLR double-knockout mice fed an atherogenic diet have 
increased plasma levels of proinflammatory interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-
α) 238. As the main pathway of hepatic removal of HDL cholesterol in mice, SR-BI is critical for the 
delivery of cholesterol to bile and the preservation of HDL functions. Hepatic SR-BI is also crucial in 
the clearance of remnant lipoproteins and atherogenic lipoprotein (a) in mice 51. In addition, HDL 
interaction with SR-BI reduces the inflammatory response to lipopolysaccharide in human macrophages 
by markedly reducing NF-κB activation 239. Furthermore, recent studies have shown that the interaction 
of macrophage SR-BI with apoptotic cells activates PI3K/Akt signaling and induces the expression of 
anti-inflammatory cytokines 240. In addition, HDL activates PI3K/Akt signaling in macrophages, which 
is mediated by SR-BI and involves interaction with its adaptor protein PDZK1 and activation of 
sphingosine 1-phosphate (S1P) receptor 1 (S1PR1) signaling 234. Thus, SR-BI regulates inflammation 
by activating Akt phosphorylation and reducing NF-κB activation.  
Recent studies suggest that endothelial cell SR-BI functions in reducing atherosclerotic lesion foam cell 
formation. Specific overexpression of SR-BI in endothelial cells decreased atherosclerosis in both 
apoE−/− and WT mice 241. Studies by our group and others have shown that a major portion of the 
endothelial cell transcytosis of HDL from the apical to the basolateral side is mediated by SR-BI, 
suggesting that SR-BI provides HDL to the subendothelium to promote cholesterol efflux from 
macrophages 161, 241. Furthermore, recent studies have shown that endothelial cell SR-BI mediates the 
uptake and transcytosis of HDL in lymphatic vessels to effectively remove cholesterol from peripheral 
tissue, thereby raising the possibility that lymphatic SR-BI also reduces foam cell formation in 
atherosclerotic lesions 242. Limiting endothelial cell inflammation is critical to reducing monocyte 
adhesion and recruitment into intima and thereby preventing lesion progression. SR-BI interaction with 
HDL prevents endothelial cell inflammation by controlling eNOS activation and expression of the 
antioxidant enzyme 3-beta-hydroxysteroid-delta 24-reductase (DHCR24) 243, 244. SR-BI-mediated 
production of nitric oxide (NO) and DHCR24 leads to less TNF-α-stimulated NF-κB activation resulting 
in reduced endothelial cell expression of inflammatory monocyte adherence proteins and chemokines, 
thereby reducing monocyte recruitment into the intima 245. Taking these findings together, SR-BI is a 
multifunctional receptor against atherosclerosis making it a viable therapeutic target. Identification of 
the detailed mechanism by which SR-BI functions, including its adaptor proteins, signaling molecules, 
and transcriptional regulators, will be important to provide the basis for new therapeutic approaches for 
atherosclerosis 227. 
Ectopic β–chain of F0F1-ATPase 
Ectopic F0F1-ATPase is a mitochondrial complex that was shown to play role in the endocytosis of 
apoA-I and HDL in hepatocytes and endothelial cells 162, 246. The F0 domain is an integral membrane 
domain that contains a transmembrane channel for protons and the F1 domain is a peripheral 
membrane protein complex containing binding sites for ATP and ADP, and the catalytic site for ATP 
synthesis or hydrolysis 247, 248. The F1 ATPase domain was found ectopically expressed on the plasma 
membrane of hepatocytes, endothelial cells, adipocytes and tumor cells 249-252.  
On endothelial cells, binding of apoA-I to ecto-F1-ATPase stimulates the hydrolysis of extracellular 
ATP into ADP and phosphate. The ADP released transduces this enzymatic activity into cellular effects 
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through the activation of ADP-responsive P2Y receptors and trigger the transendothelial transport of 
both lipid-free apoA-I and HDL. Of the two P2Y receptors preferentially activated by ADP and 
expressed by endothelial cells (P2Y1 and P2Y12), it was shown that apoA-I/HDL transcytosis was 
mediated by P2Y12, as this process could be reduced with the P2Y12 inhibitor 2-MeSAMP 162. Moreover, 
binding of apoA-I to the ectopic- F1-ATPase stimulates downstream signaling pathways, which 
subsequently promote endothelial cell proliferation and reduce apoptosis. These effects of apoA-I on 
endothelial cell survival were strictly limited to ecto-F1-ATPase activity because they persisted when 
other HDL/apoA-I receptors, such as SR-BI and ABCA1, were inhibited but were impaired when treated 
with F1-ATPase inhibitors162, 253.  In addition, it has been recently reported that ecto-F1-ATPase was 
expressed at the plasma membrane of human endothelial progenitor cells (EPC) and was involved in the 
effect of apoA-I in the proliferation and angiogenic capacity of early EPCs 254. 
In conclusion, these data support a role of the ecto-F1-ATPase/P2Y12 axis in controlling apoA-I/HDL 
crossing from the plasma compartment into the sub-endothelial space where they are in the close vicinity 
of foam cells. Further studies are needed to interpret the physiological and pathological relevance of 
ecto-F1-ATPase/P2Y12 axis in affecting atheroma formation even at an early stage of the disease when 
endothelial dysfunction occurs. 
1.6 Endothelial regulators of LDL transport 
As a first step in the pathogenesis of atherosclerosis, LDL crosses the endothelium to accumulate in the 
intima. Several studies have shown that LDL can cross intact endothelial cell layer by transcytosis.  
Low-density lipoprotein receptor  
The low-density lipoprotein receptor (LDLR) is a cell-surface glycoprotein that plays a critical role in 
the homeostatic control of blood cholesterol by mediating the removal of cholesterol-containing 
lipoprotein particles from the circulation. Brown & Goldstein originally identified the LDLR in 1973 
during their search for the molecular basis of familial hypercholesterolemia (FH), which is one of the 
most common human inborn errors of metabolism and is caused by loss of function mutations of the 
gene encoding LDLR 33.  
                                                            
Figure 14: Schematic representation of the regional composition of the LDLR. The LDLR has five 
functionally distinct regions: an N-terminal ligand-binding region, an epidermal growth factor (EGF)-precursor 
homology region, a region containing O-linked sugars, a transmembrane domain and a C-terminal cytosolic 
domain 255. 
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The human LDLR is encoded by a gene of ~45 kb located on chromosome 19p13.1–13.3. The 18 exons 
of the gene are translated into an 860-amino acid type I transmembrane protein including a signal 
sequence of 21 amino acids, which is cleaved during translocation into the endoplasmic reticulum 256. 
The exons act as functionally independent modules in the protein domain organization 256. The LDLR 
has five functionally distinct regions: an N-terminal ligand-binding region, an epidermal growth factor 
(EGF)-precursor homology region, a region containing O-linked sugars, a transmembrane domain and 
a C-terminal cytosolic domain (Figure 14). The ligand-binding region consists of seven cysteine rich 
repeats (R1-R7) of approximately 40 amino acids, called as LDLR class A repeats. This region also 
consists of a conserved sequence of acidic amino acids present in the C-terminal part of each LDL-A 
repeat, which is proposed to mediate interaction with basic amino acid residues of apoB-100 and ApoE. 
At neutral plasma pH, LDLR binds to the LDL via a 550-kDa apoB-100, which is the sole protein of 
LDL 257, 258. Studies using monoclonal antibodies to identify specific apoB-100 epitopes on the surface 
of LDL particles by electron microscopy suggest that apoB-100 is distributed over the surface of the 
LDL particle like a ribbon, with a bow contributed by the C-terminal end 259. The LDL receptor also 
binds tightly to lipoproteins that contain multiple copies of to ApoE, a 34kDa protein found in beta 
migrating forms of VLDL or certain intermediate and high-density lipoproteins 260, 261.  
Endocytosis and intracellular transport of the LDLR are regulated through its cytoplasmic domain. 
Mutational analysis has revealed a dominant role for the FDNPVY sequence (NPXY motif) in 
recruitment of the LDLR to clathrin-coated pits on the cell surface 262-265. The NPXY motif adopts a 
tight hairpin conformation that serves as a binding site for a variety of adaptor proteins and signaling 
molecules. The autosomal recessive hypercholesterolemia (ARH) gene encodes an adaptor protein that 
binds via its N-terminal phosphotyrosine binding (PBD) domain to the FDNPVY motif of the LDLR 
266. Via a canonical clathrin box sequence (LLDLE) in its C-terminal domain, ARH binds directly to 
clathrin, whereas a conserved 27-amino acid sequence interacts with the β2- subunit of the clathrin-
binding AP-2 adaptor complex 267. Mutations in the ARH gene lead to reduced internalization of the 
LDLR and a clinical phenotype indistinguishable from FH 268, 269.  The β-arrestin-2 adaptor protein was 
shown to mediate clathrin-dependent internalization of the LDLR but not of a mutant LDLR with a Y-
to-A substitution in the FDNPVY motif 270. Another clathrin- and AP-2 binding protein, Disabled-2 
(Dab-2), binds peptides corresponding to the FDNPXY motif and co-localizes with the LDLR in 
clathrin-coated pits 255, 271, 272.  
Upon binding, the LDL-LDLR complex is taken up by the cells via clathrin-mediated endocytosis. In 
endosomes the ligand dissociates from the receptor due to the local low pH. The LDL receptor is 
subsequently returned to the cell surface in a process called receptor recycling 36, 273.  In contrast to the 
internalization process, little is known about proteins involved in intracellular LDLR trafficking. Sorting 
nexin-17, a protein located in early endosomes, binds the LDLR NPXY motif, but its precise role in 
intracellular trafficking remains unclear 274 255. Recent studies have shown that show that the 
COMMD/CCDC22/CCDC93 (CCC) and the Wiskott–Aldrich syndrome protein and SCAR homologue 
(WASH) complexes are both crucial for endosomal sorting of LDLR and for its function. Inactivation 
of both these complexes has been shown to cause LDLR mislocalization, increased lysosomal 
degradation of LDLR and impaired LDL uptake 275. However, in endothelial cells receptor-mediated 
endocytosis of LDL by LDLR is shown to be dependent on caveolae-mediated pathway. Caveolae are 
50- to 100-nm cell surface flask-shaped invaginated structures that are highly abundant and play an 
important role in the cholesterol transport, endocytosis, transcytosis, and signal transduction in the 
endothelial cells 276. Caveolin-1 (Cav-1) is the major coat protein of endothelial caveolae and is 
necessary for caveolae assembly 277.  Studies of the aortic rings from caveolin-1 knockout mice revealed 
reduced LDL internalization, while cav1-/- /ApoE-/- mice were protected from atherosclerosis despite 
having increased plasma LDL levels. These data are also consistent with those obtained by Fernández-
Hernando et al., who showed that endothelial caveolin-1 could regulate LDL entry into the arterial wall 
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by showing that the permeability of the aorta to 125I-LDL is reduced in caveolin-1-deficient mice 278-280. 
Interestingly, PCSK9-mediated LDLR degradation did not impair the transcytosis, indicating that LDLR 
is not required for the LDL endothelial transcytosis 155.  
Electron microscopy studies have demonstrated that physiological levels of LDL particles can be 
internalized by two pathways; LDLR dependent and LDLR independent pathways148. The LDLR-
mediated pathway promotes LDL degradation and is downregulated at the higher concentrations of 
LDL while the additional studies have shown that at least 50% of the LDL that is endocytosed by 
the endothelium traverses the cells to reach the basolateral side via an unknown active LDLR 
independent transport mechanism 138, 281.  
SR-BI 
Previous studies have shown that SR-BI binds native LDL 282 with high affinity and is capable of 
performing bona fide receptor-mediated endocytosis 283. The findings showed a partial colocalization 
of LDL with SR-BI and overexpression of SR-BI increased LDL transcytosis, whereas knockdown 
of SR-BI using RNA interference significantly decreased LDL endothelial transcytosis. Further it 
was also shown that HDL and LDL compete for binding to SR-BI in the endothelial cells 155 161.  
Activin-like kinase 1 (ALK1) 
Recent studies using genome-wide RNAi approach in the endothelial cell line (EA.hy926) identified 
ALK1 as a novel low-affinity, high –capacity receptor for LDL transcytosis in endothelial cells. ALK1 
is a TGF-β-type 1 receptor which binds the bone morphogenetic proteins (BMP) 9 and 10 ligands with 
high affinity. ALK1 is highly expressed in primary human endothelial cells compared to the hepatocytes.  
ALK1 is one of the seven activin-like kinase receptors that shares a similar homology in the intracellular 
domain but very low homology with the extracellular amino terminal domain. The amino-terminal 
domain is responsible for the ligand binding but only ALK1 is shown to specifically bind LDL. Studies 
have shown that both LDLR and ALK1 bind to different sites on LDL. The uptake of LDL by ALK1 
was shown to be independent of its kinase activity. Experiments using total internal reflectance 
microscopy (TIRF) in primary human endothelial cells showed that knockdown of ALK1 decreased 
transcytosis of LDL from the apical to the basolateral membrane. LDL uptake was significantly reduced 
into the arterial wall of the mice with endothelial specific Acvrl1-/- and LDL -/- double knock-out mouse. 
Taken together, the data point at the role of ALK1 on LDL uptake and transcytosis through the 
endothelial cells 159. 
1.7 Aim and outline of the thesis 
From the previously mentioned chapter, it is clear that endothelial cells facilitate the uptake and 
transcytosis of HDL and LDL through specific protein interactions. The overall aim of the research 
summarized in this thesis was to provide more insight into the identification of novel protein interactors 
that are involved in regulating the endothelial uptake and transcytosis of HDL and LDL, which is crucial 
for targeting cardiovascular disease progression. 
We used both hypothesis/candidate driven and hypothesis-free approach. In the hypothesis driven 
approach we investigated the role of S1P, which is a well-known regulator of endothelial barrier integrity 
(Chapter 2). For the hypothesis-free approach, we performed kinase inhibitor screen. This identified 
VEGF as a crucial regulator of endothelial HDL uptake and transendothelial HDL transport (Chapter 
3). Finally, we validated the role of VEGF for lipoprotein endocytosis in clear-cell renal cell carcinoma, 
which is a well-known VEGF-driven disease (Chapter 4). 
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Lastly, Chapter 5 summarizes and discusses the most relevant findings described in the thesis and 
concludes with implications for future research. 
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Abstract 
Lipoproteins may pass the endothelium by paracellular and transcellular routes. Sphingosine-1-
phosphate (S1P) bound by apolipoprotein M (apoM) within HDL promotes closure.of interendothelial 
junctions. This raises the question, how S1P and its cognate receptors S1P1 and S1P3 regulate the 
transendothelial transport of lipoproteins. Pre-treatment of HAECs with inhibitors of S1P1 and S1P3 
decreased the cellular binding, association and transport of 125I-HDL but increased the binding, 
association and transport of 125I-LDL. Vice-versa the pre-treatment with S1P receptor agonists increased 
the specific cellular binding, association and transport of 125I-HDL but decreased binding, association 
and transcytosis of 125I-LDL. The stimulatory effects of the S1P1 and S1P3 agonists on endothelial 
binding, association and transport of 125I-HDL were abrogated by silencing of scavenger receptor BI 
(SR-BI). The stimulatory effect of the S1P1 inhibitor but not of the S1P3 inhibitor on endothelial 
association and transport of 125I-LDL was decreased by treatment with the fluid-phase inhibitor 
amiloride. The stimulatory effect of the S1P3 inhibitor on the cellular binding and association of 125I-
LDL was inhibited by silencing LDL receptor (LDLR). However, the S1P3 inhibitor continued to 
promote the transport of 125I-LDL through HAECs with suppressed LDLR or SR-BI. Therefore, the 
protein mediating transcytosis of 125I-LDL in response to S1P3 inhibition remains to be identified. 
Conclusion: S1P1 and S1P3 regulate the transendothelial transport of HDL and LDL in an antagonistic 
manner making them interesting targets for therapeutic interventions with atherosclerosis.  
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2.1 Introduction 
Sphingosine-1-phosphate (S1P) is an endogenous lipid agonist of five G-protein coupled receptors 
(GPCRs) termed S1P1, S1P2, S1P3, S1P4 and S1P5. 1. In the endothelium binding of S1P to the S1P1 
or S1P3 receptors promotes the closure of intercellular junctions  and hence the maintenance of 
endothelial barrier 2 . Thereby S1P controls the trafficking of solutes, proteins, and cells between intra- 
and extravascular compartments 3. S1P signaling hence contributes to edema and inflammation but is 
also targeted for treatment of inflammatory diseases such as multiple sclerosis or cancers. Also 
atherosclerosis can be interpreted as the result of disproportionate fluxes of pro-atherogenic low-density 
lipoproteins (LDL) and anti-atherogenic high density lipoproteins (HDL)  between the blood stream and 
the arterial wall: According to the response to injury and response to retention hypotheses of 
atherosclerosis, accumulation of LDL play an important role in the pathogenesis of atherosclerosis 4. 
Many protective effects by HDL are exerted in the vascular wall, notably induction of cholesterol efflux 
from macrophages for reverse cholesterol transport 4, 5. However, the mechanism by which LDL and 
HDL are transported from plasma to the subendothelial space is not well understood. Lipoproteins are 
debated to pass the endothelial barrier in a regulated manner possibly by two routes or processes, either 
through a transcellular or paracellular routes, either in an active and regulated process or by passive 
filtration by size and concentration 6, 7. Our laboratory has previously described the transport of HDL 
through endothelial cells by mechanisms involving ATP binding cassette transporter ABCG1, scavenger 
receptor SR-BI, and endothelial lipase (EL), as well as the ectopic-β-ATPase/purinergic receptor axis 8-
10. Receptor-mediated LDL transport across the endothelial cells was shown to be mediated by SR-BI 
and activin-like kinase 1 (ALK1), rather than by the LDL receptor 11-13. However, it is not yet known 
whether the S1P/S1P-receptor axis regulates the transport of LDL and HDL through the endothelial 
cells. This question is of specific relevance because HDL and LDL transport 60% of plasma S1P due to 
the presence of the S1P binding lipocalin apoM 14.By studying the effects of pharmacological inhibitors 
and agonists of S1P1 and S1P3 we found evidence for an important regulatory role of S1P receptors in 
regulating uptake of LDL and HDL by endothelial cells in an antagonistic manner. 
2.2 Materials and Methods 
Cell culture 
Human aortic endothelial cells (HAECs) from Cell Applications Inc (304-05a), were cultured in 
endothelial cell basal medium (LONZA Clonetics CC-3156 or ATCC PCS-100-030) with 5% fetal 
bovine serum (GIBCO), 100U/mL of penicillin and 100µg/mL streptomycin (Sigma-Aldrich), 
supplemented with singleQuots (LONZA Clonetics CC-4176 or ATCC PCS-100-041, containing hFGF, 
hVEGF, hIGF-1, hEGF, hydrocortisone, ascorbic acid, heparin) at 37ºC in a humidified 5% CO2, 95% 
air incubator.  
Lipoprotein Isolation and labeling 
LDL (1.019<d<1.063 g/mL) and HDL (1.063<d<1.21 g/mL) were isolated from fresh human 
normolipidemic plasma of blood donors by sequential ultracentrifugation as described previously 15, 16. 
LDL and HDL were radioiodinated with Na125I by the McFarlane monochloride procedure modified for 
lipoproteins 16, 17. Specific activities between 300-900 cpm/ ng of protein were obtained.  
Small Interfering RNA Transfection 
Endothelial cells were reverse transfected with small interfering RNA (Ambion silencer select, Life 
technologies) targeted to SR-BI (s2648, s2649, s2650) or LDLR (s224006, s224007, s4) or ACVRL1 
(s986, s988) or non-silencing control (4390843) at a final concentration of 5nmol/L using Lipofectamine 
RNA iMAX transfection reagent (Invitrogen, 13778150) in an antibiotic-free medium.  All experiments 
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were performed 72 hours post-transfection and efficiency of transfection was confirmed with at least 
two siRNAs against each gene using quantitative RT-PCR and western blotting.  
Quantitative real time PCR 
Total RNA was isolated using TRI reagent (Sigma T9424) according to the manufacturer’s instruction. 
Genomic DNA was removed by digestion using DNase (Roche) and RNase inhibitor (Ribolock, Thermo 
Scientific).  Reverse transcription was performed using M-MLVRT (Invitrogen, 200U/µL) following 
the standard protocol as described by the manufacturer. Quantitative PCR was done with Lightcycler 
FastStart DNA Master SYBR Green I (Roche) using gene specific primers as followed:  
SCARB1 (For: CTG TGG GTG AGA TCA TGT GG; Rev: GCC AGA AGT CAA CCT TGC TC),  
LDL-R (For: AAGGACACAGCACACAACCA; Rev: CATTTCCTCTGCCAGCAACG),  
ACVRL1 (primer sequence) normalized to GAPDH (For: CCC ATG TTC GTC ATG GGT GT; Rev: 
TGG TCA TGA GTC CTT CCA CGA TA). 
Lipoprotein Binding, Cell association and Transport 
The methods for the quantification of binding, association and transport of radiolabeled HDL and LDL 
by endothelial cells have been previously described 5, 11, 13. All assays were performed in DMEM (Sigma) 
containing 25mmol/L HEPES and 0.2% BSA instead of serum. Where indicated, cells were pretreated 
for 30mins at 37 ºC with either S1P1 agonist SEW2871 (Cat No:2284, Tocris, 20 nM) or S1P3 agonist 
CYM-5541 (Cat No: SML0680, Sigma, 100 nM) or S1P1 inhibitor W146 (Cat No:3602, Tocris, 20 nM) 
or S1P3 inhibitor TY52156 (Cat No:2404, Axon Medchem, 110 nM). For fluid-phase experiments, cells 
were treated with fluid-phase inhibitor amiloride (Cat No: A7410, Sigma, 20 µM) for 30 min before 
S1P1 inhibitor treatment. Following the pharmacological drug treatments, the cells were incubated with 
10µg/mL of 125I-HDL or 125I-LDL without (total) or with 40 times excess of non-labeled HDL/ LDL 
(unspecific) for 1hr at 4 ºC for cellular binding and at 37ºC for association and transport experiments. 
Specific cellular binding/ association/ transport was calculated by subtracting the values obtained in the 
presence of excess unlabeled HDL/ LDL (unspecific) from those obtained in the absence of unlabeled 
HDL/ LDL (total).  
Dextran uptake assay 
To test fluid-phase particle uptake, cells were incubated with fluorescein isothiocyanate–dextran 
(FD40S, Sigma, 500 µg/ml) for 1h at 37ºC. Prior to the dextran incubation, cells were pre-treated with 
amiloride (Cat No: A7410, Sigma, 20 µM) or S1P1 inhibitor W146 (Cat No:3602, Tocris, 20 nM) or 
S1P3 inhibitor TY52156 (Cat No:2404, Axon Medchem, 110 nM) for 30mins where indicated. 
Following the dextran incubation, cells were washed twice with Tris-BSA and PBS++. The cells were 
later lysed in RIPA buffer and the fluorescence was measured using TECAN plate reader with a 
wavelength range from 495 to 519nm. The fluorescence reads were normalized to the protein using 
micro BCA protein measurement method. 
Inulin permeability 
HAECs were cultured on trans-well inserts for 72hours and cells were later treated with indicated 
pharmacological drug inhibitors as indicated for 30mins. Post-treatments, cells in the apical 
compartment were incubated with 2 mCi/mL of  3H-inulin, and the filtrated radioactivity was collected 
in the basolateral compartment after 1 hour 16, 18.  
Western Blotting  
Endothelial cells were lysed in RIPA buffer (10mmol/L Tris pH 7.4, 150mmol/L NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, complete EDTA (Roche)) with protease and phosphotase inhibitors. 
Equal amounts of protein were separated on SDS-PAGE and trans-blotted onto PVDF membrane (GE 
Healthcare). Membranes were blocked in appropriate blocking buffer recommended for the antibody 
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(PBS-T supplemented with 5% milk or BSA) and incubated either for 1hour or overnight on shaker at 
4 ºC with primary antibodies at a dilution of 1:1000 in the same blocking buffer. Membranes were 
incubated for 1hour with HRP-conjugated secondary antibody (Dako) in blocking buffer at a dilution of 
1:2500. Membranes were further incubated with chemiluminescence substrate for 1min (Pierce ECL 
plus, Thermo scientific) and imaged using Fusion Fx (Vilber). As indicated, TATA binding protein was 
used as loading control with primary antibody at 1:5000 and secondary antibody at 1:10000 dilutions. 
The silencing efficiencies of SR-BI (NB400-131, Novus) and LDLR (ab52818, Abcam) were evaluated 
and compared to TATA binding protein (ab51841, Abcam). The phospho-expression of Akt S473 
(9271L, CST) was compared to TBP. 
Cell surface expression analysis  
Biotinylation of intact cells was performed using 20mg/mL EZ-Link sulfo-NHS-S-S-Biotin (Thermo 
Scientific) in the cold for 1 hour with mild shaking and quenched with ice-cold 50mM Tris pH 7.4. Cells 
were lysed in RIPA buffer (total cell lysate) and 200-500µg of lysates were incubated with 20µL of 
BSA-blocked streptavidin beads suspension (GE Healthcare) for 16hours at 4ºC and pelleted by 
centrifugation; the pellet represents surface proteins. Proteins were dissociated from the pellet by boiling 
with SDS loading buffer and analyzed by SDS-PAGE and immunoblotted with SR-BI antibody (NB400-
131, Novus), LDL-receptor (LDLR, ab52818, Abcam) and TATA binding protein (TBP, ab51841, 
Abcam) used as intracellular control. 
Statistical Analysis 
The data sets for all validation experiments were analyzed using the GraphPad Prism 5 software. 
Comparison between groups was performed using Kruskal-Wallis one-way ANOVA followed by 
Dunn’s post-test. The data was obtained from at least three independent experiments, performed in 
triplicates or quadruplets. Values are expressed as mean±SEM. P<0.05 was regarded as significant. 
2.3 Results 
S1P1 and S1P3 activation regulates cellular association and transendothelial transport of HDL 
and LDL antagonistically  
HAECs expressed both the S1P1 and S1P3 receptors as analyzed at the mRNA (Figure 2.1A) level. To 
test which S1P receptor regulates the HDL and LDL uptake by endothelial cells, we treated the cells 
with S1P receptor agonists or inhibitors for 30mins prior to the assays. The efficacy of the agonist 
treatments on S1P1 and S1P3 activation was validated by increased phosphorylation of downstream 
signaling kinase Akt (Figure 2.1B).  
         
Figure 2.1: Expression and activation of S1P1 and S1P3 in HAECs A, mRNA levels of S1P1 and S1P3 in 
HAECs were measured by real-time polymerase chain reaction. B, HAECs were cultured for 72hours. Cells were 
then treated with the S1P1 agonist (SEW2871, 20nM), or the S1P3 agonist (CYM5541, 100nM) for 30mins, at 37 
ºC as indicated. Cell lysates were analysed by western blotting for phospho Akt (Ser-473) and TATA-binding 
protein (TBP) was used as a loading control. 
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Since the S1P/S1P-receptor axis plays an important role in regulating the endothelial barrier function, 
we tested the permeability of 3H-inulin from apical to basolateral compartments in a trans-well system. 
Pre-treatment of cells with either S1P agonists or inhibitors did not induce paracellular leakage of 3H-
inulin, (Figure 2.2).  
                                                      
Figure 2.2: S1P1 and S1P3 do not induce the paracellular leakage in HAECs HAECs were cultured for 
72hours on trans-well inserts. Cells were then treated with the S1P1 agonist (SEW2871, 20nM), or the S1P3 
agonist (CYM5541, 100nM) or the S1P1 inhibitor (W146, 20nM), or the S1P3 inhibitor (TY52156, 110nM) for 
30mins, at 37 ºC as indicated. The transport of 3H-Inulin from the apical to basolateral compartment was measured 
at 37 ºC for 1hour. The results are represented as means±SEM of two independent triplicate experiments (n=2). 
Figure 2.3: S1P1 and S1P3 agonists regulate HDL and LDL binding, association and transendothelial 
transport in HAECs HAECs were cultured for 72hours. Cells were then treated with S1P1 agonist (SEW2871, 
20nM), or S1P3 agonist (CYM5541, 100nM) for 30mins, at 37 ºC as indicated. To study cellular binding, 
association and transport, HAECs were incubated with 10µg/mL of 125I-HDL or 125I-LDL for 1hour in the absence 
(total) or in the presence of 40-fold excess of unlabeled HDL and LDL, respectively, to record unspecific 
interactions. Specific binding, association and transport were calculated by subtracting unspecific values from total 
values.  A, Specific binding was measured by incubating cells with 125I-HDL (A) or 125I-LDL (D) at 4 ºC. To 
measure specific cell association, cells were incubated with 125I-HDL (B) or 125I-LDL (E) at 37 ºC. For the 
measurement of transport, HAECs were cultured on inserts. The transport of 125I-HDL (C) and 125I-LDL (F) from 
the apical to basolateral compartment was measured at 37 ºC. The results are represented as means±SEM of three 
independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
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Treatment of endothelial cells with either S1P1 agonist SEW2871 or S1P3 agonist CYM5541 increased 
the specific cellular binding of 125I-HDL at 4ºC by 95% and 43%, respectively (Figure 2.3A). Also, 
treatment with either S1P1 agonist or S1P3 agonist increased the cellular association of 125I-HDL at 
37ºC by 60% and 66%, respectively and the transendothelial transport of 125I-HDL from apical to 
basolateral compartments by 35% and 33%, respectively (Figure 2.3B, C).  By contrast, S1P1 or S1P3 
agonist treatment decreased the specific cellular binding of 125I-LDL by 47% and 42%, (Figure 2.3D) 
association by 36% and 47%, respectively (Figure 2.3E) and transendothelial transport of 125I-LDL by 
35% and 36%, respectively (Figure 2.3F).  
 
Figure 2.4: S1P1 and S1P3 inhibitors regulate binding, association and transendothelial transport of HDL 
and LDL in HAECs HAECs were cultured for 72hours. Cells were then treated with the S1P1 inhibitor (W146, 
20nM), or the S1P3 inhibitor (TY52156, 110nM) for 30mins, at 37 ºC as indicated. To study cellular binding, 
association and transport, HAECs were incubated with 10µg/mL of 125I-HDL or 125I-LDL for 1hour in the absence 
(total) or in the presence of 40-fold excess of unlabeled HDL and LDL, respectively, to record unspecific 
interactions. Specific binding, association and transport were calculated by subtracting unspecific values from total 
values.  A, Binding was measured by incubating cells with 125I-HDL (A) or 125I-LDL (D, G) at 4 ºC. To measure 
cell association, cells were incubated with 125I-HDL (B) or 125I-LDL (E, H) at 37 ºC. For the measurement of 
transport, HAECs were cultured on inserts. The transport of 125I-HDL (C) and 125I-LDL (F, I) from the apical to 
basolateral compartment was measured at 37 ºC. The results are represented as means±SEM of three independent 
triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. n.s represents “not significant”. 
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We next determined whether the pharmacological inhibition of the S1P receptors influence the cellular 
binding, association and transendothelial transport of radioiodinated HDL and LDL in endothelial cells. 
Cells were pre-treated with pharmacological drug inhibitors against S1P1 or S1P3 for 30mins prior to 
the assays. Treatment with either the S1P1 inhibitor W146 or the S1P3 inhibitor TY52156 decreased 
the specific cellular binding of 125I-HDL by 60% and 70% (Figure 2.4A) and cellular association by 
65% and 45%, respectively (Figure 2.4B). Treatment of cells with S1P1 or S1P3 inhibitor also decreased 
the transendothelial transport of 125I-HDL from apical to basolateral compartments by 50% and 42%, 
respectively (Figure 2.4C). By contrast, treatment of the cells with the S1P1 inhibitor increased total 
cellular association and transendothelial transport of 125I-LDL by 55% and 42%, respectively but did not 
affect the cellular binding of 125I-LDL to the endothelial cells (Figure 2.4D-F).  However, treatment of 
HAECs with S1P3 inhibitor increased specific cellular binding of 125I-LDL by 38% (Figure 2.4D) as 
well as cellular association and transport by 25% and 30%, respectively (Figure 2.4E, F).  
Taken together, these results indicate that S1P1 and S1P3 regulate endothelial cellular binding, 
association as well as transport of HDL and LDL antagonistically. 
S1P1 and S1P3 regulate cellular binding, association and transendothelial transport of HDL via 
SR-BI 
We have previously demonstrated that the availability of SR-BI cell surface levels as a crucial factor for 
the transendothelial transport of HDL19. Because of the fast effects of S1P1 and S1P3 agonists on cellular 
binding, association and transport of 125I-HDL, we hypothesized that S1P1 and S1P3 regulate the 
availability of SR-BI on the cell surface in HAECs. To test this hypothesis, we performed a cell surface 
biotinylation experiment. Pre-treatment of HAECs with either S1P1 or S1P3 agonist increased the cell 
surface SR-BI protein levels compared to the control condition (2.5A). To determine whether S1P1 and 
S1P3 regulate trans-endothelial transport of HDL through SR-BI, we silenced SR-BI using RNA 
interference. The knockdown was efficient at the protein level (Figure 2.9A). Silencing SR-BI alone 
significantly decreased 125I-HDL specific cellular binding by 45%, cellular association by 40% and 
transport by 50%, respectively. Pre-treatment with either the S1P1 or the S1P3 agonist for 30mins did 
not stimulate the cellular binding or cellular association or transport of 125I-HDL through endothelial 
cells with suppressed SR-BI (Figure 2.5B-G).   
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Figure 2.5: S1P1 and S1P3 agonists modulate SR-BI dependent binding, association and transport of HDL 
by HAECs A, Western blots of SR-BI, LDL-receptor (LDLR) and anti-TATA binding protein (TBP) in total cell 
lysates (left) and on the cell surface (right).  HAECs were cultured for 72hours. Cells were then treated with the 
S1P1 inhibitor (W146, 20nM), or the S1P3 inhibitor (TY52156, 110nM) for 30mins, at 37 ºC as indicated. The 
western blot was probed with anti-SR-BI (80 kDa), anti-LDLR (95 kDa and 160 kDa), anti-ABCG1 (90 kDa) as 
well as anti-endothelial lipase (EL) (60 kDa) and anti- TATA binding protein (TBP) (40 kDa, as control for 
intracellular protein expression). To study cellular binding, association and transport of 125I-HDL, HAECs were 
transfected with a specific siRNA against SR-BI or with non-silencing control siRNA (NS control) and assays 
were performed 72hours post-transfection. Cellular binding of 125I-HDL was measured at 4 ºC by pre-treating cells 
with the S1P1 agonist (A) or the S1P3 agonist (E). Cellular association of 125I-HDL was measured at 37 ºC by pre-
treating cells with the S1P1 agonist (C) or the S1P3 agonist (F). For the measurement of transport of 125I-HDL, 
HAECs were cultured on inserts. The transport of 125I-HDL was measured by pre-treatment with the S1P1 agonist 
(D) or the S1P3 agonist (G) from the apical to basolateral compartment was measured at 37 ºC. The results are 
represented as means±SEM of three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
S1P1 regulates cellular association and transendothelial transport of LDL via fluid-phase 
pathway 
As previously described (Figure 2.4D-F), pre-treatment of HAECs with the S1P1 inhibitor did not affect 
the binding of 125I-LDL by the cells at 4ºC and the presence of excess unlabeled LDL did not decrease 
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the cellular association and transport of 125I-LDL through the endothelial cells. These phenomena point 
to fluid-phase uptake (Figure 2.6A, B).  
Figure 2.6: S1P1 and S1P3 inhibitors regulate cellular association and transendothelial transport of LDL 
in HAECs HAECs were cultured for 72hours. Cells were then treated with the S1P1 inhibitor (W146, 20nM), or 
the S1P3 inhibitor (TY52156, 110nM) for 30mins, at 37 ºC as indicated. To study cellular association and 
transport, HAECs were incubated with 10µg/mL of 125I-LDL for 1hour in the absence (total) or in the presence of 
40-fold excess of unlabeled LDL, respectively, to record unspecific interactions. Specific association and transport 
were calculated by subtracting unspecific values from total values.  A, To measure cell association, cells were 
incubated with 125I-LDL at 37 ºC.  B, For the measurement of transport, HAECs were cultured on inserts. The 
transport of 125I-LDL from the apical to basolateral compartment was measured at 37 ºC. The results are 
represented as means±SEM of three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
In line with this hypothesis, pre-treatment of HAECs with the S1P1 inhibitor significantly increased the 
endothelial uptake of FITC-labeled dextran which is a marker for fluid-phase endocytosis. The uptake 
of FITC-dextran but not 125I-LDL was markedly decreased by pre-treatment of cells with amiloride, that 
inhibits Na+/H+ channels needed for the induction of fluid-phase trafficking by localized pH shift (Figure 
2.7A) 20. Interestingly, the S1P1 inhibitor failed to stimulate the cellular association and transport of 125I-
LDL across the endothelial cells in the presence of amiloride (Figure 2.7B, C). Taken together, these 
findings indicate that S1P1 inhibitition promotes cellular association and transport of 125I-LDL through 
fluid-phase. The failure of amiloride to decrease the transport of 125I-LDL in the absence of the S1P1 
inhibitor indicates that LDL is also transported by processes that are independent of fluid phase.  
S1P3 regulates cellular binding and association of LDL through LDLR but the transendothelial 
transport of LDL via LDLR and SR-BI independent pathway 
Treatment of HAECs with the S1P3 inhibitor significantly increased the specific cellular binding and 
association of 125I-LDL, indicating a receptor-mediated endocytic pathway (Figure 2.6A, B). To identify 
how the S1P3 inhibitor promotes the cellular binding and association of 125I-LDL, we silenced LDLR 
and SR-BI using RNA interference. The knockdown of LDLR (Figure 2.8A) and SR-BI (Figure 2.9A) 
was efficient at the protein level. Silencing LDLR alone significantly decreased specific cellular binding 
and association of 125I-LDL by 60% and 70%, respectively. Pre-treatment with the S1P3 inhibitor for 
30mins did not stimulate the cellular binding and association of 125I-LDL in the absence of LDLR. 
Silencing of LDLR had no effect on the transport of 125I-LDL (Figure 2.8B-D). Silencing of SR-BI alone 
decreased the cellular binding and association of 125I-LDL by 28% and 35%, respectively as well as 
decreased the transport of 125I-LDL by 26%. However, the stimulatory effect of the S1P3 inhibitor on 
cellular binding, association and transport of 125I-LDL was unchanged by the RNA interference of SR-
BI (Figure 2.9B-D), indicating that the S1P3 inhibitor stimulates transendothelial transport of 125I-LDL 
independently of SR-BI.  
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Figure 2.7: S1P1 inhibitor promotes cellular association and transendothelial transport of LDL via fluid-
phase in HAECs HAECs were cultured for 72hours. Cells were then treated with amiloride (20 µM ) or the S1P1 
inhibitor (W146, 20nM) or the S1P3 inhibitor (TY52156, 110nM) for 30mins, at 37 ºC as indicated. A, To study 
cellular association of Dextran, cells were incubated with 1mg/mL of FITC-labeled dextran for 1 hour. B, To study 
cellular association and C, transport, HAECs were incubated with 10µg/mL of 125I-LDL for 1hour in the absence 
(total) or in the presence of 40-fold excess of unlabeled LDL, respectively, to record unspecific interactions. The 
results are represented as means±SEM of three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, 
*P≤ 0.05. n.s represents “not significant” 
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Figure 2.8: S1P3 inhibitor stimulates binding and association but not transport of LDL in HAECs via LDL 
receptor A, Protein levels of LDLR were measured using western blotting following transfection of endothelial 
cells with specific siRNAs against LDLR. TATA-binding protein (TBP) was used as a loading control. B-D, 
HAECs were transfected either with siRNA against LDLR or with non-silencing siRNA (NS control) for 72hours. 
Cells were then treated with the S1P3 inhibitor (TY52156, 110nM) for 30mins, at 37 ºC as indicated. To study 
cellular binding, association and transport, HAECs were incubated with 10µg/mL of 125I-LDL for 1hour in the 
absence (total) or in the presence of 40-fold excess of unlabeled HDL and LDL, respectively, to record unspecific 
interactions. Specific binding, association and transport were calculated by subtracting unspecific values from total 
values.  B, Binding was measured by incubating cells with 125I-LDL at 4 ºC. C, To measure cell association, cells 
were incubated with 125I-LDL at 37 ºC. D, For the measurement of transport, HAECs were cultured on inserts. The 
transport of 125I-LDL from the apical to basolateral compartment was measured at 37 ºC. The results are 
represented as means±SEM of three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
n.s  represents “not significant”. 
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Figure 2.9: S1P3 inhibitor stimulates binding, association and transport of LDL in HAECs independent of 
SR-BI A, Protein levels of SR-BI were measured using western blotting following transfection of endothelial cells 
with specific siRNAs against SR-BI. TATA-binding protein (TBP) was used as a loading control. B-D, HAECs 
were transfected either with siRNA against SR-BI or with non-silencing siRNA (NS control) for 72hours. Cells 
were then treated with the S1P3 inhibitor (TY52156, 110nM) for 30mins, at 37 ºC as indicated. To study cellular 
binding, association and transport, HAECs were incubated with 10µg/mL of 125I-LDL for 1hour in the absence 
(total) or in the presence of 40-fold excess of unlabeled HDL and LDL, respectively, to record unspecific 
interactions. Specific binding, association and transport were calculated by subtracting unspecific values from total 
values.  B, Binding was measured by incubating cells with 125I-LDL at 4 ºC. C, To measure cell association, cells 
were incubated with 125I-LDL at 37 ºC. D, For the measurement of transport, HAECs were cultured on inserts. The 
transport of 125I-LDL from the apical to basolateral compartment was measured at 37 ºC. The results are 
represented as means±SEM of three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05.  
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2.4 Discussion 
It is yet controversial whether transendothelial lipoprotein transport is mediated by specific mechanisms 
or the result of passive filtration 6, 7. The antagonistic effects of S1P-receptor agonists and -antagonists 
on the transendothelial transport of HDL and LDL demonstrated here support the previous notion of our 
but also other laboratories that the transport of lipoproteins through monolayers of aortic endothelial 
cells happens in a regulated manner rather than by passive filtration 8-10, 19, 20.  
At first sight, our findings of opposite regulation of transendothelial HDL and LDL transport are 
surprising because S1P is known as an important regulator of intercellular junction closure in the 
endothelium and because S1P is carried by either lipoprotein. Activation of S1P1, through the G-protein 
Gi, and S1P3, through activation of Gi, Gq, and G12/13, promote cellular motility, vascular maturation, 
focal contact formation, and decreased permeability through modulation of Rho family GTPases, 
PI3K/Akt and mitogen activated protein (MAP) kinases 21. On contrary, inactivation of S1P1 and S1P3 
signaling was shown to increase endothelial permeability and to promote edema as well as 
inflammation1, 22-24. Although more moderately, also the decrease of plasma S1P levels in mice which 
lack the S1P binding protein apoM was associated with impaired endothelial barrier function and the 
occurrence with edema and exudation of Evan’s Blue 25. However, in our in vitro transwell cell culture 
model we did not observe any differences in the inulin permeability upon treatment with S1P1 or S1P3 
inhibitors.   
The cellular binding, association and transport of HDL were enhanced upon activation of S1P1 and 
S1P3 with their respective agonists but reduced in the presence of S1P1 and S1P3 inhibitors. Vice versa, 
the transport of LDL was inhibited and stimulated by the same agonists and antagonists, respectively, 
of S1P1 and S1P3. The use of drugs has the limitation of potential off-target effects. The use of S1P 
dissolved in cell culture medium as the more physiological agonist of S1P receptors did not show any 
consistent effect on HDL transport (Rohrer et al. unpublished results). However, it is important to note 
that also other activities of S1P on endothelial cells were previously found to depend on the presence of 
its specific binding protein or chaperone: apoM and HDL-bound S1P but not albumin-bound S1P were 
reported to inhibit the expression of adhesion molecules and activate endothelial nitric oxide synthase 
26-28. In agreement with both this hypothesis and our results on pharmacological interventions, apoM- 
and hence S1P-depleted HDL of humans were found to be less effectively bound, internalized and 
transported by HAECs than complete HDL (Rohrer, Christoffersen et al., unpublished results) 25.  
Likewise, S1P-poor HDL of apom knock-out mice showed reduced binding, association and transport 
by HAECs compared to HDL from the wild type littermates (Rohrer, Stoffel, Parks et al., unpublished 
results) 29-31.  Conversely, S1P-enriched HDL of mice transgenic for human apoM showed enhanced 
binding, association and transport (Rohrer, Stoffel, et al., unpublished results) 31-33.  Taken together these 
findings indicate a physiological role of S1P in the regulation transendothelial HDL transport. However, 
we cannot exclude any additional S1P-independent impact of apoM on the interaction of HDL with 
endothelial cells, for example binding to a yet unknown apoM receptor, or selection of HDL subclasses, 
which because of differences in size or composition beyond presence/absence of apoM/S1P are 
differently interacting with HAECs 34, 35. Thus, the effects of our pharmacological interferences can be 
interpreted as being more specific than the findings obtained by the comparative analysis of apoM/S1P-
free/poor lipoproteins versus apoM and S1P containing lipoproteins. Despite this limitation, it will be 
interesting to investigate the transport of apoM-free LDL versus apoM-containing LDL. The feasibility 
of these experiments is however limited by the lower concentration of apoM and S1P in human LDL as 
compared to human HDL and even more so by the overall low concentration of LDL in mice. 
Experiments with mouse LDL will probably only be possible if done on LDL isolated from apoB-
overexpressing or LDL-receptor deficient mice crossed with apoM knock-out mice 36.  
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The opposite effects of S1P-receptor agonists as well S1P-receptor antagonists on transendothelial 
transport of HDL and LDL can be explained by the activation of several downstream responses 37, which 
have different impact on receptors, and intracellular itineraries of HDL and LDL. In fact, we found, that 
the stimulatory effect of both S1P1- and S1P3-receptor agonists on HDL transport involves SR-BI 
whereas the stimulatory effect of the S1P1- and S1P3-receptor antagonists on LDL transport involved 
fluid phase uptake and a yet unresolved mechanism, respectively.  
                                        
Figure 2.10: S1P1 and S1P3 agonists modulate SR-BI dependent binding, association and transport of HDL 
by HAECs Both the S1P1 and S1P3 agonists stimulated the translocation of SR-BI to the cell surface, which 
further increased the cellular binding, association and transport of HDL. 
Both S1P1- and S1P3-agonism stimulated the translocation of SR-BI from the intracellular 
compartments to the cell surface and thereby enhanced the binding of HDL (Figure 2.10). Thus S1P-
receptor activation has the same effect as the activation of VEGF receptor 2 by VEGF-A. This may be 
explained by the fact that activation of either receptor induces Akt phosphorylation 38, 39 which we 
previously found to mediate the stimulatory effect of VEGF on both SR-BI translocation and binding, 
uptake and transport of HDL by HAECs 19. However, SR-BI was previously reported by others and 
shown by us to mediate binding, association and transport of LDL by HAECs 12, 19. We also replicated 
this finding in the present study (Figure 2.9). Therefore, it was surprising that stimulation of both S1P1 
and S1P3 rather inhibited transendothelial transport. This discrepancy can be explained by the fact that 
other receptors and intracellular itineraries overrule the contribution of SR-BI in binding and transport 
of LDL. In fact, we found two pathways activated by S1P1- or S1P3-antagonists and hence inhibited by 
S1P1- or S1P3-agonists: Both S1P1 and S1P3 agonist treatment decreased the cell surface expression 
of the LDL receptor and thereby contributed to the decreased cellular binding and association of LDL. 
Obviously, the increased cell surface abundance of SR-BI could not compensate for the reduced 
abundance of the LDL receptor for LDL binding upon activation of S1P1 or S1P3. 
The inhibition of S1P1 promoted LDL cellular association and transport through the endothelial cells 
via fluid-phase. Indirect evidence for this is provided by the increased FITC-dextran uptake and the 
failure to compete the transport of iodinated LDL with unlabeled LDL in the presence of the S1P1 
inhibitor (Figure 2.11). Moreover, the the S1P1 antagonist failed to stimulate LDL transport in the 
presence of amiloride. However, and interestingly, inhibition of S1P1 did not promote the uptake of HD. 
In line with this, our lab has previously found neither any effect of amiloride on HDL uptake by HAECs 
nor any co-localization of FITC-Dextran and fluorescent HDL in HAECs 20. Moreover, and rather by 
contrast, inhibition of S1P1 decreased the specific cellular binding, association and transport of HDL 
through HAECs. This indicates that the SR-BI-dependent internalization of HDL by HAECs overrules 
any contribution of fluid-phase transport to the transendothelial transport of HDL. 
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S1P3 inhibition increased the cellular binding, association, and transport of LDL through endothelial 
cells. By RNA interference, we revealed the involvement of the LDL receptor in the S1P3 inhibitor 
mediated cellular binding and association of LDL (Figure 2.11).  However, and agreement with a 
previous report 12, silencing of LDLR did not interfere with the transendothelial transport of LDL. Thus, 
S1P3-stimulated LDL-uptake via the LDL-receptor probably leads to intracellular degradation rather 
than re-secretion of LDL. Likewise, we ruled out SR-BI as the mediator of enhanced transendothelial 
LDL transport upon S1P3 inhibition. By contrast, to the S1P1 inhibitor, the S1P3 inhibtor stimulated 
the transendothelial transport of ioidinated LDL by a mechanism, which could be competed by non-
labeled LDL. Thus, we postulate the involvement of a yet unidentified receptor that allows 
transendothelial LDL transport, for example ALK1 that was recently identified by a genome-wide 
RNAi-screen as an endothelial LDL binding protein mediating uptake and transcytosis of LDL 13.  
                                   
Figure 2.11: S1P1 and S1P3 inhibitors regulate association and transport of LDL by HAECs Both the S1P1 
and S1P3 inhibitors stimulated the uptake and transport of LDL. S1P1 inhibitor increased the transport of LDL via 
fluid-phase transcytosis. S1P3 increased the cellular binding and uptake of LDL through LDL receptor. The 
candidate protein regulator of LDL transport by S1P3 inhibitor remains unidentified.  
In conclusion, we here showed that the S1P1 and S1P3 regulate endothelial binding, uptake and transport 
of HDL and LDL in an antagonistic manner. By inhibiting the transendothelial transport of pro-
atherogenic LDL and promoting the transendothelial transport of potentially anti-atherogenic HDL, S1P 
and its cognate receptors S1P1 or S1P3 may play an important role in the pathogenesis of atherosclerosis 
and serve as interesting targets for protection against atherosclerosis. However, any therapeutic 
interference may need to be endothelium-specific as previous animal experiments on S1P-receptor 
modulators or knock-out of S1P metabolizing enzymes or S1P receptors yielded controversial findings 
on the role of S1P in the pathogenesis of atherosclerosis 24, 40-43. 
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Abstract 
Objective: Low and high-density lipoproteins (LDL and HDL) must pass the endothelial layer to exert 
pro- and anti-atherogenic activities, respectively, within the vascular wall. However, the rate limiting 
factors that mediate transendothelial transport of lipoproteins are yet little known. Therefore, we 
performed a high-throughput screen with kinase drug inhibitors to identify modulators of 
transendothelial LDL and HDL transport. 
Approach and Results: Microscopy based high-content screening was performed by incubating human 
aortic endothelial cells (HAECs) with 141 kinase inhibiting drugs and fluorescent labeled LDL or HDL. 
Inhibitors of VEGF receptors (VEGFR) significantly decreased the uptake of HDL but not LDL. 
Silencing of VEGFR2 significantly decreased cellular binding, association, and transendothelial 
transport of 125I-HDL but not 125I-LDL. RNA interference with VEGFR1 or VEGFR3 had no effect. 
Binding, uptake and transport of HDL but not LDL were strongly reduced in the absence of VEGF-A 
from the cell culture medium and were restored by the addition of VEGF-A. The restoring effect of 
VEGF-A on endothelial binding, uptake and transport of HDL was abrogated by pharmacological 
inhibition of PI3K/Akt or p38MAPK as well as silencing of scavenger receptor BI (SR-BI). Moreover, 
the presence of VEGF-A was found to be a pre-requisite for the localization of SR-BI in the plasma 
membrane of endothelial cells. 
Conclusions: The identification of VEGF as a regulatory factor of transendothelial transport of HDL 
but not LDL supports the concept that the endothelium is a specific and hence druggable barrier for the 
entry of lipoproteins into the vascular wall. 
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3.1 Introduction 
Accumulation of low density lipoproteins (LDL) and lipids in the subendothelial matrix and 
macrophages is crucial in the pathogenesis of atherosclerosis 1. Conversely, removal of cholesterol from 
the subendothelial space by cholesterol efflux and subsequent reverse cholesterol transport (RCT) has 
been postulated to confer protection against atherosclerosis 2. To reach the subendothelial space, both 
LDL and HDL have to cross the intact endothelial barrier. It is yet controversial whether transendothelial 
HDL transport is mediated by specific mechanisms or the result of passive filtration 3, 4. Our laboratory 
previously showed that aortic endothelial cells are able to specifically bind, internalize and transport 
HDL in a saturable and temperature-dependent manner via a non-classical endocytic route involving 
dynamin and cytosketal networks 5, 6. We also demonstrated that transcytosis of mature HDL is regulated 
by ATP binding cassette transporter ABCG1, scavenger receptor SR-BI, and endothelial lipase (EL), as 
well as the ectopic-β-ATPase/purinergic receptor axis 6-8. Other laboratories reported that endothelial 
cells internalize LDL by at least two pathways 3: The classical one leads to lysosomal degradation and 
involves clathrin-coated pits and the LDL-receptor 9, 10. The other non-degrading pathway allows the 
transendothelial transport of LDL and involves caveolae 11, SR-BI 12 and activin-like kinase 1 (ALK1) 
13. 
Genome-wide RNA interference studies have shown that both clathrin- and caveolin-dependent 
endocytosis are regulated by kinases 316. The kinases regulating the endocytosis of lipoproteins 
especially by endothelial cells are unknown. To identify such signaling cascades regulating the uptake 
of LDL and HDL, we performed a microscopy-based high-content screening on human aortic 
endothelial cells using a kinase inhibitor drug library. Starting with this unbiased strategy, we found 
evidence for an important regulatory role of vascular endothelial growth factor receptors in regulating 
uptake of HDL but not LDL by endothelial cells. 
3.2 Materials and Methods 
Cell culture 
Human aortic endothelial cells (HAECs) from Cell Applications Inc (304-05a), were cultured in 
endothelial cell basal medium (LONZA Clonetics CC-3156 or ATCC PCS-100-030) with 5% fetal 
bovine serum (GIBCO), 100U/mL of penicillin and 100µg/mL streptomycin (Sigma-Aldrich), 
supplemented with singleQuots (LONZA Clonetics CC-4176 or ATCC PCS-100-041, containing hFGF, 
hVEGF, hIGF-1, hEGF, hydrocortisone, ascorbic acid, heparin) hereafter referred to as medium A or 
singleQuots without VEGF, hereafter referred to as medium B at 37ºC in a humidified 5% CO2, 95% 
air incubator. According to the product description by ATCC, medium A contains 5 ng/ml VEGF-A. 
Lonza does not provide any public information on the VEGF-A content of its medium A. For some 
experiments (if indicated) we supplemented the VEGF-free medium B with 25 ng/ml VEGF-A (Sigma, 
V7259) 
Lipoprotein Isolation and labeling 
LDL (1.019<d<1.063 g/mL) and HDL (1.063<d<1.21 g/mL) were isolated from fresh human 
normolipidemic plasma of blood donors by sequential ultracentrifugation as described previously 15, 16. 
LDL and HDL were fluorescently labeled with Atto-488 (Atto-Tec, AD 488-35) and Atto-594-NHS-
ester dyes, respectively (Atto-Tec, AD 594-35). The reaction was performed at a pH 8.0 adjusted by 
adding 1M NaHCO3 to obtain a final concentration of 0.1M in dark at room temperature for 1hour. The 
labeled lipoproteins were separated from free dye by gel filtration chromatography using PD-10 
desalting columns (GE healthcare, 170851-01). LDL and HDL were radioiodinated with Na125I by the 
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McFarlane monochloride procedure modified for lipoproteins 16, 17. Specific activities between 300-900 
cpm/ ng of protein were obtained.  
Kinase inhibitor screen 
HAECs were seeded in 384 well plates using a washer dispenser (Biotek, EL406) at a density of 1000 
cells per well in 80ul of their respective media. The cells were allowed to grow for 72 hours at 37ºC in 
a humidified 5% CO2, 95% air incubator. Following culture, cells were treated with 141 drugs 
encompassing kinase inhibitor library targeting 20 kinases (Table 3.I) or with dimethyl sulfoxide 
(control-vehicle). For each drug, seven different concentrations were used at a dilution range of 128, 
640, 3200, 16000, 80000, 400000, 2000000. After 1 hour of drug treatment, cells were incubated with 
either fluorescent labeled Atto594-HDL or LDL [RFP (Red fluorescent protein) channel] or medium 
without any fluorescent labeled lipoprotein (Blank control) for another hour. The cells were later washed 
with PBS using 384-well head manifold (Biotek, EL406), fixed with 2% paraformaldehyde and nuclei 
were stained with Hoechst- 33258 (Sigma, 861405). Four compounds, previously reported to interfere 
with the uptake of lipoproteins into endothelial cells were used as positive control drugs at seven 
concentrations ranging from 128 ng/ml to 2 mg/ml: Tetrahydrolipstatin (THL) to inhibit endothelial 
lipase, BLT1 to inhibit SR-BI, colchicine to interfere with the cytoskeleton, and dynasore to interfere 
with vesicle formation.  
                                
Table 3.I: List of targets of 141 drug compounds. The drug compounds inhibit a wide range of target kinases, 
which comprises of both receptor-tyrosine kinases and their downstream signaling kinases.  
The assay plates were processed using Molecular Device wide-field fluorescence microscope and nine 
images per well were acquired with 20X short working distance objective. The primary microscope 
generated images were analyzed using Cell profiler to segment nuclei in DAPI channel and foci 
(vesicles) in RFP channel (Figure 3.1).  
Target Full name of the target
ABL Abelson murine leukemia viral oncogene homolog 1
ALK Anaplastic lymphoma kinase
c-Kit Tyrosine-protein kinase kit or CD117
c-Met Tyrosine-protein kinase met
EGFR Epidermal growth factor receptor
FGFR Fibroblast growth factor receptor
FLT-3 Fms-like tyrosine kinase 3
HER2 Receptor tyrosine-protein kinase erbB-2 or CD340
IGF-1R Insulin growth factor receptor
VEGFR Vascular endothelial growth factor receptor
Aurora Aurora kinase
CDK Cyclin-dependent kinase
CHK Check-point kinase
GSK-3 Glycogen synthase kinase-3
JNK c-Jun N-terminal kinase
JAK/STAT Janus kinase and signal transducer and activator of transcription proteins
MEK Mitogen-activated protein kinase kinase
mTOR Mammalian target of rapamycin
PI3K/AKT phosphotidyl-inositol 3 kinase/protein kinase B
p38 MAPK p38 mitogen-activated protein kinase
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Figure 3.1. Description of the workflow. The microscopy generated images are initially assessed for quality 
based on the performance of control drug compounds followed by shading correction and dynamic background 
subtraction. The nine images acquired from each well are stitched together and signal intensities of both DAPI and 
RFP channel are measured using Cellprofiler.  
Image acquisition and analysis 
Several hundred features for each cell were extracted – for nucleus, cytoplasm and foci. The raw images 
had nuclei that were stained many times weaker than the others. For example, in Figure 3.2, a line is 
drawn connecting a brightly stained nucleus and a weakly stained nucleus to measure the grey values. 
The difference in the staining intensities across various images was recorded between 5 and 10. The 
Hoechst stained images were enhanced by taking the 100th root of all intensity values and normalized to 
the brightest value in each image.  
  
Figure 3.2: Normalization of nuclei – DAPI channel. (a) Staining of nuclei with Hoechst. (b) Difference in 
staining intensities between two nuclei connected by a line in 5(a). (c) Normalized nuclei staining by enhancing 
100th root of all intensity values. 
Nuclei were further filtered based on detected shapes to avoid as many artefacts as possible. A two-step 
segmentation was applied to account for the large variability in Hoechst staining. Segmented nuclei 
were filtered based on “Solidity measure” with a minimum threshold of 0.93. Solidity measure is 
potentially a better differentiator of cells with irregular shape versus round cells. It is the ratio of the 
area of the cell to the enclosed convex hull container. The images in Figure 3.3 show the segmented 
nuclei and a 30-pixel wide ring around them, overlaid on the RFP channel image. The RFP images were 
enhanced by taking the square root of all intensity values and normalizing to the brightest value in each 
image. Three measures in particular were designed to measure the uptake of the fluorescent-labeled 
HDL/LDL. The number in yellow determines the number of foci detected in the cell (cytoplasm + 
nucleus). The number in red shows the area-normalised fraction of the intensity in the innermost of three 
equal-width concentric rings in the cytoplasm; where numbers larger than unity correspond to above 
cytoplasm-average intensity. The number in cyan is the second component of granularity (resampled at 
0.5, radius of structuring element = 1 pixel). 
Analysis was done at the well-level, i.e., all cell-level measurements were aggregated before analysis. 
The aggregation was done using the open-source software KNIME. KNIME was also used to merge the 
aggregated measurements with the annotation file, containing the names and concentrations of 
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compounds, the cell type, ligand type. For some measures, such as cell-count, the aggregation method 
was summation. For most measures, the aggregation method was to calculate the median of all cell 
values in an image, and then the median of the nine images (there are nine images per well). 
 
     
Figure 3.3: Segmentation of nuclei (DAPI) and cytoplasm (RFP channel). (a) Nuclei selected with a threshold 
solidity measure of 0.93 (b) Segmented nuclei from cytoplasm with HDL containing vesicles (RFP). (c) 
Measurement of respective signal intensities in DAPI and RFP channels. 
To assure quality and limit variance and error, two biological replicate experiments were performed 
with HAECs. As an indication of reproducibility, the nuclei numbers (Figure 3.4, pink dots = HDL, blue 
dots = LDL and green dots = no addition of labeled lipoprotein) as well as median foci intensity of Atto 
594-labelled LDL and HDL were assessed (Figure 3.5, Plates 1-5 = Run 1 and Plates 6-10 = Run 2) in 
control vehicle treated wells (dimethyl sulfoxide) per 384-well assay plate and observed negligible 
variance within and between runs.  
Normalization and dose-response curves 
Each assay plate was normalised using Genedata Screener (Genedata, Basel, Switzerland) by subtracting 
and dividing by the value in the blank control wells. This was done for each feature of interest according 
to the following formula: 
                                 
where x is the feature of interest, e.g. cell count, (x) is the median of all blank control wells in the plate, 
and N(x) is the normalized value in percent. In this example, a value of -100 means that no cells were 
detected, a value of +100 means that twice as many cells were detected as in the blank control wells. 
Post-normalization, the RFP foci per cell values were fitted as a function of drug-concentration in 
Genedata Screener. The formula used to fit the dose-response data was a logistic function of the Hill 
Model type.   
                                             Y(X) = S∞ +       S0 - S∞   
                                                                    1 + (X/ IC50) nHill 
where X is the drug concentration, Y is the activity, S0 is fitted activity level at zero concentration (zero 
activity), S∞ is fitted activity level at infinite concentration (infinite activity), nHill is the Hill coefficient 
for the curve which is the measure of the slope at IC50, IC50 is the concentration at which the uptake of 
fluorescent HDL or LDL was inhibited by 50%. The fit parameters were constrained so that 0.5 ≤ nHill 
≤ 4, S0 = 0, S∞ = -100. Prior to applying the Fisher exact test analysis, the drugs were classified as active 
based on the possibility to fit Hill model, and the rest of the drugs were assigned as inactive. The only 
arbitrary feature of this procedure is the choice to fit the logistic model only when the fluorescent signal 
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drop was more than 50%. The reproducibility of the dose-response curves for foci per cell was assessed 
by the performance of two independent duplicate experiments. 
 
 
Figure 3.4: Reproducibility of drug screening experiments on the cellular uptake of LDL or HDL by HAECs 
as reflected by number of nuclei per plate in vehicle treated wells. Each run with one lipoprotein encompassed 
five plates. Average nuclei numbers (Y-axis) are plotted against screening plates (X-axis). HAECs incubated with 
fluorescently labeled LDL and HDL represented by blue and pink dots, respectively and vehicle treated wells that 
did not contain any label (lipoprotein) are represented by green dots.  
   
Figure 3.5: Reproducibility of drug screening experiments on the cellular uptake of LDL and HDL by 
HAECs as reflected by median foci intensity in vehicle treated wells Each run with labeled-lipoprotein 
(HDL/LDL) encompassed five plates. Median foci intensity of the Atto-labeled lipoprotein (Y-axis) is plotted 
against screening plates (X-axis). Plates 1-5 represent run 1 and plates 6-10 represent run 2.  
To assess the intra- and inter-assay variability after normalization, colchicine dose-response curves 
(used as positive control drug) for the LDL and HDL median foci intensity feature were generated 
(Figure 3.6), which did not differ significantly across the two screening runs. For LDL foci intensity, 
after nonlinear regression analysis, the logIC50 of colchicine was 3.624 (95%CI: 3.060 to 4.188) for run 
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1 and 3.411 (95%CI: 2.956 to 3.866) for run 2 respectively. For HDL foci intensity, after nonlinear 
regression analysis, the logIC50 of colchicine was 3.674 (95%CI: 3.139 to 4.208) for run 1 and 3.612 
(95%CI: 3.165 to 4.059) for run 2 respectively. 
                                                                            
Figure 3.6: Reproducibility of drug screening experiments on the cellular uptake of LDL and HDL by 
HAECs as reflected by median foci intensity in Colchicine treated wells (positive control) Dose response 
curves for seven different concentrations of colchicine (X-axis) are plotted against median foci intensity of the 
Atto-labeled lipoprotein (Y-axis). Data points with circles represent Run 1 and with squares represent Run 2. 
For each compound interaction, the amount of downregulation was calculated relative to a control 
reaction in the presence of vehicle (dimethyl sulfoxide). The analysis of the dose-response data for LDL 
and HDL uptake by the use of the Hill model identified two and nine drugs, respectively, with a Hill 
coefficient of 4 which therefore were suspicious of toxicity and hence excluded from further analysis.  
 
Small Interfering RNA Transfection 
Endothelial cells were reverse transfected with small interfering RNA (Ambion silencer select, Life 
technologies) targeted to VEGFR1 (s5287, s5288) or VEGFR2 (s7822, s7824) or VEGFR3 (s5294, 
s5295) or AKT (s659, s660) or MAPK14 (p38 MAPK) (s3585, s3586) or MAP2K1 & MAPK2K2 
(MEK1/2) (s11167, s11170) or SR-BI (s2648, s2649, s2650) or non-silencing control (4390843) at a 
final concentration of 5nmol/L using Lipofectamine RNA iMAX transfection reagent (Invitrogen, 
13778150) in an antibiotic-free medium A or B as indicated.  All experiments were performed 72 hours 
post-transfection and efficiency of transfection was confirmed with at least two siRNAs against each 
gene using quantitative RT-PCR and western blotting.  
Quantitative real time PCR 
Total RNA was isolated using TRI reagent (Sigma T9424) according to the manufacturer’s instruction. 
Genomic DNA was removed by digestion using DNase (Roche) and RNase inhibitor (Ribolock, Thermo 
Scientific).  Reverse transcription was performed using M-MLVRT (Invitrogen, 200U/µL) following 
the standard protocol as described by the manufacturer. Quantitative PCR was done with Lightcycler 
FastStart DNA Master SYBR Green I (Roche) using gene specific primers as followed:  
VEGFR1 (For: CTG AAG GAA GGG AGC TCG TC; Rev: GGC GTG GTG TGC TTA TTT GG), 
VEGFR2 (For: CGG TCA ACA AAG TCG GGA GA; Rev: CAG TGC ACC ACA AAG ACA CG), 
VEGFR3 (For: TCC TAC GTG TTC GTG AGA GAC; Rev: CAC CAG GAA GGG GTT GGA 
AA),SR-BI (For: CTG TGG GTG AGA TCA TGT GG; Rev: GCC AGA AGT CAA CCT TGC TC), 
normalized to GAPDH (For: CCC ATG TTC GTC ATG GGT GT; Rev: TGG TCA TGA GTC CTT 
CCA CGA TA). 
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Wide-field Fluorescence Microscopy for coverslips 
Endothelial cells were cultured in medium A or medium B as monolayers on coverslips. After 72hours, 
cells were subjected to treatment as indicated, followed by incubation with 50µg/mL of Atto594 labeled 
HDL or Atto488 labeled LDL for 1hour at 37 ºC as previously described 5. Cells were then washed, 
fixed with 2% paraformaldehyde and images were acquired on a Zeiss Axiovert 200M. 
MTT proliferation assay 
Endothelial cells were cultured in medium A or medium B at a density of 105 cells per well in a 24 well 
plate. After 72 hours of culture, the supernatant was removed and cells were washed twice with PBS. 
The cells were then incubated with 30µL of MTT solution (5mg/ml in PBS,Sigma, M5655) diluted in 
270µL of DMEM for 1 hour. The resultant formazan salts were extracted with dimethyl sulfoxide 
(DMSO) and absorbance intensity was read at 550nm and reference wavelength at 650nm (DMSO). The 
rate of cell proliferation is calculated relative to the cells cultured in medium A. 
Lipoprotein Binding, Cell association and Transport 
The methods for the quantification of binding, association and transport of radiolabeled HDL and LDL 
by endothelial cells have been previously described 6, 16, 18. All assays were performed in DMEM (Sigma) 
containing 25mmol/L HEPES and 0.2% BSA instead of serum. Where indicated, cells were pretreated 
for 30mins at 37 ºC with PI3K inhibitor wortmannin (Sigma, 200nmol/L) or Akt inhibitor MK2206 
(Selleckchem, 1µmol/L) or Raf/MEK/ERK inhibitor U0126 (Abcam, 10µmol/L) or p38MAPK inhibitor 
PD169316 (Calbiochem, 100nmol/L), followed by pre-treatment with VEGF-A165 (Sigma, 25ng/ml) for 
1hr at 37 ºC. Following treatments, the cells were incubated with 10µg/mL of 125I-HDL/ LDL without 
(total) or with a 40 time excess of non-labeled HDL/ LDL (unspecific) for 1hr at 4 ºC for cellular binding 
and at 37ºC for association and transport experiments. Specific cellular binding/ association/ transport 
was calculated by subtracting the values obtained in the presence of excess unlabeled HDL/ LDL 
(unspecific) from those obtained in the absence of unlabeled HDL/ LDL (total). 
Western Blotting  
Endothelial cells were lysed in RIPA buffer (10mmol/L Tris pH 7.4, 150mmol/L NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, complete EDTA (Roche)) with protease and phosphotase inhibitors. 
Equal amounts of protein were separated on SDS-PAGE and trans-blotted onto PVDF membrane (GE 
Healthcare). Membranes were blocked in appropriate blocking buffer recommended for the antibody 
(TBS-T supplemented with 5% milk or BSA) and incubated either for 1hour or overnight on shaker at 
4 ºC with primary antibodies at a dilution of 1:1000 in the same blocking buffer. Membranes were 
incubated for 1hour with HRP-conjugated secondary antibody (Dako) in blocking buffer at a dilution of 
1:2500. Membranes were further incubated with chemiluminescence substrate for 1min (Pierce ECL 
plus, Thermo scientific) and imaged using Fusion Fx (Vilber). As indicated Beta-Actin, GAPDH or 
TATA binding protein was used as loading control with primary antibody at 1:5000 and secondary 
antibody at 1:10000 dilutions. The silencing efficiencies of VEGFR1 (2893, CST), VEGFR2 (9686, 
CST) and VEGFR3 (ab27278, Abcam) were evaluated and compared to Beta-Actin (ab8226, Abcam). 
The expression of SR-BI (NB400-131, Novus) was evaluated and compared to the expression of 
GAPDH (ab9484, Abcam). The silencing efficiencies of Akt (9272, CST), p38 MAPK (9212, CST) and 
MEK1/2 (8727, CST) were compared to TATA binding protein (TBP, ab51841, Abcam). The Phospho-
expressions of VEGFR2 (3817, CST), Akt S473 (9271, CST), p38 MAPK Thr180/Tyr182 (9211, CST), 
p44/42 MAPK Thr202/Tyr204 & Thr185/Tyr187 (9106, CST) were compared to the total expression of 
VEGFR2 (9698, CST), Akt (9272, CST), p38 MAPK (9212, CST) and p44/42 MAPK (4695, CST) 
respectively.  
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Cell surface expression analysis  
Biotinylation of intact cells was performed using 20mg/mL EZ-Link sulfo-NHS-S-S-Biotin (Thermo 
Scientific) in the cold for 1 hour with mild shaking and quenched with ice-cold Tris pH 7.4. Cells were 
lysed in RIPA buffer (total cell lysate) and 200-500µg of lysates were incubated with 20µL of BSA- 
blocked streptavidin beads suspension (GE Healthcare) for 16hours at 4 ºC and pelleted by 
centrifugation; the pellet represents surface proteins. Proteins were dissociated from the pellet by boiling 
with SDS loading buffer and analyzed by SDS-PAGE and immunoblotting with SR-BI antibody 
(NB400-131, Novus) and LDL receptor (LDLR, ab30532, Abcam), ABCG1 (NB400-132, Novus). 
TATA binding protein (TBP, ab51841, Abcam) and endothelial lipase (EL, NB400-118, Novus) were 
used as intracellular and plasma membrane controls. 
Statistical Analysis 
Probability of finding active and inactive drugs for a given target compared to non-targeting drugs was 
performed using Fisher exact test analysis. The drugs were pre-classified as active based on their ability 
to fit the Hill logistic model only when the RFP foci signal dropped more than 50%. The data sets for 
all validation experiments were analyzed using the GraphPad Prism 5 software. Comparison between 
groups in follow up biochemical validation experiments was performed using Kruskal-Wallis one-way 
ANOVA followed by Dunn’s post-test. The data was obtained from at least three independent 
experiments, performed in triplicates or quadruplets. Values are expressed as mean±SEM. P<0.05 was 
regarded as significant. 
3.3 Results 
Screening of kinase inhibitors 
Following culture for 72 hours in 384 well plates at a density of 1000 cells per well, HAECs were treated 
with 141 kinase inhibiting drugs for one hour at seven different dilutions spanning four orders of 
magnitude.  Thereafter cells were incubated with fluorescent-labeled Atto 594-LDL or Atto 594-HDL 
for another hour. After washing, fixation and nuclei staining, nine images per well were acquired using 
a molecular devices widefield microscope.  The microscope generated images were processed by Cell 
profiler to segment nuclei and RFP foci intensity (vesicles) per cell. For each compound interaction, the 
amount of downregulation was calculated relative to a control reaction in the presence of vehicle 
(dimethyl sulfoxide). The analysis of the dose-response data for LDL and HDL uptake by the use of the 
Hill model (see methods) identified two and nine drugs, respectively, with a Hill coefficient of 4 which 
therefore were suspicious of toxicity and hence excluded from further analysis. The drugs were pre-
classified as active based on their ability to fit the Hill logistic model only when the RFP foci signal 
dropped more than 50%. Finally using Fisher’s exact test, we statistically evaluated the probability of 
finding drugs targeting a kinase that actively decrease the uptake of fluorescent LDL or HDL in the 
presence of maximal concentration versus non-targeting drugs. After correction of p values for multiple 
statistical testing, VEGFR emerged as the only target whose inhibition significantly interfered with the 
HDL uptake by HAECs. However, this analysis did not reveal any target whose inhibition led to a 
significant and consistent decrease in LDL uptake (Table 3.II).  
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Target 
LDL HDL 
n m n' m' p-value n m n' m' p-value 
ABL 1 5 26 113 0.71653 2 4 51 88 0.714 
ALK 1 3 26 115 0.56562 1 3 52 89 0.842 
c-Kit 1 6 26 112 0.77159 3 4 50 88 0.505 
c-Met 4 7 23 111 0.12361 5 6 48 86 0.369 
EGFR 3 11 24 107 0.50494 8 6 45 86 0.084 
FGFR 2 4 25 114 0.31014 3 3 50 89 0.383 
FLT-3 0 1 27 117 1 0 1 53 91 1 
HER2 2 5 25 113 0.38616 4 3 49 89 0.221 
IGF-1R 1 0 26 118 0.18621 1 0 52 92 0.366 
VEGFR 9 22 18 96 0.08137 18 13 35 79 0.005 
Aurora 5 10 22 108 0.11871 7 8 46 84 0.278 
CDK 2 6 25 112 0.45878 1 7 52 85 0.977 
CHK 0 1 27 117 1 0 1 53 91 1 
GSK-3 0 3 27 115 1 0 3 53 89 1 
JNK 0 1 27 117 1 0 1 53 91 1 
JAK/STA
T 
1 3 26 115 0.56562 0 4 53 88 1 
MEK 1 10 26 108 0.90542 4 7 49 85 0.623 
mTOR 0 10 27 108 1 1 9 52 83 0.991 
PI3K/AKT 1 17 26 101 0.98121 2 16 51 76 0.998 
p38 
MAPK 
2 5 25 113 0.38616 2 5 51 87 0.798 
Table 3.II: Fisher exact test analysis of binary activity signal for uptake of LDL and HDL For each target, 
Fisher exact test analysis was used to calculate the probability to get more active drugs (m) and less active drugs 
(n), for a given target, and at the same time less active drugs (m’) and more active (n’) drugs for non-targets. The 
drugs were pre-classified as active based on their ability to fit the Hill logistic model only when the RFP foci signal 
dropped more than 50%. Inhibition of targets with ** P≤ 0.01 are interpreted to be more likely than the inhibition 
of all other targets to decrease the uptake of LDL or HDL. The data were obtained from two replicate experiments.  
VEGFR2 regulates endothelial binding, association and transport of HDL but not LDL  
We first confirmed the regulatory role of VEGFR in the uptake of HDL by HAECs and to identify the 
relevant VEGF receptor by a knock-down strategy. HAECs expressed all three VEGF receptors: 
VEGFR1, VEGFR2 and VEGFR3 as analyzed by qRT-PCR (Figure 3.7A). To test which VEGF 
receptor was involved in HDL uptake, each of the three VEGF receptors was targeted using RNA 
interference. Although knock-down was efficient for each VEGFR on the mRNA level (Figure 3.7B) 
and protein level (Figure 3.7C), only the silencing of VEGFR2 decreased the cellular uptake of 
fluorescent-labeled Atto594-HDL whereas silencing VEGFR1 and VEGFR3 showed no effect (Left 
lane of Figure 3.8). These findings were confirmed using radioiodinated HDL, where silencing of 
73 
 
VEGFR2 significantly reduced the specific 4ºC binding of 125I-HDL to ECs by 60% (Figure 3.9A), the 
specific 37°C cellular association by 80% (Figure 3.9B) and the specific transendothelial transport of 
125I-HDL from apical to basal compartment at 37 ºC by 60% (Figure 3.9C). However, neither cellular 
uptake of fluorescent-labeled Atto488-LDL (Figure 3.8) nor specific cellular binding, association and 
transendothelial transport of 125I-LDL were affected by silencing of any VEGF receptor (Figure 3.9D-
F). Taken together, these results indicate a specific effect of VEGFR2 on endothelial binding and uptake 
as well as trans-endothelial transport of HDL but not LDL. 
             
Figure 3.7: Expression of VEGF receptors (A) and efficiency of RNA interference (B, C) A, mRNA levels of 
VEGFR1, VEGFR2 and VEGFR3 in HAECs were measured by real-time polymerase chain reaction. HAECs were 
transfected with specific siRNA against VEGFR1, VEGFR2, or VEGFR3 or with non-silencing control siRNA 
(NS control). Assays were performed 72hours after transfection. Silencing efficiency was analyzed at the B, 
mRNA level using qRT-PCR and C, protein level using western blotting. The western blots were probed with 
antibodies against VEGFR1 (180 kDa), VEGFR2 (210 kDa, 230 kDa) and VEGFR3 (195 kDa) respectively and 
Beta-actin (42 kDa) was used as the loading control. 
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Figure 3.8: Effect of VEGF receptors on the uptake of HDL (left lane) and LDL (right lane) by HAECs 
HAECs were transfected with a specific siRNA against VEGFR2 or with non-silencing control siRNA (NS 
control) and fluorescent lipoprotein uptake assay was performed 72hours after transfection. Uptake of Atto594-
HDL (red) and Atto488-LDL (green) into transfected endothelial cells was analyzed by wide-field fluorescence 
microscopy. ECs were incubated with 50ug/ml of Atto594-HDL or 50ug/ml Atto488-LDL for 1hour prior to 
fixation and nuclei were counterstained with DAPI (blue). Scale bar is 20µM. 
VEGF-A regulates endothelial binding, association and transport of HDL but not LDL  
Binding of VEGF-A to its receptor VEGFR2 induces conformational changes and receptor dimerization 
which in turn triggers kinase activation and auto-phosphorylation of tyrosine residues 19. To investigate 
whether VEGF-A regulates trans-endothelial transport of HDL, we cultured ECs either in the VEGF-A 
containing medium A or in the VEGF-A-free medium B. Upon Western blot analysis we found that, 
HAECs cultured in VEGF-free medium for 72hours, lose phosphorylation of Tyr residues 1054 and 
1059 in the major tyrosine kinase catalytic domain of VEGFR2, (Figure 3.10). As shown in the top panel 
of Figure 3.11, cells cultured in VEGF-free medium for 72 hours decreased the cellular uptake of 
Atto594-HDL compared to cells cultured in VEGF containing medium (control). Interestingly, pre-
treatment of cells cultured in medium B supplemented with 25 ng/ml VEGF-A for 1 hour showed a 
significant increase in the uptake of Atto594-HDL. Confirming these microscopic findings, pre-
treatment of cells for 1hour with VEGF-A significantly increased 4ºC cellular binding of 125I-HDL 
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(Figure 3.12A) and 37°C cellular association of 125I-HDL (Figure 3.12B) as well as apical-to-basolateral 
transendothelial transport of 125I-HDL (Figure 3.12C) compared to cells cultured in VEGF-free medium.  
                      
Figure 3.9: VEGFR2 mediates binding, association and transendothelial transport of HDL but not LDL in 
HAECs HAECs were transfected with a specific siRNA against VEGFR2 or with non-silencing control siRNA 
(NS control) and assays were performed 72hours after transfection. To study cellular binding, association and 
transport, transfected ECs were incubated with 10µg/mL of 125I-HDL or 125I-LDL for 1hour in the absence (total) 
or in the presence of 40-fold excess of unlabeled HDL and LDL, respectively, to record unspecific interactions. 
Specific binding, association and transport were calculated by subtracting unspecific values from total values.  A, 
Specific binding was measured by incubating cells with 125I-HDL (A) or 125I-LDL (D) at 4 ºC. To measure specific 
cell association, cells were incubated with 125I-HDL (B) or 125I-LDL (E) at 37 ºC. For the measrument of transport 
HAECs were cultured on inserts. The transport of 125I-HDL (C) and 125I-LDL (F) from the apical to basolateral 
compartment was measured at 37 ºC. The results are represented as means±SEM of three independent triplicate 
experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05 and ns represents “not significant”. 
By contrast, cells cultured in VEGF-free medium for 72 hours, did not show any decrease in the uptake 
of Atto488-LDL compared to the control condition (Bottom lane of Figure 3.11). Likewise, presence, 
absence or supplementation of VEGF-A had no effect on the cellular binding, association and transport 
of 125I-LDL (Figures 3.12D-F). Taken together, these results indicate that VEGF-mediated VEGFR2 
receptor activation is required for endothelial binding and uptake as well as trans-endothelial transport 
of HDL but not LDL. 
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Figure 3.11: Effect of VEGF-A treatment on HDL (left lane) and LDL (right lane) uptake by HAECs HAECs 
were cultured in the presence of VEGF-A (control) or absence of VEGF-A (no VEGF) for 72hours or cells were 
pre-treated with 25ng/ml of VEGF165 for 1hour prior to the incubation with fluorescent lipoproteins. ECs were 
incubated with 50ug/ml of Atto594-HDL or Atto488-LDL for 1hour prior to fixation and nuclei were 
counterstained with DAPI (blue). Uptake of Atto594-HDL (red) and Atto488-LDL (green) in endothelial cells was 
analyzed by wide-field microscopy. Scale bar is 20µM. 
 
 
 
Figure 3.10:  Effect of VEGF-A phosphorylation 
of VEGFR2 and its downstream kinases (A). 
HAECs were cultured in regular medium 
containing VEGF-A (control) or in medium free of 
VEGF-A (no VEGF) for 72hours or cells were pre-
treated with 25ng/ml of VEGF165 for 1hour prior to 
protein extraction. A: Cell lysates were analysed by 
western blotting for phospho VEGFR2 (Tyrosine 
1054/1059) and total VEGFR2, phospho Akt (Ser-
473) and total Akt, phospho p38 MAPK 
(Thr180/Tyr182) and total p38 MAPK, phospho  
ERK1/2 (Thr202/Tyr204 & Thr185/Tyr187) and 
total ERK1/2. 
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Figure 3.12: Effect of VEGF-A on binding, association and transendothelial transport of HDL and LDL in 
HAECs HAECs were cultured in medium containing VEGF-A (control) or lacking VEGF-A (no VEGF) for 
72hours. Cells were pre-treated with 25ng/mL of VEGF-A165 for 1hour prior to the assays if indicated. Specific 
binding was measured by incubating cells with 125I-HDL (A) and 125I-LDL (D) at 4 ºC. Specific cell association 
was analyzed by incubating cells with 125I-HDL (B) and 125I-LDL (E) at 37 ºC. HAECs were cultured on inserts 
and transport of 125I-HDL (C) and 125I-LDL (F) from the apical to basolateral compartment was measured at 37 
ºC. The results are represented as mean±SEM of three independent triplicate experiments (n=3). ***P≤ 0.001, 
**P≤ 0.01, *P≤ 0.05 and ns represents “not significant”. 
 
VEGF-A regulates endothelial binding and association of HDL through p38MAPK and                                                                                                                                                                                                                                                                                                                                                                
PI3K/Akt 
We determined whether the knock down of the downstream kinases of VEGF signaling, namely 
phosphatidyl-inositol 3 kinase (PI3K), p38 mitogen activated protein kinase (p38MAPK), and mitogen-
activated protein kinase kinase (MEK) interfere with endothelial binding and association of HDL. The 
knockdown was found efficient for each kinase on the protein level (Figure 3.13). Western blot analysis 
revealed that residue Ser473 of Akt (the downstream kinase targeted by PI3K), residues Thr180 and 
Tyr182 of p38 MAPK as well as residues Thr202, Tyr204, Thr185, and Tyr187 of p44/42 MAPK 
(ERK1/2, which is a common kinase target of MEK1 & MEK2) were phosphorylated in the presence 
but not in the absence of VEGF (Figure 3.10). Silencing of either Akt or p38 MAPK or MEK1/2 
decreased the cellular binding and association of 125I-HDL. However, VEGF-A treatment restored the 
cellular binding and association of 125I-HDL by endothelial cells lacking MEK1/2 but not by endothelial 
cells lacking Akt or p38 MAPK. (Figure 3.14A & B). Taken together, these results show that VEGF-
induced binding and association of HDL depends on the activation of PI3K/Akt and p38MAPK but 
independent of the MEK/ERK pathway. Interestingly, endothelial binding or cell association of 125I-
LDL was not affected by silencing of Akt but significantly decreased by silencing of p38 MAPK and 
MEK (Figure 3.15A&B). 
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Figure 3.13: Silencing efficiency of AKT, p38 MAPK and MEK1/2 Protein levels of Akt, p38 MAPK and 
MEK1/2 were measured using western blotting following transfection of ECs with specific siRNAs against AKT, 
MAPK14 (p38 MAPK), MAP2K1/MAP2K2 (MEK1/2). TATA-binding protein (TBP) was used as a loading 
control.  
 
 
 
Figure 3.14: VEGF-A regulates HDL binding and association through PI3K/Akt and p38 MAPK HAECs 
were transfected with specific siRNA against AKT or MAPK14 (p38 MAPK) or MAP2K1/MAP2K2 (MEK1/2) 
or with non-silencing control (NS control) siRNA in the presence or absence of VEGF-A containing medium and 
assays were performed 72hours post-transfection. A, Specific binding was measured by incubating cells with 125I-
HDL at 4 ºC. B, Specific cell association was analyzed by incubating cells with 125I-HDL at 37 ºC. The results are 
represented as mean±SEM and three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
†††P≤ 0.001, ††P≤ 0.01, †P≤ 0.05 and ns represents “not significant”. 
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Figure 3.15: Binding and association of 125I-LDL through p38 MAPK and MEK1/2 HAECs were transfected 
with specific siRNA against AKT or MAPK14 (p38 MAPK) or MAP2K1/MAP2K2 (MEK1/2) or with non-
silencing control (NS control) siRNA in the presence of VEGF-A    containing medium and assays were performed 
72hours post-transfection. A, Specific binding was measured by incubating cells with 125I-LDL at 4 ºC. B, Specific 
cell association was analyzed by incubating cells with 125I-LDL at 37 ºC. The results are represented as mean±SEM 
and three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05 and ns represents “not 
significant”. 
VEGF-A regulates binding, association and transport of HDL via SR-BI  
We have previously demonstrated that SR-BI, ABCG1 and EL regulate binding and trans-endothelial 
transport of HDL. Because of the fast effects of VEGF-A on cellular binding, association and transport 
of 125I-HDL, we hypothesized that VEGF-A regulates the availability of one of these HDL interacting 
proteins on the cell surface in HAECs. To test this hypothesis, we performed a cell surface biotinylation 
experiment. HAECs cultured in the VEGF-free cell culture medium did not show any SR-BI on the cell 
surface. Pre-treatment with VEGF-A restored the expression of cell surface SR-BI. By contrast the 
presence or absence of VEGF-A had no effect on the cell surface expression of LDLR, ABCG1, or EL. 
(Figure 3.16). To determine whether VEGF-A regulated HDL trans-endothelial transport through SR-
BI, we silenced SR-BI using RNA interference. The knockdown was efficient at the mRNA (Figure 
3.17A) and protein levels (Figure 3.17B). Silencing SR-BI alone significantly decreased 125I-HDL 
cellular binding and association by 50-55% and transport by 60%, respectively. Pre-treatment with 
VEGF-A for 1hour did not restore the cellular binding, association and transport of 125I-HDL inhibited 
by suppression of SR-BI (Figure 3.18A-C).  
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Figure 3.16: VEGF-A regulates cell surface expression of SR-BI Western blots of SR-BI, LDL-receptor, ATP 
binding cassette transporter ABCG1, endothelial lipase (EL), and anti-TATA binding protein (TBP) in total cell 
lysates (left) and on the cell surface (right). HAECs were cultured in the presence or absence of VEGF for 72hours 
and cells were then pre-treated with 25ng/mL of VEGF165 for 1hour if indicated. The western blot was probed with 
anti-SR-BI (82 kDa), anti-LDLR (95 kDa and 160 kDa), anti-ABCG1 (90 kDa) as well as anti-endothelial lipase 
(EL) (60 kDa) and anti- TATA binding protein (TBP) (40 kDa, as control for intracellular protein expression). 
 
Figure 3.17: Efficiency of silencing SR-BI A, mRNA levels of SR-BI were analyzed following transfection of 
ECs with specific siRNAs against SR-BI. GAPDH was used as a housekeeping control. B, SR-BI (82 kDa) protein 
expression levels measured by western blotting, GAPDH (38 kDa) used as loading control.  
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Figure 3.18: VEGF-A modulates SR-BI dependent binding, association and transport of HDL by HAECs 
HAECs were transfected with a specific siRNA against SR-BI or with non-silencing control siRNA (NS control) 
in the presence or absence of VEGF-A containing medium and assays were performed 72hours post-transfection. 
A, Specific binding was measured by incubating cells with 125I-HDL at 4 ºC. B, Specific cell association was 
analyzed by incubating cells with 125I-HDL at 37 ºC. C, ECs were cultured on inserts and transport of 125I-HDL 
from the apical to basolateral compartment was measured at 37 ºC. The results are represented as mean±SEM of 
three independent triplicate experiments (n=3). ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
3.4 Discussion 
We previously reported that bovine aortic endothelial cells bind, internalize and transport HDL in a 
specific process dependent on SR-BI, ABCG1 6, EL 7, and ectopic beta-ATPase 8. Here we show that 
human aortic endothelial cells (HAECs) also bind, internalize and transport HDL as well as LDL. Using 
a high-content drug screening approach we identified VEGF-A/VEGFR2 signaling as a rate-limiting 
factor for the cell surface abundance of SR-BI and, as a consequence, regulator of uptake and transport 
of HDL by HAECs (Figure 3.19). Interestingly, VEGF-A and VEGFR2 had no effect on endothelial 
binding, uptake and transport of LDL. 
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VEGFs are important regulators of both vasculogenesis and angiogenesis in the adult 20. In mammals, 
the VEGF family encompasses five different isoforms namely, VEGF-A, -B, -C, and -D as well as 
placenta growth factor 
 (PLGF). These ligands bind to three VEGF receptors - VEGFR1, VEGFR2, and VEGFR3 - in an 
overlapping pattern. VEGF-A, VEGF-B, and PLGF bind to VEGFR1 21-23; VEGF-A binds to VEGFR2 
24; VEGF-C and VEGF-D bind to VEGFR3 25, 26. Among VEGF-A receptors, VEGFR1 has the highest 
affinity and acts as a negative regulator by sequestering VEGF-A from binding to VEGFR2 27, hence 
VEGFR2 is the key receptor mediating most of the cellular effects of VEGF-A in endothelial cells.  In 
accordance with this, our results show that RNA interference with VEGFR2 but not with VEGFR1 
decrease HDL uptake (Figure 3.8). Our data show some analogy with those reported by Lim et al. and 
Martel et al, who observed improved lymphatic function and transport of HDL after VEGF-C treatment 
in mice 28, 29   
Binding of VEGF-A induces conformational changes and dimerization of VEGFR2 which in turn 
triggers kinase activation, tyrosine phosphorylation of the dimerized VEGFR2 and subsequent 
phosphorylation of SH2-containing intracellular signaling proteins, including phospholipase C-γ1 
(PLCγ1), Src family tyrosine kinases, and phosphatidylinositol 3-kinase (PI3K) and Ras GTPase-
activating protein residues of Ras-Raf-MEK-MAPK pathway 30-33. VEGF was also shown to induce 
actin remodeling through activation of CDC42 and p38MAPK 34. Both by pharmacological inhibition 
and RNA interference we revealed the involvement of PI3K/Akt, p38MAPK, and the Ras-Raf-MEK 
pathway in binding and uptake of HDL (Figure 3.14). However, the inhibition of the Ras-Raf-MEK 
pathway but not the inhibition of PI3K/Akt and p38MAPK could be overcome by VEGF stimulation. 
Thus, VEGF regulates the interaction of HDL with endothelial cells by activating PI3K/Akt and 
p38MAPK but not the Ras-Raf-MEK pathway. PI3K is known to be involved in endosomal membrane 
trafficking 35, 36 and its inhibition by wortmannin in polarized cells affects early trafficking in the 
endocytic pathway as well as inward vesicularization for the formation of multivesicular bodies in the 
later stages 37.  For example, PI3K was shown to mediate the stimulatory effect of insulin on the cell 
surface translocation of the glucose transporter-4 (GLUT-4) 36, 38. It has also been shown in hepatocytes, 
that insulin regulates the cell surface expression of SR-BI and selective lipid uptake dependent on PI3K 
activation 39. VEGF-A is known to stimulate actin reorganization, which in turn contributes to HDL 
uptake 5, and cell migration depending on activation of p38MAPK but not ERK1/2 MAP kinase 40, 41. 
Thus it will be interesting to identify agonists beyond VEGF that regulate the endothelial binding, uptake 
and transport of HDL by activating the MEK pathway. In this regard, it is also important to note our 
finding that RNA interference with MEK but not with Akt inhibited the binding and association of LDL 
with endothelial cells (Figure 3.15).  
We found that in HAECs, VEGF-A is required for the translocation of SR-BI from intracellular 
compartments to the cell surface which in turn facilitates the binding, uptake and transport of HDL 
(Figure 3.16 & 3.18). Similarly the cell-surface translocation of SR-BI is enhanced by insulin in 
hepatocytes 39  and by both insulin and angiotensin-II in adipocytes 42.In hepatocytes, cell surface 
expression of SR-BI was shown to be dependent on PDZK1 43 which is a tissue specific adaptor protein 
with 4 PDZ domains. However, in our hands interference with PDZK1 did not limit the binding of HDL 
(data not shown) indirectly confirming that in endothelial cells targeting of SR-BI to the plasma 
membrane does not depend on PDZK1 44.  
SR-BI has been shown to be involved in the protective effects of HDL on the endothelium, namely 
angiogenesis, migration, activation of endothelial nitric oxide synthase, and monocyte adhesion 45. 
Recent studies have shown the association of enhanced expression of SR-BI expression in endothelial 
cells with decreased atherosclerosis in mice 46. Thus, the requirement of VEGF on maintaining cell 
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surface expression of SR-BI may have vascular effects beyond regulating transendothelial lipoprotein 
transport. 
HDL was previously reported to enhance hypoxia-induced angiogenesis by stimulating the expression 
of VEGF and VEGFR2 in endothelial cells by a mechanism involving SR-BI 47, 48. It thus appears that 
in endothelial cells, HDL and SR-BI are both upstream regulators and downstream targets of the 
VEGF/VEGFR2 system. 
We confirmed previous reports 3, 10-13 that endothelial cells internalize and transcytose LDL. We also 
confirmed the previous report of Armstrong et al. 12 that this process involves SR-BI (Velagapudi, 
Rohrer, von Eckardstein; unpublished observations). However, despite regulating the cell surface 
abundance of SR-BI, VEGF does not regulate the transendothelial transport of LDL. Neither the 
interference with the VEGF receptors by drugs or RNAi, nor the removal or addition of VEGF had any 
significant effect on the binding, uptake or transport of LDL by HAECs. These lipoprotein-specific 
effects of VEGF on the processing of HDL and LDL by HAECs indicate the existence of additional 
regulators and routes of transendothelial transport, for example ALK1 which was recently identified by 
a genome-wide RNAi-screen as an endothelial LDL binding protein mediating uptake and transcytosis 
of LDL 13.  
                                  
Figure 3.19: VEGF-A modulates SR-BI dependent binding, association and transport of HDL by HAECs 
The VEGF-A/VEGFR2 regulates endothelial binding, uptake and transport of HDL through PI3K/Akt and p38 
MAPK and, as the final result, cell surface expression of SR-BI. 
From a more general perspective, our findings provide further evidence that transendothelial lipoprotein 
transport occurs by regulated processes 3, 6-8, 12, 13 rather than passive filtration 4.  Dys-regulated 
transendothelial lipoprotein transport may influence the pathogenesis of atherosclerosis beyond plasma 
levels of LDL and HDL. In fact, it was recently shown in LDL receptor deficient mice that acute 
lowering of LDL-cholesterol with anti-ApoB antisense oligonucleotides rapidly reduces the 
permeability of the aortic endothelium for LDL and causes regression of atherosclerosis independently 
of LDL pool size 49.  It is less obvious how changes in arterial permeability for HDL may affect 
atherosclerosis. At first sight, increased availability of HDL in the subendothelium will be protective, 
for example by enhancing cholesterol efflux from macrophage foam cells. However, this will only be 
effective if HDL also leave the arterial wall to conclude reverse cholesterol transport. Disturbed egress 
of HDL from the arterial wall, potentially via the lymphatics 29, will lead to the accumulation of HDL 
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in the arterial wall. These particles will be eventually oxidized and become dysfunctional 50, 51 and 
thereby promote rather than inhibit cholesterol accumulation and hence atherosclerosis.  
In conclusion, we here showed that the VEGF-A/VEGFR2 regulates endothelial binding, uptake and 
transport of HDL through PI3K/Akt and p38 MAPK and, as the final result, cell surface expression of 
SR-BI. Thereby VEGF-A may play an important regulatory role for the vascular protective effects of 
HDL as well as reverse cholesterol transport. 
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Abstract 
Background: Most clear cell renal cell carcinoma (ccRCC) are characterized by VHL inactivation. 
ccRCC tumor cells have typically clear cytoplasm partly due to lipid accumulation. We investigated 
(apo)lipoproteins and their receptor, the scavenger receptor BI (SR-BI) in primary human renal tumors 
and in RCC cell lines.  
Methods: ApoA-I, apoB and SR-BI were analyzed in 356 RCCs by immunohistochemistry as well as 
in von Hippel-Lindau (VHL) gene defective RCC cell line 786-O and a stably transfected VHL re-
expressing derivative (786-O-VHL). In addition, uptake of radio-iodinated HDL or LDL was measured. 
Results: ApoA-I, apoB, and SR-BI expression showed significant associations with clear cell RCC 
subtype, markers of HIF-1α activity, high tumor stage, differentiation grade, and better survival. Neither 
786-O nor 786-O-VHL expressed apoA-I and apoB. 786-O cells showed enhanced VEGF and SR-BI 
expression compared to 786-O-VHL. 125I-LDL and 125I-HDL up-take was significantly higher in 786-O 
than 786-VHL cells. Uptake of 125I-LDL into 786-VHL was strongly increased by pretreatment with 
VEGF, whereas blocking of SR-BI with neutralizing antibodies significantly reduced the uptake of 125I-
LDL into 786-O as well as into VEGF stimulated 786-VHL. Unlike 786-O-VHL and normal renal 
tubular cells, 786-O did not degrade 125I-LDL. 
Conclusion: Lipid metabolic reprogramming with cholesterol accumulation is caused by enhanced 
uptake of LDL and HDL via SR-BI into a non-degrading cytoplasmic compartment. VHL inactivation 
induces cell surface translocation of SR-BI by activating VEGF in a HIF-1α dependent manner. These 
data are important for novel treatments targeting lipid and cholesterol dependence of renal cancer cells.  
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4.1 Introduction 
Clear cell renal cell carcinoma (ccRCC) is the most common adult kidney cancer subtype 1, followed by 
papillary, chromophobe and translocation RCC. Classification of these renal cell carcinoma (RCC) 
subtypes is based on histologically predominant cytoplasmic features (clear cell RCC), characteristic 
staining (chromophobe RCC), architectural features (papillary RCC) or specific molecular alterations 
(translocation RCC) (Figure 4.1). ccRCC, received its name from the microscopic appearance upon 
staining of formalin fixed and paraffin embedded (FFPE) sections with hematoxylin-eosin 2. The clear 
appearance of the cytoplasm is due to the accumulation of glycogen and lipids that are dissolved 
during routine processing with deparaffinization of FFPE sections using xylene and ethanol. The most 
prominent lipid stored in renal tumor cells is cholesterol, largely in the esterified form 3. Various cancer 
cell lines can show lipid and cholesterol avidity, which is due to either increasing the uptake of 
exogenous lipids and lipoproteins or over activating their endogenous synthesis. The mechanisms for 
cholesterol accumulation in ccRCC cells is not well understood. Three principle pathways have to be 
considered, two of which have been ruled out previously, namely excessive cholesterol synthesis by the 
finding of decreased rather than increased activity of the rate limiting enzyme HMG-CoA reductase 4 as 
well as abnormal cholesterol efflux 3. The third explanation is most likely, namely excessive uptake of 
cholesterol from plasma lipoproteins beyond the capacity of utilization and processing. However, 
neither the lipoprotein classes nor the receptors and cellular pathways involved are as yet understood.  
                               
Figure 4.1: Distinct subtypes of renal cell carcinoma Histology of most common RCC subtypes: A, Clear cell 
RCC – cells with lipid rich ample cytoplasm. B, Type 1 Papillary RCC – small basophilic cells with scarce 
cytoplasm, organized in a spindle-shaped pattern, in a single layer of cells surrounding the basal 
membrane. C, Type 2 Papillary RCC – cells organized in a spindle-shaped pattern with papillae covered by cells 
with abundant eosinophilic granular cytoplasm with prominent nucleoli. D: Chromophobe RCC – large pale cells 
with reticulated cytoplasm and perinuclear halos 5.  
Malignantly transformed renal cancer lacks the low-density lipoprotein receptor (LDLR), which is the 
main entry route for exogenous cholesterol into the majority of cells including many tumor cells 6. In 
contrast, the expression of the very low-density lipoprotein receptor (VLDLR) was found increased in 
ccRCC compared to the normal kidney tissue 7.  Scavenger receptor-BI (SR-BI)  is also abundantly 
expressed in ccRCC 7 and known to mediate selective lipid uptake from both high-density lipoproteins 
(HDL) and low-density lipoproteins (LDL) 8-11.  
We have previously found that the cell surface abundance of SR-BI in endothelial cells is regulated by 
vascular endothelial growth factor (VEGF).  Interestingly, VEGF activity is increased in the majority of 
ccRCC 12-14 due to the constitutive activation of hypoxia-inducible factor 1 alpha (HIF1) by somatic 
mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. The VHL protein is a component of 
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the E3-ubiquitin ligase complex that ubiquitylates HIF-1α and HIF-2α for proteasome-mediated 
degradation 15. Thus, the loss of VHL function leads to HIF- stabilization despite an adequately 
oxygenated tissue microenvironment, which in turn results in uncontrolled activation of HIF- target 
genes that regulate erythropoiesis (erythropoietin), angiogenesis (VEGF), glycolysis (glucose 
transporters and glycolytic pathway enzymes), and apoptosis (BNIP3)16-20. Therefore, we investigated 
the hypothesis that the lipid accumulation in ccRCC results from the enhanced uptake of HDL and LDL 
due to increased HIF-1α and hence VEGF activity. To this end we combined immunohistochemical 
studies in human renal tumors with experiments in two ccRCC cell lines differing by pVHL activity.  
4.2 Materials and Methods 
Patients, Tissue microarray Construction and Immunohistochemistry  
RCC patients were identified from the database of the Institute of Pathology and Molecular Pathology, 
University Hospital Zurich, Switzerland. All RCCs were histologically re-evaluated by one pathologist 
(H.M.) and selected on the basis of hematoxylin and eosin-stained tissue sections. The patient cohort 
and the construction of tissue microarrays (TMA) of RCC were previously described 21 22. Tumors were 
staged and histologically classified according to the World Health Organization classification 23. Overall 
survival data were obtained by the Cancer Registry of the Canton Zurich. The clinical and pathologic 
parameters of the tumors on the TMA are summarized in Table 4.I. For some cases there was no 
information available. This study was approved by the local commission of ethics (KEK-ZH no. 2011-
0072/4). TMA sections (2.5 μm) were transferred to glass slides followed by immunohistochemical 
analysis according to the Ventana (Tucson, AZ, USA) automat protocols listed in Table 4.II. apoA-I 
(1:1000 dilution, 600-101-109, Rockland), apoB (1:200 dilution, ab20737, Abcam), SR-BI (1:200 
dilution, NB400-131, Novus), CD34 (Pre-diluted, 790-2927, Ventana Roche), HIF-1α (1:400 dilution, 
ab16066, Abcam), CA9 (1:6000 dilution, ab15086, Abcam), Glut1 (1:1000 dilution, 07-1401, 
Millipore). The staining intensities were classified as absent (0), weak (1), moderate (2), and strong (3). 
For detailed analysis, TMAs were scanned using the NanoZoomer Digital Slide Scanner (Hamamatsu 
Photonics K.K.). 
Cell culture 
The ccRCC-derived 786-O cells which lack functional pVHL were supplied by American Type Culture 
Collection (ATCC) and cultured in RPMI-1640 (Sigma, R8758) with 10% fetal bovine serum (Gibco) 
and 100U/mL of penicillin and 100µg/mL streptomycin (Sigma-Aldrich). Stable transfectant of 786-O 
re-expressing pVHL-isoform 30 (786-O-VHL) was provided by Prof. Dr. Wilhelm Krek (ETH, Zurich), 
generated as described24 and cultured using the same conditions as mentioned for 786-O. 0.5 mg/mL of 
G418 (Gibco, 10131) was used as selection antibiotic. Both cell lines were authenticated by 
authentication service of Microsynth (Balgach, Switzerland) and were previously used by our group in 
different studies 25, 26. 
Lipoprotein Isolation and labeling 
LDL (1.019<d<1.063 g/mL) and HDL (1.063<d<1.21 g/mL) were isolated from fresh human 
normolipidemic plasma of blood donors by sequential ultracentrifugation as described previously 27, 28. 
LDL and HDL were radioiodinated with Na125I by the McFarlane monochloride procedure modified for 
lipoproteins 28, 29. Specific activities between 300-900 cpm/ng of protein were obtained.  
Lipoprotein cell association and degradation assays 
All assays were performed in RPMI-1640 (Sigma) containing 25mmol/L HEPES and 0.2% BSA instead 
of serum. Where indicated, cells were pre-treated with Sorafenib Tosylate (Selleckchem, 90nM) or 
Sunitinib Malate (Selleckchem, 80nM) for 30 minutes or with VEGF-A (Sigma, 25ng/ml) or anti-SR-
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BI neutralizing antibody (1:500, Novus NB400-113) or anti-IgG control (1:500, Santa Cruz-2027) for 
1hr at 37 ºC. Following treatments, the cells were incubated with 10µg/mL of 125I-HDL or 125I-LDL in 
the absence or presence of a 40 times excess of non-labeled HDL and LDL respectively for 1hr at 37ºC 
for association experiments. For the degradation experiments, the cells and the medium alone (Blank 
condition) were incubated with 15µg/mL of 125I-HDL or 125I-LDL in the absence or presence of a 40 
times excess of non-labeled HDL and LDL respectively. After 4 hours of incubation at 37 °C, the amount 
of 125I-HDL or 125I-LDL degradation products released into the medium were measured. To distinguish 
the cellular degradation products (amino acid bound radioactivity) from the free radioactivity in the 
supernatant after TCA precipitation, the supernatant was oxidized by hydrogen peroxide and the free 
iodine extracted by trichloromethane. The radioactivity of the water phase containing the cellular 
degradation products was measured using a Perkin Elmer γ-counter  The counts in the medium alone 
condition which are due to the presence of small amounts of acid-soluble 125I-tyrosine are subtracted 
from all conditions to correct for background 30. Specific cellular association or degradation were 
calculated by subtracting the values obtained in the presence of excess unlabeled HDL or LDL 
(unspecific) from those obtained in the absence of unlabeled HDL and LDL (total) respectively. 
Clinical parameters Patients (%) 
RCC subtype 
Clear-cell 264 
Papillary type I 24 
Papillary type II 24 
Chromophobe 15 
Oncocytoma 19 
Other 8 
pT stage* 
1 102 
2 26 
3 128 
4 7 
ISUP grading* 
1 5 
2 68 
3 89 
4 101 
Sex*  
Women 96 
Men 168 
Events* 
Censor 133 
Death 107 
Table 4.I: Clinicopathological characteristics of patients and tumors The clinical and pathological 
characteristics of patient cohort are summarized here. *clear cell RCC only.  
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Real-time polymerase chain reaction 
Total RNA was isolated using TRI reagent (Sigma T9424) according to the manufacturer’s instruction. 
Genomic DNA was removed by digestion using DNase (Roche) and RNase inhibitor (Ribolock, Thermo 
Scientific).  Reverse transcription was performed using M-MLVRT (Invitrogen, 200U/µL) following 
the standard protocol as described by the manufacturer. Quantitative PCR was done with Lightcycler 
FastStart DNA Master SYBR Green I (Roche) using gene specific primers as followed:  
APOA1 (For: ATGAAAGCTGCGGTGCTG; Rev: AGGTCCTTCACTCGATCCCA) 
APOB (For: TGCCTCTCCTGGGTGTTCTA; Rev: CCCGAAGGCTGAAATGGTCT) 
VEGF (For: CTGTCTAATGCCCTGGAGCC; Rev: ACGCGAGTCTGTGTTTTTGC) 
LDL-R (For: AAGGACACAGCACACAACCA; Rev: CATTTCCTCTGCCAGCAACG) 
SCARB1 (For: CTGTGGGTGAGATCATGTGG; Rev: GCCAGAAGTCAACCTTGCTC) 
BNIP3 (For: GGAAGATGATATTGAAAGAAGGAAAG, Rev: CGCCTTCCAATATAGATCCCC) 
SLC2A1 (For: ACTGTCGTGTCGCTGTTTG, Rev: CCAGGACCCACTTCAAAGAA) 
PDK1 (For: CACGCTGGGTAATGAGGATT, Rev: GGAGGTCTCAACACGAGGT) 
CAIX (For: GGGTGTCATCTGGACTGTGTT, Rev: CTTCTGTGCTGCCTTCTCATC) 
VEGFR1 (For: CTGAAGGAAGGGAGCTCGTC, Rev: GGCGTGGTGTGCTTATTTGG) 
VEGFR2 (For: CGGTCAACAAAGTCGGGAGA, Rev: CAGTGCACCACAAAGACACG) 
VEGFR3 (For: TCCTACGTGTTCGTGAGAGAC, Rev: CACCAGGAAGGGGTTGGAAA) 
NRP1 (For: AGGACAGAGACTGCAAGTATGAC, Rev: AACATTCAGGACCTCTCTTGA) 
GAPDH (For: CCCATGTTCGTCATGGGTGT; Rev: TGGTCATGAGTCCTTCCACGA TA). 
Antibody Supplier Clone Species Automat Dilution Pre-
incubation 
Incubation 
time 
Apo-Al Rockland 600-101-
109 
goat 
polyclonal 
Ventana 
Discovery 
1:1000 CC1 32min 44min 
ApoB Abcam Ab20737 rabbit 
polyclonal 
Ventana 
Discovery 
1:200 CC1 32min 60min 
SR-BI Novus NB400-
131 
goat 
polyclonal 
Ventana 
Discovery 
1:200 CC1 64min 60min 
Glut1 Millipore 07-1401 rabbit 
polyclonal 
Ventana 
Discovery 
1:1000 CC1 32min 44min 
HIF-1α Abcam Ab16066 mouse 
monoclonal 
Leica Bond 1:400 H2(60) 30min 
CD34 Ventana 
Roche 
790-2927 mouse 
monoclonal 
Ventana 
Ultra 
pre-
diluted 
CC1 16min 32min 
CA9 Abcam Ab15086 rabbit 
polyclonal 
Leica Bond 1:6000 H2(30) 95°C 30min 
Table 4.II: Immunohistochemistry protocol The table represents the list of the antibodies and the protocol 
used to perform immunostaining on RCC tissue microarrays. 
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Small interfering RNA transfection 
786-O and 786-O-VHL cells were reverse transfected with small interfering RNA (Ambion silencer 
select, Life technologies) targeted to LDLR (s224006, s224007, s4) or NRP1 (s16844, s16843) or non-
silencing control (4390843) at a final concentration of 5nmol/L using Lipofectamine RNA iMAX 
transfection reagent (Invitrogen, 13778150) in an antibiotic-free RPMI medium.  All experiments were 
performed 72 hours post-transfection and efficiency of transfection was confirmed with at two siRNAs 
against each gene using qRT-PCR.  
Western Blotting  
Cells were lysed in RIPA buffer (10mmol/L Tris pH 7.4, 150mmol/L NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS, complete EDTA (Roche)) with protease inhibitors (Roche). Equal amounts of 
protein were separated on SDS-PAGE and trans-blotted onto PVDF membrane (GE Healthcare). 
Membranes were blocked in appropriate blocking buffer recommended for the antibody (TBS-T 
supplemented with 5% milk) and incubated overnight on a shaker at 4 ºC with primary antibodies in the 
same blocking buffer. Membranes were incubated for 1hour with an HRP-conjugated secondary 
antibody (Dako) in the blocking buffer. Membranes were further incubated with chemiluminescence 
substrate for 1min (Pierce ECL plus, Thermo scientific) and imaged using Fusion Fx (Vilber). The 
expression of apoA-I (1:1000, 600-101-109, Rockland), apoB (1:250, ab20737, Abcam), LDLR 
(1:1000, ab30532, Abcam), SR-BI (1:1000, Novus, NB400-131) were evaluated and compared to the 
expression of either TATA binding protein (1:1000, TBP, ab51841, Abcam) or Na+/K+- ATPase (1:200, 
SC-21712, Santa Cruz) which were used as loading control. 
Cell surface expression analysis  
Biotinylation of intact cells was performed using 20mg/mL EZ-Link sulfo-NHS-S-S-Biotin (Thermo 
Scientific) in the cold for 1 hour with mild shaking and quenched with ice-cold 50mM Tris pH 7.4. Cells 
were lysed in RIPA buffer (total cell lysate) and 200-500µg of lysates were incubated with 20µL of 
BSA-blocked streptavidin beads suspension (GE Healthcare) for 16hours at 4 ºC and pelleted by 
centrifugation; the pellet represents surface proteins. Proteins were dissociated from the pellet by boiling 
with SDS loading buffer and analyzed by SDS-PAGE and immunoblotted with SR-BI antibody (NB400-
131, Novus) and TATA binding protein (TBP, ab51841, Abcam) used as intracellular control. 
Statistical Analysis 
Contingency table analysis and Pearson’s chi-square tests were used to analyze the associations between 
protein expression patterns and clinical parameters. Overall survival rates were determined according to 
the Kaplan– 
Meier method and analyzed for statistical differences using a log rank test. The data sets for all in vitro 
experiments were analyzed using the GraphPad Prism 5 software. Comparison between groups in 
experiments was performed using t-test or Kruskal-Wallis test followed by Dunn’s comparison between 
groups. Values are expressed as mean±SEM. P<0.05 was regarded as significant. 
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4.3 Results 
Lipoprotein and apolipoprotein expression and pathological parameters 
Immunostaining was performed on RCC tissue microarrays (TMA) for the major apolipoproteins of 
HDL and LDL, apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) respectively (Figures 4.2A 
and B), as well as receptor scavenger receptor BI (SR-BI, Figure 4.2C). Based on the staining intensities, 
expression levels in tumors were graded from 0 to 3 for apoA-I and SR-BI expression, and from 0 to 2 
for apoB expression as staining intensities were generally lower. Immunoreactivity with anti-apoA-I or 
anti SR-BI antibodies but not immunoreactivity with anti-apoB antibodies significantly differentiated 
ccRCC from papillary RCC. The 175 ccRCCs showed significantly stronger immunoreactivity against 
apoA-I and SR-BI than papillary RCC (Table 4.III).  
Strong cytoplasmic apoA-I and membranous SR-BI expression (staining intensity 2 and 3) was seen in 
approximately 75% and 56% of ccRCC, whereas, only 16% of ccRCC (staining intensity 2) showed 
strong cytoplasmic apoB expression. Of note, apoA-I and apoB expression were significantly correlated 
(P < 0.001) but not with SR-BI positivity (Table 4.III).  
We next evaluated the associations of the lipoprotein immunoreactivities in ccRCC with tumor stage 
(pT) and tumor grade.  pT1/pT2 tumor stage represent organ confined and pT3/pT4 represent late stage 
metastasizing tumors. By this definition, only anti-apoB-immunoreactivity was significantly associated 
with tumor stage (Table 4.III, p = 0.0371). Four nuclear grades ranging from 1 to 4 were defined and 
showed significant associations with the immunoreactivity of apoA-I (P = 0.025) and apoB (P = 
0.0006) but not SR-BI (Table 4.III). The higher the grade the less likely the tumors were 
immunoreactive against anti-apoA-I or anti-apoB antibodies.  
Expression of apolipoproteins, SR-BI, and VHL downstream targets  
The protein encoded by the VHL gene, von Hippel–Lindau protein, acts as an adaptor protein to recruit 
various effectors to target proteins. Therefore, we statistically evaluated the associations of lipoprotein 
immunoreactivity with markers of VHL downstream targets (Table 4.III), namely microvessel density 
recorded by CD34 abundance, nuclear abundance of HIF1, and the protein abundance of HIF-1α 
targets CA9 and GLUT1. Interestingly, the immunoreactivity for apoA-I showed significant positive 
associations with each of the four markers (CD34: P < 0.001; HIF1a: P = 0.0078; CA9: P = 0.0272; 
GLUT1: P = 0.0175). By contrast, SR-BI immunoreactivity showed no significant association with any 
marker. ApoB immunoreactivity was significantly and positively associated with microvessel density 
(P = 0.0197) and nuclear HIF-1α staining (P = 0.0049).  
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Table 4.III Correlation of apoA-I, apoB and SR-BI expression with different measured features: Correlation 
analysis between ccRCC tumor tissue microarray sections immunostained for apoA-I, apoB ,SR-BI  and different 
pathological parameters as well as HIF-target proteins. The values in the table represents the P value, n.s means 
No significance.  
 
                            
Figure 4.2: Apolipoprotein and SR-BI expression in renal cell carcinoma TMA Immunostaining of A, apoA-
I B, apoB and C, SR-BI of human tissue microarrays. The grading from 0-3 represents the staining intensity from 
negative to the strongest.  
Measured features apoA-I apoB SR-BI 
apoA-I - 0.0001 n.s 
apoB 0.0001 - n.s 
SR-BI n.s n.s - 
ISUP grade 0.025 0.0006 n.s 
Tumor stage n.s 0.037 n.s 
Microvessel density 
(CD34) 
0.0001 0.0197 n.s 
HIF-1α 0.0078 0.0049 n.s 
CA9 0.0272 n.s n.s 
GLUT1 0.0175 n.s n.s 
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Lipoprotein and apolipoprotein expression and patient survival 
Finally, we used the Kaplan-Meier method and log-rank test to evaluate the associations of apoA-I, 
apoB and SR-BI immunoreactivity with overall survival. Stronger immunoreactivity of apoA-I, apoB, 
and SR-BI are associated with better survival (Figure 4.3A-C), but, this association was significant for 
anti-apoA-I expression only (p-Value = 0.0407, Figure 4.3A). However also this association lost 
statistical significance upon multivariate analysis taking into account tumor stage and grade. 
 
Figure 4.3 Kaplan-Meier curves depicting overall survival (OS) according to differential expression of 
apolipoproteins and SR-BI in ccRCC tissue microarray sections A, Kaplan-Meier analysis of OS of apoA-I 
immunoreactivity, B, Kaplan-Meier analysis of OS of apoB immunoreactivity and C, Kaplan-Meier analysis of 
OS of SR-BI immunoreactivity. 
Lipoprotein RNA expression in ccRCC cell lines 
APOA1 and APOB transcripts were seen in hepatocellular derived carcinoma cells, Huh7 (positive 
control) but neither in 786-O cells which lacks functional VHL nor in 786-O cells which are stably 
transfected with wild-type VHL (786-O-VHL), nor in human aortic endothelial cells (HAECs) that 
served as the negative control (Figure 4.4A and 4.4B). Western blot analysis of the ccRCC cell lines 
neither revealed any ApoA-I nor ApoB protein expression (Figure 4.4C,D). 
To test the hypothesis that apolipoprotein accumulation in ccRCC is caused by excessive lipoprotein 
uptake, 786-O as well as HAECs were incubated with radio-iodinated HDL or LDL at 37°C for 1 hour 
14. Compared to HAECs, the cellular association of 125I-HDL in 786-O cells was very low (Figure 4.5A) 
whereas the cellular association of 125I-LDL was very high (Figure 4.5B).  
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Figure 4.4: mRNA and protein expression of apolipoproteins in renal carcinoma 786-O cells mRNA levels 
of APOA1 (113bp, A) and APOB (111bp, B) were measured by real-time polymerase chain reaction in 786-O 
cells compared to Huh7 and HAECs (used as positive and negative controls respectively). The control reaction 
was carried out in the presence of water. Also included were 786-O-VHL transfected cells and RCC4 and RCC4-
VHL transfected cells (RCC4 represents another renal-cell carcinoma cell line model). Western blot analysis of 
ApoA-I (C) and apoB (D) in 786-O and 786-VHL cells compared to HDL (C) and LDL (D), respectively, as the 
positive controls. The western blots were probed with anti-ApoA-I (30kDa), anti-ApoB (540 kDa), and anti-TATA 
binding protein (TBP, 40kDa), anti-Na+/K+-ATPase (60kDa) were used as loading controls. 
         
Figure 4.5: Radioiodinated lipoprotein cellular association in renal carcinoma 786-O cells To study cellular 
association, HAECs and 786-O cells were incubated with 10µg/mL of A, 125I-HDL or B, 125I-LDL for 1 hour in 
the absence (total) or in the presence of 40-fold excess of unlabeled HDL or LDL (unspecific). Specific association 
was calculated by subtracting unspecific values from total values. The results are represented as mean±SEM of 
three independent triplicate experiments. ***P≤ 0.001. 
Loss of VHL function enhances the uptake but inhibits the degradation of LDL 
To investigate the involvement of VHL in regulating the cellular association of radioiodinated 
lipoproteins, we compared 786-O cells with 786-O-VHL cells. Parental 786-O cells showed higher 
mRNA expression of the HIF-1α responsive genes VEGF, BNIP3, PDK1 and SLC2A1 (Figure 4.6A-
E) compared to the 786-VHL cells.  
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The 786-VHL cells showed decreased cellular association of both 125I-HDL and 125I-LDL compared to 
the parental 786-O cells. Interestingly, pre-treatment with VEGF for 1 hour increased the specific 
cellular association of 125I-HDL as well as 125I-LDL in 786-O-VHL cells but had no effect in 786-O cells 
(Figure 4.7A & B). Pre-treatment of 786-O cells with VEGF receptor inhibitors for 30 minutes decreased 
specific cellular association of both 125I-HDL and 125I-LDL but had no effect in 786-O-VHL cells (Figure 
4.8A-D).  
 
Figure 4.6: mRNA expression of HIF-1α target genes in ccRCC cells Quantification of A, VEGF mRNA B, 
BNIP3 mRNA C, PDK1 mRNA and D, SLC2A1 mRNA (GLUT1) E, CAIX mRNA. GAPDH was used a house 
keeping control gene. 
                 
Figure 4.7: VHL promotes cellular association of 125I-HDL and 125I-LDL in renal carcinoma 786-O cells 
786-O and 786-VHL cells were pre-treated with 25ng/ml of VEGF for 1 hour prior to assays as indicated, followed 
by incubation with 10µg/mL of A, 125I-HDL or B, 125I-LDL at 37 ºC for 1hour in the absence (total) or in the 
presence of 40-fold excess of unlabeled HDL or LDL (unspecific). Specific cellular association was calculated by 
subtracting unspecific values from total values. The results are represented as mean±SEM of three independent 
triplicate experiments. ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05. 
99 
 
                        
Figure 4.8: Receptor tyrosine kinases promote cellular association of 125I-HDL and 125I-LDL in renal 
carcinoma 786-O cells 786-O and 786-O-VHL cells were pre-treated with either Sorafenib (90nM) or Sunitinib 
(80nM)  for 30 minutes prior to assays as indicated, followed by incubation with 10µg/mL of 125I-HDL or 125I-
LDL. 786-O cells incubated with A, 125I-HDL B, 125I-LDL. 786-O-VHL cells incubated with C, 125I-HDL D, 
125I-LDL at 37 ºC for 1hour in the absence (total) or in the presence of 40-fold excess of unlabeled HDL or LDL 
(unspecific). Specific cellular association was calculated by subtracting unspecific values from total values. The 
results are represented as mean±SEM of three independent experiments. ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05, 
“n.s” represents no significance. 
Interestingly, both the ccRCC cell lines expressed neither VEGFR1 nor VEGFR2 nor VEGFR3, but 
expressed neuropilin-1 (NRP1) which is a co-receptor of VEGFR (Figure 4.9). The 786-O cells showed 
higher expression of NRP1 compared to the 786-VHL cells (Figure 4.10A). To test whether NRP1 is 
involved in the regulation of cellular association of radioiodinated lipoproteins, we targeted NRP1 using 
RNA interference and validated the knock-down efficiency at the mRNA level (Figure 4.10B, C). 
Silencing NRP1 decreased the specific cellular association of 125I-HDL as well as 125I-LDL in both 786-
O and 786-O-VHL cells. Interestingly, pre-treatment with VEGF for 1hour stimulated the specific 
cellular association of neither 125I-HDL nor 125I-LDL in 786-VHL cells in which NRP1 was knocked-
down (Figure 4.11A-D).  
786-O-VHL cells showed considerable degradation of 125I-LDL similar to the hepatocyte cell line Huh7 
and healthy kidney cell line HK-2 cells. By contrast, degradation of 125I-LDL was strongly reduced in 
the parental 786-O cells, which lack functional VHL (Figure 4.12A&B). There was no detectable 
degradation of cell-associated 125I-HDL in either of the ccRCC cell lines (Data not shown). Together, 
these results indicate that the loss of VHL function increases the lipoprotein uptake in ccRCC into a 
non-degrading compartment.  
 
100 
 
 
Figure 4.9 qRT-PCR expression of VEGF receptors and NRP1 in ccRCC cells Amplication curves of PCR 
products of A, VEGFR1 B, VEGFR2 C, VEGFR3 D, NRP1 in 786-O and 786-O-VHL cells.  
                               
Figure 4.10: qRT-PCR expression of NRP1 and efficiency of NRP1 RNA interference in ccRCC cells A, 
Quantification of NRP1 mRNA expression. GAPDH was used as a house keeping control gene. B, 786-O C, 786-
O-VHL cells were transfected with a specific siRNA against NRP1 or with non-silencing control siRNA (NS 
control) and silencing efficiency was analyzed at mRNA level using qRT-PCR after 72hours of transfection. 
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Figure 4.11: NRP1 promotes cellular association of 125I-HDL and 125I-LDL in renal carcinoma 786-O cells 
786-O and 786-O-VHL cells were transfected with specific siRNA against NRP1 or with non-silencing control 
siRNA (NS control). After 72hours of transfection, the cells were pre-treated with 25ng/ml of VEGF for 1 hour 
prior to assays as indicated, followed by incubation with 10µg/mL of 125I-HDL or 125I-LDL. 786-O cells 
incubated with A, 125I-HDL B, 125I-LDL. 786-O-VHL cells incubated with C, 125I-HDL D, 125I-LDL at 37 ºC for 
1hour in the absence (total) or in the presence of 40-fold excess of unlabeled HDL or LDL (unspecific). Specific 
cellular association was calculated by subtracting unspecific values from total values. The results are represented 
as mean±SEM of three independent experiments. ***P≤ 0.001, **P≤ 0.01, *P≤ 0.05, †††P≤ 0.001 ††P≤ 0.01, 
†P≤ 0.05. 
        
Figure 4.12: Degradation of  125I-LDL in renal carcinoma 786-O cells Cells were incubated with 15µg/mL of  
125I-LDL at 37 ºC for 4 hours in the absence (total) or in the presence of 40-fold excess of unlabeled LDL 
(unspecific). A, The adhered cells were processed to analyze cellular association. B, The supernatant was collected 
and processed to analyze the degradation of 125I-LDL as described in the methods section. Specific values were 
calculated by subtracting unspecific values from total values. The specific degradation was calculated by 
normalizing to the specific cellular uptake. The results are represented as mean±SEM of three independent 
experiments, with significance determined by unpaired t test. ***P≤ 0.001, **P≤ 0.01. 
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SR-BI mediates cellular association and binding of 125I-LDL in ccRCC 
We next aimed to unravel the receptor which enhances the lipoprotein uptake by ccRCC cells. We first 
assessed the expression of two candidate receptors, LDLR and SR-BI. We found lower expression of 
LDLR in the 786-O cells compared to 786-VHL and HK-2. In addition, the presence of several lower 
molecular weight anti-LDLR-immunoreactive bands cell lines suggests that the two ccRCC cell lines 
degrade the LDL receptor more extensively compared to the HK-2 cells (Figure 4.13A). To test whether 
LDLR mediates the cellular uptake of LDL in ccRCC cells, the LDLR was targeted using RNA 
interference. Although the knockdown efficiently suppressed protein abundance of LDLR, it did not 
affect the cellular uptake of 125I-LDL (Figure 4.13 B,C). This finding is in agreement with a previous 
report 6, but in contrast to the enhanced uptake of LDL by 786-O cells. 
 
Figure 4.13: Cellular uptake of 125I-LDL in ccRCC is independent of LDLR A,Western blot analysis of LDLR 
and TATA-binding protein (TBP) in 786-O and 786-O-VHL cells compared to healthy kidney cells (HK-2). The 
mature glycosylated LDLR is 160kDa while the degradation product is between 55-35kDa. 786-O and 786-O-
VHL were transfected with siRNA against LDLR or with non-silencing control siRNA (NS control). B, The 
silencing efficiency was analyzed 72 hours post-transfection at the protein level using western blotting. The 
western blots were probed with anti-LDLR (160kDa) and anti-TBP (40kDa, used as a loading control). C, Specific 
cell association was analyzed by incubating ccRCC cells with 125I-LDL at 37 ºC for 1hour. 
Total lysates of 786-O and 786-VHL cells did not differ in SR-BI protein levels. However, cell-surface 
biotinylation revealed strongly increased expression of SR-BI on the cell surface of parental 786-O cells 
compared to that of 786-VHL cells (Figure 4.14A). To test whether the cellular association of 
lipoproteins in renal carcinoma cells involves SR-BI, we incubated the cells with an SR-BI neutralizing 
antibody. In both 786-O and 786-VHL cells the specific cellular association of 125I-HDL as well as 125I-
LDL was significantly decreased in the presence of the neutralizing antibody (Figures 4.14 B,C). Taken 
together, these results indicate that the uptake of HDL and LDL by ccRCC cells is dependent on the 
cell-surface expression of SR-BI. 
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Figure 4.14: SR-BI mediates cellular association of 125I-HDL and 125I-LDL in ccRCC cells A, Cell surface 
expression of SR-BI in renal carcinoma cells. Western blot analysis of SR-BI and TATA-binding protein (TBP) 
in total cell lysates (left) and on the cell surface (right) in 786-O and 786-O-VHL cells. The western blots were 
probed with anti-SR-BI (82kDa) and anti-TBP (40kDa, used as a control for intracellular protein expression). 786-
O and 786-O-VHL cells were pre-treated with 25ng/ml of VEGF for 1 hour prior to assays, followed by incubation 
with 10µg/mL of B, 125I-HDL or C, 125I-LDL for 1hour in the absence (total) or in the presence of 40-fold excess 
of unlabeled HDL or LDL (unspecific) at 37 ºC. Specific association was calculated by subtracting unspecific 
values from total values. The results are represented as mean±SEM of three independent experiments. ***P≤ 
0.001, **P≤ 0.01, *P≤ 0.05, †††P≤ 0.001 ††P≤ 0.01, †P≤ 0.05. IgG control represents isotype control and anti-
SR-BI Nab represents treatment with SR-BI neutralizing antibody. 
 
4.4 Discussion 
In this study, we identified a mechanism of intracellular lipid accumulation by enhanced uptake of LDL 
and HDL via SR-BI in clear cell RCC. The identification of immunoreactivity for apoA-I and apoB in 
ccRCC but not or less so in other renal tumors provides strong evidence that this lipid storage is 
characteristic for ccRCC, which is characterized by VHL inactivation and consecutive HIF activation. 
Of note, the maintained apoA-I and apoB immunoreactivity suggests that the lipoproteins are not or only 
partially degraded. In line with this, we found that the ccRCC cell line 786-0 does not produce any apoB 
and apoA-I but readily takes up LDL and – to much lesser extent - HDL, however without degrading 
them.  
The intracellular storage of LDL is very unusual because the internalization of LDL into other cells, 
notably hepatocytes, macrophages but also renal mesangial or tubular cells, is followed by degradation 
30-32. Most cells internalize LDL via the LDL-receptor into clathrin-coated pits 33, 34. LDL is then 
trafficked into an endosomal/lysosomal route, depending on the presence or absence of PCSK9 either 
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together or separated from the receptor 35, 36. The apoB moiety and cholesteryl esters of LDL are 
hydrolysed by lysosomal proteases and acid lipases respectively 37-39. Internalisation of apoB-containing 
lipoproteins by other members of the LDL receptor family, for example LRP1, LRP2, or the VLDL 
receptor into a broad variety of cells  is also followed by lysosomal degradation of both their proteins 
and lipids 40. Interestingly, the VLDL receptor was previously reported to be up-regulated in ccRCC and 
to promote lipid uptake into ccRCC cells. However, this study only recorded the uptake of lipoprotein-
derived lipids rather than the lipoproteins’ protein moiety 7. Likewise macrophages degrade modified 
LDL internalized by class A scavenger receptors 41. In hepatocytes and macrophages but also other cells, 
any cholesteryl ester storage in lipid droplets results from the re-esterification of cholesterol in the ER 
after transfer from the lysosomes 42. The intracellular storage of endocytosed holoparticles hence appears 
to be a specific finding in ccRCC cells.  
The most likely reason for this atypical behavior of ccRCC cells is the involvement of SR-BI rather than 
the LDL-receptor in LDL internalization. We found strong immunoreactivity of SR-BI in ccRCC but 
not in other renal tumors. Also other scientists have previously reported strong expression of SR-BI in 
ccRCC 7. We also confirmed the findings of others, that ccRCC cell lines strongly express SR-BI but 
much less so the LDL receptor 6, 7. We here extend these previous findings by showing that the inhibition 
of SR-BI but not the interference with LDLR prevents the uptake of LDL as well as HDL into ccRCC 
cells (Figure 4.13 and 4.14). The mechanism by which SR-BI promotes cellular lipoprotein uptake is 
not clear: SR-BI is traditionally regarded as a receptor which binds HDL as well as LDL and provides 
bidirectional fluxes of cholesterol from these lipoproteins into cells or from the plasma membrane to the 
lipoprotein depending on the concentration gradient 8, 12. However, several examples have been reported 
where ablation or blockage of SR-BI also inhibited the uptake of lipoproteins. Notably vascular 
endothelial cells were reported by our and other laboratories to internalize and transcytose HDL and 
LDL in an SR-BI dependent manner 13, 43. However, it is not clear whether SR-BI or one of its splice 
variants directly serve as an endocytic receptor 44, 45 or whether SR-BI only enables other pathways of 
endocytosis. Such indirect effects of SR-BI may include the activation of other receptors by altering the 
cholesterol distribution within the plasma membrane or signaling via its PDZ domain 46. SR-BI mediated 
endocytosis of HDL and LDL into endothelial cells is followed by re-secretion and hence allows 
transcytosis of lipoproteins, for example from the blood stream into the arterial wall or into the brain as 
well as from the extravascular tissue into the lymph 47. This raises the question whether ccRCC cells not 
only fail to degrade but also to re-secrete the internalized lipoproteins.  
VEGF signaling activated by loss of VHL function appears to be the reason for the enhanced SR-BI 
mediated uptake of HDL and LDL into ccRCC cells: Compared to wild type VHL expressing 786-O-
VHL cells, VHL lacking 786-O cells show increased expression of VEGF among other HIF-1α target 
genes, increased cell surface expression of SR-BI (Figure 4.14A), and increased uptake of both LDL 
and HDL (Figure 4.5A&B). The uptake of both HDL and LDL was enhanced in 786-O-VHL cells by 
pre-treatment with VEGF (Figure 4.7A&B) but lowered in 786-O cells by VEGFR inhibitors (Figure 
4.8A-D). These findings are in line with the previous report of HIF-1α -dependent lipid uptake into 
ccRCC 7. They are in line with our previous observation in HAECs where VEGF promoted the 
translocation of SR-BI to the cell membrane as well as the uptake and transcytosis of HDL 14. In this 
regard it is noteworthy to reconcile the significant correlation of VHL/HIF-1α downstream targets 
(Glut1, CAIX and high microvessel density) with immunoreactivity of both apoA-I and apoB in our 
study, suggesting that increased apoA-I and apoB levels are a consequence of VHL/HIF-1α signaling 
activation. Activated VEGF signaling in ccRCC due to increased HIF-1α activity may enhance 
lipoprotein uptake into the tumor not only by direct actions on tumor cells but also indirectly by 
promoting their transport from the circulation into the tumor tissue. VEGF is known to activate the 
downstream signaling by binding to VEGF receptors 48. However, we did not detect the expression of 
any of the three VEGF receptors in the ccRCC cells (Figure 4.9). Importantly, in line with previous 
105 
 
findings 49, we detected higher expression of NRP1 in the VHL lacking 786-O cells compared to the 
wild type VHL expressing 786-O-VHL cells. Upon binding of VEGF NRP1 elicits angiogenesis and 
tumorigenesis both dependently and independently of VEGF receptors45. The enhanced uptake of HDL 
and LDL in 786-O-VHL cells by pre-treatment with VEGF was abrogated by the suppression of NRP1 
(Figure 4.11). Altogether, our findings identify a novel role of NRP1 in the cholesterol accumulation of 
ccRCC. 
 
Figure 4.15: Loss of VHL promotes uptake of HDL and LDL in renal cell carcinoma cells In clear cell renal 
cell carcinoma, somatic mutations in VHL and subsequent HIF-1α activation induce the expression of VEGF. 
VEGF further induces the cell surface translocation of SR-BI, thereby promoting the excessive uptake and 
accumulation of HDL and LDL in ccRCC cells.  
Our observations provide plausible explanation for the origin of cholesteryl ester accumulation in 
ccRCC. However, they do not allow any conclusion whether or not enhanced lipoprotein uptake into 
ccRCC has any impact on the clinical course of this disease. Excessive lipids and cholesterol in cancer 
cells are considered as markers of cancer aggressiveness 50.In our study. In line with this, 
immunoreactivity for apoA-I, apoB, or SR-BI was associated with the differentiation of renal 
carcinomas into ccRCC as well as with tumor grade (apoB) or tumor stage (apoB and SR-BI). However, 
expression of apoB or SR-BI showed no association with prognosis. Rather by contrast apoA-I 
immunoreactivity was an indicator of better survival but this association did not remain significant after 
adjustment for tumor stage and grade. Previously, in a study of 100 Chinese patients, SR-BI expression 
was associated with the prognosis of ccRCC 51. We did not replicate this observation in our larger cohort 
of 172 patients. However, it is important to note, that in our in vitro experiments the cell surface 
expression of SR-BI rather than the total SR-BI content was depending on VHL and VEGF. The semi-
quantitative scoring immunostaining intensity does however not discriminate between the larger pool of 
intracellular SR-BI and the smaller pool of cell surface SR-BI. Interestingly, genome-wide association 
studies identified a borderline significant association of the rs4765623 polymorphism in SCARB1 with 
ccRCC susceptibility 52 indicating some pathogenic role of SR-BI in ccRCC.  
Our data are important for the understanding of lipid metabolic reprogramming as a hallmark of cancer. 
Exacerbated glucose uptake and glycolysis utilization leading to increased lactate production (Warburg 
effect) is one of the first adaptive events of the cancer cells 53, 54. However, cancer cells also rely on 
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glutamine consumption, which provides carbon needed for amino-acid, nucleotide and lipid biosynthesis 
54, 55. Importantly, alterations
 
in lipid- and cholesterol-associated pathways are now regarded as potential 
targets in cancer therapy 50. Drugs targeting lipid and cholesterol dependencies, modulating lipid raft 
components to induce cell death signaling as well as drugs targeting lipid mediators of tumor-stroma 
interactions are tested in preclinical trials 50.  
In conclusion, we identified SR-BI mediated intracellular accumulation of intact lipoproteins as the 
likely origin of cholesterol accumulation and the characteristic clear cytoplasm of ccRCC. VEGF 
induced SR-BI cell surface translocation may be the underlying mechanism. 
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5. Conclusion and discussion 
Atherosclerosis remains the major cause of mortality and morbidity in the world. According to the 
response to injury and response to retention theories, the accumulation of apoB containing lipoproteins 
within the vascular wall play a crucial role in the pathogenesis of atherosclerosis 1. HDL have to enter 
and leave the arterial wall to play their presumed anti-atherogenic role in reverse cholesterol transport 
2. Imbalance in the influx and efflux of the lipoproteins across the arterial wall hence is an important 
determinant of disease susceptibility. Hence, identifying the factors involved in the lipoprotein transport 
through the endothelial cells will give a better understanding of the development and progression of the 
disease, which will help to design novel therapeutic targets 3, 4. Therefore, in this thesis we aimed to 
identify the receptors and signalling kinase cascades involved in regulating the transport of the 
lipoproteins across the endothelium. Based on hypothesis-driven and hypothesis-free approaches we 
found that S1P/S1PR and VEGF/VEGFR axes contribute to the regulation of the lipoprotein transport 
through the endothelium. 
Activation of S1P1 and S1P3 as well as VEGFR2 with their respective agonists stimulated the 
translocation of SR-BI from cytosol to the plasma membrane, thereby increasing the cellular binding, 
uptake and transport of HDL through the endothelial cells (Figure 5.1). The activation of the S1P1 and 
the S1P3 receptors activates intracellular signaling pathways encompassing trimeric G-proteins (Gi, Gq, 
and G12/13) and other signalling molecules including small G proteins Rac1 and Rho, PI3K/Akt and 
mitogen activated protein kinases5. The Rho GTPases regulate actin cytoskeletal architecture and cell 
polarity. Actin cytoskeleton plays a role in apical and basolateral vesicular trafficking in polarized cells. 
Rho GTPases  and Rac1 regulate actin dynamics as well as endocytic trafficking pathway by modulating 
PI3K, respectively 6. Therefore, it will be interesting to investigate whether the S1P1 and S1P3 mediated 
HDL endocytosis and transport is dependent on the activation of Rho/Rac GTPases.  
Binding of VEGF-A induces conformational changes and dimerization of VEGFR2 which in turn 
triggers kinase activation, tyrosine phosphorylation of the dimerized VEGFR2 and subsequent 
phosphorylation of SH2-containing intracellular signaling proteins, including phospholipase C-γ1 
(PLCγ1), Src family tyrosine kinases, and phosphatidylinositol 3-kinase (PI3K) and GTPase-activating 
protein residues of Ras, Raf, MEK and MAPK 7-10.  By both pharmacological inhibition and RNA 
interference, we revealed the involvement of PI3K/Akt, p38MAPK, and the Ras-Raf-MEK pathway in 
binding and uptake of HDL. However, the inhibition of the Ras-Raf-MEK pathway but not the inhibition 
of PI3K/Akt and p38MAPK could be overcome by VEGF stimulation. Thus, VEGF regulates the 
interaction of HDL with endothelial cells by activating PI3K/Akt and p38MAPK but not the Ras-Raf-
MEK pathway. Thus, it will be interesting to identify agonists beyond VEGF that regulate the 
endothelial binding, uptake and transport of HDL by activating the MEK/ERK pathway. Since, S1P1 
and S1P3 were previously shown to activate the MEK/ERK pathway, it will be interesting to study its 
involvement in S1P1 and S1P3 dependent regulation of endothelial cellular binding, uptake and 
transport of HDL. It has been previously shown that VEGF promotes the activation of S1P1 receptor 
and its downstream signaling kinases such as PI3K/Akt and members of mitogen-activated protein 
kinase family (MAPK) 11, 12. We also found that PI3K/Akt and p38 MAPK are involved in the VEGF-
mediated cellular binding and uptake of HDL. Therefore, it will be interesting to investigate the role of 
cross-talk between S1P/S1PR and VEGF/VEGFR2 in the regulation of transendothelial transport of 
HDL.  
Interestingly and in contrast to the effects of S1P on HDL transport, we found that treatment of 
endothelial cells with either the S1P1 or the S1P3 agonists decrease the cellular binding, uptake and 
transport of LDL through HAECs. Moreover, the inhibition of both S1P1 and S1P3 increased the 
transendothelial transport of LDL through different mechanisms. The S1P1 inhibitor was found to 
enhance the total cellular uptake and transport of LDL through fluid-phase (Figure 5.1). Pre-treatment 
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of cells with a fluid-phase uptake inhibitor decreased the total cellular uptake and transport of LDL 
stimulated by the S1P1 inhibitor. The treatment of endothelial cells with the S1P3 inhibitor increased 
the cellular binding and uptake of LDL through LDLR and transport independent of both LDLR and 
SR-BI. We confirmed previous reports that endothelial cells internalize and transcytose LDL in a 
process involving SR-BI 13. Interestingly, VEGF-A and VEGFR2 had no effect on binding, uptake and 
transport of LDL in HAECs. However, despite regulating the cell surface abundance of SR-BI, neither 
S1P nor VEGF regulate the transendothelial transport of LDL. These lipoprotein-specific effects of 
S1P/S1P1 & S1P3 and VEGF/VEGFR2 on the processing of HDL and LDL by HAECs indicate the 
existence of additional regulators and routes of transendothelial transport, for example ALK1 which was 
recently identified by a genome-wide RNAi-screen as an endothelial LDL binding protein mediating 
uptake and transport of LDL 14.  
                         
 
Figure 5.1: Rate-limiting factors involved in the regulation of HDL transport by HAECs Activation of S1P1 
and S1P3 receptors as well as VEGFR2 with their respective agonists stimulated the translocation of SR-BI to the 
cell surface, which further increased the transport of HDL across the endothelial cells. The transport of LDL is 
increased in the presence of S1P1 inhibitor through fluid-phase. The mechanism through which S1P3 inhibitor 
increased the transport of LDL through the endothelial cells remains unknown. 
Finally, we tried to translate our findings on the regulation of transendothelial lipoprotein transport into 
the elucidation of pathomechanisms in human disease. In clear cell renal cell carcinoma (ccRCC) 
somatic mutations in VHL and subsequent HIF-1α activation induce the expression of VEGF. Thereby, 
we identified VEGF as the driver of LDL and HDL accumulation in ccRCC again by promoting the SR-
BI abundance in the cell membrane. (Figure 4.15). Moreover, our findings in ccRCC raise the question 
whether SR-BI is a therapeutic target in clear-cell renal cell carcinoma. We also found that treatment of 
ccRCC cells with the inhibitors against VEGF receptors or NRP1 decreased the uptake of HDL as well 
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as LDL. In view of our findings on the upregulation of HDL transport in endothelial cells, this 
mechanism may not only happen in tumor cells but also in the microvasculature of ccRCC. Infact, we 
found significant correlation between apoA-I and apoB expression and CD34 expression of the 
microvasculature marker. Interestingly, treatment of mice with renal cell carcinoma with neutralizing 
antibody against S1P has been shown to increase their sensitivity to sunitinib treatment, which inhibits 
VEGF tyrosine kinase receptors 15.
 
 Therefore, it will be interesting to study the cross-talk between 
S1P/S1PR and VEGF/NRP1 with respect to the transport of lipoproteins into the tumor cells or through 
the vasculature of ccRCC.  
In conclusion, the identification of S1P/S1PR and VEGF/VEGFR signaling cascade in regulating the 
transport of HDL and LDL through HAECs helped to advance our understanding of lipoprotein 
accumulation in both atherosclerosis and in specific cancer namely, ccRCC. The analogous findings 
provide another example of shared pathomechanisms between the two most frequent causes of death, 
namely cardiovascular diseases (CVD) and cancer 16. 
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